

Award No. W81XWH-12-1-0550, EDMS 5544

TITLE: Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient

PRINCIPAL INVESTIGATOR: Peter E. Morris, MD

CONTRACTING ORGANIZATION: University of Kentucky Research Foundation
Lexington, KY 40536

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2016		2. REPORT TYPE Annual		3. DATES COVERED 20Sep2015 - 19Sep2016	
4. TITLE AND SUBTITLE Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient				5a. CONTRACT NUMBER W81XWH-12-1-0550	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Peter Morris, James Holmes, Brad Freeman, Bruce Cairns, Michael Berry, L. Doug Case E-Mail: pemorris@wakehealth.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Kentucky Research Foundation Lexington, KY 40536				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This is a multicenter, randomized controlled trial to determine whether early ICU rehabilitation, for Burn Intensive Care Unit (BICU) patients will decrease hospital length of stay. 50 subjects will be randomized at each of three sites for a total of 150 subjects. The study has completed all regulatory requirements, completed site protocol developments and has begun to enroll patients. The goal enrollment minimums are an average of 2.5 patients enrolled per month, per site; 7.5 patients enrolled per month, across the study. This study will increase understanding of the effect of rehabilitation on ICU Burn patients, through ultrasound and strength assessments of muscles, performed at study entry (ultrasound), ICU & Hospital discharge and at 3, 6 and 12 months (ultrasound & strength assessments) post-enrollment. Functional testing with Short Physical Performance Battery (SPPB) and Health Related Quality of Life (HRQoL) testing will determine if standardized early rehab improves functional performance, quality of life and employment status. Accomplishments Year #1: Database build, design web entry case report forms, site training; finalized IRB consent forms and began enrollment, 3 subjects to date, with outpatient follow-up 3, 6, and 12 month sessions planned. Accomplishments Year #2: Active Study with enrollment of study subjects at all three sites. Completion of training of ultrasound techniques at all three sites. Out-patient follow-up has begun for those enrolled within the first year of the study.					
15. SUBJECT TERMS Critical Injury, Burn Patient, Rehabilitation Therapy					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	56	19b. TELEPHONE NUMBER (include area code)

PROJECT:
Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient
Annual Report
W81XWH-12-1-0550
Year 4, Q1-Q4
Table of Contents

	<u>Page</u>
Introduction.....	4
Keywords.....	4
Overall Project Summary.....	4
Key Research Accomplishments.....	5
Conclusion.....	7
Publications, Abstracts, and Presentations	7
Inventions, Patents, and Licenses.....	8
Reportable Outcomes.....	8
Other Achievements.....	8
References.....	8
Appendices.....	9

Introduction:

This project was originally funded in order to conduct a multicenter, randomized controlled trial to determine whether early ICU rehabilitation, for Burn Intensive Care Unit (BICU) patients, would decrease hospital length of stay. The original protocol specified fifty subjects to be randomized at each of three sites for a total of 150 subjects. Study start-up was initiated in Year #1 and all sites began to enroll patients. Twenty-three study subjects were been enrolled. Out-patient visits during the post-enrollment, post-hospital discharge phase of the study were also initiated and the outpatient phase of testing was instituted. The sites were committed to increasing enrollment goals to match above planned – and the enrollment did show a tick upwards in the last year that the protocol was active.

This study however did receive great discussion across the investigators due to a recently completed similar study that was administered within a medical ICU population. The results of the medical ICU early rehab study are reviewed below and the subsequent steps taken by the PI's are as well described. That particular medical ICU population study has been published recently and appeared in JAMA.

Keywords:

Burn Injury, Critical Care, Intensive Care, Standardized Rehabilitation Therapy

Overall Project Summary:

Monthly study conferences were conducted with discussion across PI's and coordinators. These conferences led to recommendations addressing enrollment volume within the study. These conversations were detailed and examined possibilities at each site to identify improvements in process.

Patient screening and patient enrollment:

Patient screening was ongoing at all three sites.

Patient review:

To date, twenty-three study subjects were enrolled. Appropriate timelines were adhered to in regards to study enrollment windows. Appropriate execution of study inclusion and exclusion rules was conducted. Each study subject had an appropriate study IRB consent form, with appropriate dated signatures, obtained prior to randomization. Randomization procedures were engaged and functioned without difficulty.

To date both study arms were engaged with study subjects. Standardized rehabilitation therapy and usual care were delivered to study subjects. Success was achieved in the delivery of multiple intervention arm rehabilitation sessions including delivery of resistance training exercise with Therabands. Blinded exercise physiologists had conducted the strength and functional assessments according to protocol.

Key Research Accomplishments:

- All IRB and HRPO obligations were met
- All subcontract sites had working relationships with Wake Forest to receive study payments
- All payments on this grant mechanism have been put on hold and have been on hold since April 29th, 2015, when Dr. Morris moved from Wake Forest to the University of Kentucky (see below for subsequent plans to continue with this award).
- Electronic secure remote entry database was functioning
- SUMMARY OF CHANGES WITHIN ORIGINAL STUDY:

Two observations led the Principle Investigators to reconsider the design and execution of the original study, "Early ICU Rehabilitation Therapy for the Critically Injured Burn Patient". The original study set out to examine the effect of early intensive rehabilitation compared with usual care in severely burned patients.

The first observation included the results of a recently concluded Medical ICU Early Rehab study. This Medical ICU Rehab study failed to demonstrate an effect on prespecified in-hospital study endpoints. Extrapolating from these findings, the investigators seriously considered that Medical ICU trial's data to help predict the Burn Rehab Study outcome. The investigators now hold that it is unlikely that a treatment effect will be observed in the Burn Rehab study, even with full burn patient trial enrollment. Thus, an argument for halting the study for reasons of futility was developed and carried out.

The second observation arose directly from the Burn Rehab study itself. The Burn Rehab study's observation was a commonly occurring patient care delivery pattern within the severely burned patient population. This second observation was managing the protocol in light of frequent trips to the operating room. That is, the necessity of frequent planned operative interventions for the purposes of burn wound debridement, soft tissue coverage or related procedures often precluded delivery of the rehabilitation protocol. These multiple planned surgeries often disrupted scheduled rehabilitation sessions in patients randomized to the early, aggressive intervention arm of the Burn Rehab study. Specifically, because of these multiple operations, patients would often be too sedated to participate in prescribed rehabilitation therapy, would be about to go to the operating room or would be unavailable for participation because the scheduled rehabilitation session conflicted with the patient's operation.

The disruptive effect of the multiple operating room trips was by nature a characteristic of a burn population. Such operating room trips however, were not previously encountered when the rehabilitation intervention was studied in medical ICU patients (which served as the prototype for the study conducted in burn patients). Thus, such a need to account for the volume of operating room trips was not formulated into the original Burn Patient study design.

Collectively, the two observations resulted in the original study being placed on administrative hold and then closed. Enrollment in the "Early ICU Rehabilitation Therapy for the Critically Injured Burn Patient" has been terminated by the Principle Investigators. This step was undertaken to allow for reconfiguration and refocus of the investigative effort and resources. A new set of tasks were then designed within the original Scope of Work addressing the frequent operative needs of Burn patients and are presented here.

In the new phase of this current grant award, we will design a completely new Burn population Rehab study structure through a national database review. We propose to examine medical records within a large national hospital database (University Hospital Consortium's database) to identify optimal care delivery patterns reflected by outcome analysis. A barrier to the rehabilitation efforts within the original study's intervention arm was the immobilization of the critically ill patient, whether due to the injury or as a side effect of supportive care. Minimizing the duration of this immobilization and developing strategies to lessen its impact are the goals of this proposed continuation plan. To the extent that periods of immobility are due partly as a consequence of variability in operative practice, understanding and minimizing such variability has the potential to translate into more timely recovery of the severely injured patient, including those sustaining burns.

Thus, critical to the effort of revising our investigative, interventional approach, is this proposal of the 2nd Phase of this study. This 2nd Phase of the Study will develop a deeper understanding of clinical factors surrounding the "repetitive and re-look" procedures within the Critically Ill Burn Patient Population. In this final phase of the current award, the UHC database review study will increase the medical literature's understanding of what contributes to variability in practice surrounding the care of burn patients with conditions necessitating multiple planned operations. This insight will be essential to the future design and execution of a revised Burn ICU Rehabilitation study (a future grant application). The optimal future design will more effectively coordinate interventions among and across critical care, surgical, nursing, physical therapy, respiratory therapy and related disciplines.

Accordingly, the investigators feel that the proposed continuation plan will both fall within the scope of work of the original proposal and will be essential to developing strategies to optimizing the care of the severely burned patient.

One model system for studying the phenomenon of variability in practice in the setting of multiple planned operations is need to have critically ill burn patients return to the operating room. The concept of return to the operating room for burn surgical therapies was developed as a management strategy for patients in which the constellation of injuries precludes definitive repair at the time of ICU admission or index operation, when the patient is not sufficiently stable to tolerate a definitive operation, when there is concern that all injuries may not be accurately identified at the index operation, or in an effort to stage the needed surgical therapy.

Subsequently, use of this strategy has become more commonplace and applied along local practice rather than national standards. As a result, use of return procedures to the operating room for burn patients has variability with both institutions and practitioners. The more extensive the burn injury, the higher comorbidities or a greater number of related injuries or organ dysfunctions, then there will be a corresponding population of burn patients with greatest volumes of operating room visits. These needs for multiple operating room visits may correlate with longer duration of mechanical ventilation, greater intensive care unit (ICU) and hospital lengths of stay (LOS), and higher utilization of operating room resources. In turn, because of this prolongation of hospitalization, these patients also appear at increased risk of complications. Adding to and confounding variability in the return to the operating room, is potential lack of availability of operating room resources to accommodate multiple operations and inconsistency in patient management between operating rooms sessions (such as approaches to ventilator weaning, sedation, and mobilization). Cumulatively, this variability translates not only into increased resource expenditure but poses a barrier to early rehabilitation and restoration of function.

Our overarching hypothesis of the 2nd Phase of this grant award is that variation in practice among patients requiring planned repetitive operative therapy negatively impacts resource utilization and treatment of critically ill burn patients. Efforts to standardize these aspects of care have potential to more effectively target rehabilitative interventions in the setting of burn patients.

Conclusion:

Our 2nd Phase proposal consists of three highly interrelated specific aims:

In Specific Aim 1, we will utilize highly granular administrative databases to demonstrate and quantify inter-institutional variability in a model system - use of return to operating room procedures in critically ill burn patients.

In Specific Aim 2, we will utilize the information obtained in SA1 as a foundation for developing a standardized approach to planned return operating room procedures for critically ill burn patients.

In Specific Aim 3, we will adapt and synthesize a written pilot approach developed in SA2 to optimizing rehabilitative care in patients sustaining significant burn injuries and who require multiple planned operative interventions.

Publications, Abstracts, and Presentations:

a. Manuscripts:

1. Lay Press:
2. Peer-Reviewed Scientific Journals:

Morris PE, Berry MJ, Files DC, Thompson JC, Hauser J, Flores L, Dhar S, Chmelo E, Lovato J, Case LD, Bakhru RN, Sarwal A, Parry SM, Campbell P, Mote A, Winkelman C, Hite RD, Nicklas B, Chatterjee A, Young MP. Standardized Rehabilitation and Hospital Length of Stay Among Patients With Acute Respiratory Failure: A Randomized Clinical Trial. *JAMA*. 2016 Jun 28;315(24):2694-702. doi: 10.1001/jama.2016.7201

Jolley SE, Moss M, Needham DM, Caldwell E, Morris PE, Miller RR, Ringwood N, Anders M, Koo KK, Gundel SE, Parry SM, Hough CL. Point Prevalence Study of Mobilization Practices for Acute Respiratory Failure Patients in the United States. *Critical Care Medicine*, 2016 in press. DOI: 10.1097/CCM.0000000000002058

Balas M, Devlin JW, Verceles AC, Morris P, Ely EW. Adapting the ABCDEF Bundle to meet the needs of patients requiring prolonged mechanical ventilation in the long-term acute care hospital setting: historical perspectives and practical implications. *Semin Resp Crit Care Med* 2016; 37:1-17

3. Invited Articles:

4. Abstracts:

Point Prevalence Study of Intensive Care Unit Mobility Across the Acute Respiratory Distress Syndrome Network. Sarah E. Jolley, Marc Moss, Dale M. Needham, Ellen S. Caldwell, Peter E. Morris, Russell R. Miller, Nancy Ringwood, Megan G. Anders, Karen Koo, Selina M. Parry, Stephanie Gundel, Catherine L. Hough, A104. MOVING THE NEEDLE ON ICU-ASSOCIATED NEUROMUSCULAR WEAKNESS, 2015: A6349, 10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A6349

Feasibility of Fall Risk Assessments Within Acute Respiratory Failure Survivors with the Falls Efficacy Scale-International. Selina M. Parry, Rita N. Bakhru, Daniel C. Files, Sanjay Dhar, Michael T. Young, Lori Flores, J Lovato, Jordan Hauser, Elizabeth A. Chmelo, P Mote, Clifton Thompson, Pam Campbell, Linda Denehy, L Case, Michael J. Berry, Peter E. Morris, C47. SURVIVING SEPSIS: MANAGING THE CARE CONTINUUM, 2015: A4495, 10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4495

Metabolomic Analysis of the TARGET Cohort Identifies Serum Signatures That Outperform Lactate in Sepsis Prognosis. Raymond J. Langley, , Lori Flores, Robert Mohny, J Lovato, L Case, Kevin S. Harrod, Peter E. Morris. C23. SEPSIS: RISK, RECOGNITION, AND RESUSCITATION, 2015: A4007, 10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4007

The Design and Implementation of a MICU Survivors' Clinic: A Fellow's Journey Starting from Square One. James Davidson, Daniel C. Files, Rita N. Bakhru, , Kristin Griffin, Peter E. Morris. C47. SURVIVING SEPSIS: MANAGING THE CARE CONTINUUM, 2015: A4499, 10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4499

Cardiac and Skeletal Muscle Dysfunction in an Aging Mouse Model of Acute Lung Injury. Michael A. Sanchez, , Chun Liu, Jasmina Varagic, Peter E. Morris, Daniel C. Files. A57. LUNG INJURY, REPAIR, AND FIBROSIS: THE PLOT THICKENS FOR THREE'S COMPANY, 2015: A2054, 10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A2054

Love NJ, Morris PE, Case LD, Lovato J, Berry MJ. Relationship Between Self-Report and Performance Based Measures of Physical Function Following an ICU Stay. Med Sci Sports Exerc. 2016 May;48(5 Suppl 1):282. doi: 10.1249/01.mss.0000485849.11592.a1.

b. Presentations: by Peter Morris, MD (PI)

1. October 2015, Brisbane Australia, National Annual Meeting of the Australia Physiotherapist Association, New Paradigms for Early ICU Rehab
2. October 2015, University of Melbourne, Update on Early ICU Rehabilitation
3. October 2015, The Albert Hospital, Melbourne, Australia, Clinical Review of ICU Rehab Techniques
4. November 2015, Medical Grand Rounds, The Cleveland Clinic, Cleveland, Ohio, The Message From Recent Clinical Trials in Early ICU Rehabilitation Studies

Inventions, Patents, and Licenses:

Nothing to report

Reportable Outcomes:

Nothing to report

Other Achievements:

Nothing to report

Appendices:

Manuscript and abstract publications

Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Standardized Rehabilitation and Hospital Length of Stay Among Patients With Acute Respiratory Failure

A Randomized Clinical Trial

Peter E. Morris, MD; Michael J. Berry, PhD; D. Clark Files, MD; J. Clifton Thompson, RN; Jordan Hauser, MS; Lori Flores, RN; Sanjay Dhar, MD; Elizabeth Chmelo, MS; James Lovato, MS; L. Douglas Case, PhD; Rita N. Bakhru, MD, MS; Aarti Sarwal, MD; Selina M. Parry, PhD; Pamela Campbell, RN; Arthur Mote; Chris Winkelman, PhD; Robert D. Hite, MD; Barbara Nicklas, PhD; Arjun Chatterjee, MD, MS; Michael P. Young, MD

IMPORTANCE Physical rehabilitation in the intensive care unit (ICU) may improve the outcomes of patients with acute respiratory failure.

OBJECTIVE To compare standardized rehabilitation therapy (SRT) to usual ICU care in acute respiratory failure.

DESIGN, SETTING, AND PARTICIPANTS Single-center, randomized clinical trial at Wake Forest Baptist Medical Center, North Carolina. Adult patients (mean age, 58 years; women, 55%) admitted to the ICU with acute respiratory failure requiring mechanical ventilation were randomized to SRT (n=150) or usual care (n=150) from October 2009 through May 2014 with 6-month follow-up.

INTERVENTIONS Patients in the SRT group received daily therapy until hospital discharge, consisting of passive range of motion, physical therapy, and progressive resistance exercise. The usual care group received weekday physical therapy when ordered by the clinical team. For the SRT group, the median (interquartile range [IQR]) days of delivery of therapy were 8.0 (5.0-14.0) for passive range of motion, 5.0 (3.0-8.0) for physical therapy, and 3.0 (1.0-5.0) for progressive resistance exercise. The median days of delivery of physical therapy for the usual care group was 1.0 (IQR, 0.0-8.0).

MAIN OUTCOMES AND MEASURES Both groups underwent assessor-blinded testing at ICU and hospital discharge and at 2, 4, and 6 months. The primary outcome was hospital length of stay (LOS). Secondary outcomes were ventilator days, ICU days, Short Physical Performance Battery (SPPB) score, 36-item Short-Form Health Surveys (SF-36) for physical and mental health and physical function scale score, Functional Performance Inventory (FPI) score, Mini-Mental State Examination (MMSE) score, and handgrip and handheld dynamometer strength.

RESULTS Among 300 randomized patients, the median hospital LOS was 10 days (IQR, 6 to 17) for the SRT group and 10 days (IQR, 7 to 16) for the usual care group (median difference, 0 [95% CI, -1.5 to 3], $P = .41$). There was no difference in duration of ventilation or ICU care. There was no effect at 6 months for handgrip (difference, 2.0 kg [95% CI, -1.3 to 5.4], $P = .23$) and handheld dynamometer strength (difference, 0.4 lb [95% CI, -2.9 to 3.7], $P = .82$), SF-36 physical health score (difference, 3.4 [95% CI, -0.02 to 7.0], $P = .05$), SF-36 mental health score (difference, 2.4 [95% CI, -1.2 to 6.0], $P = .19$), or MMSE score (difference, 0.6 [95% CI, -0.2 to 1.4], $P = .17$). There were higher scores at 6 months in the SRT group for the SPPB score (difference, 1.1 [95% CI, 0.04 to 2.1], $P = .04$), SF-36 physical function scale score (difference, 12.2 [95% CI, 3.8 to 20.7], $P = .001$), and the FPI score (difference, 0.2 [95% CI, 0.04 to 0.4], $P = .02$).

CONCLUSIONS AND RELEVANCE Among patients hospitalized with acute respiratory failure, SRT compared with usual care did not decrease hospital LOS.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00976833

JAMA. 2016;315(24):2694-2702. doi:10.1001/jama.2016.7201

← Editorial page 2671

← Related article page 2703

+ Supplemental content at jama.com

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Peter E. Morris, MD, Division of Pulmonary, Critical Care and Sleep Medicine, University of Kentucky, 740 S Limestone, L-543, Kentucky Clinic, Lexington, KY 40536 (peter.morris@uky.edu).

Section Editor: Derek C. Angus, MD, MPH, Associate Editor, JAMA (angusdc@upmc.edu).

Acute respiratory failure is associated with high mortality and prolonged morbidity, with impaired physical function for many survivors. Interventions directed at attenuating the profound muscle wasting in patients with acute respiratory failure are patient-centered.¹ Such therapies designed to improve patient-reported weakness and impaired physical function could reduce recovery time in patients with acute respiratory failure. As well, such interventions could potentially improve long-term health-related quality of life, which for this population is commonly below normal following hospital discharge.²⁻⁴ Reports have suggested that a rehabilitation program, delivered by an intensive care unit (ICU) rehabilitation team, may be associated with reduced length of stay (LOS) and improved physical function, although findings to the contrary exist as well.⁵⁻¹¹ This randomized clinical trial was designed to test the hypothesis that early delivery of a standardized, multifaceted ICU and hospital rehabilitation program would decrease hospital LOS and improve physical function for patients with acute respiratory failure.

Methods

Study Design and Oversight

The institutional review board at the enrolling hospital approved the clinical trial. Written consent was obtained from participants or their legally authorized representative. Race and ethnicity data were collected per the National Institutes of Health reporting policy and determined by patient or surrogate self-reporting based on fixed categories. The study was a single-center, assessor-blinded, randomized investigation with 2 groups: standardized rehabilitation therapy (SRT) and usual care conducted at Wake Forest Baptist Medical Center in Winston Salem, North Carolina. The SRT group received rehabilitation therapy 7 days a week, from enrollment through hospital discharge, including days spent in a regular floor bed. The usual care group received routine care as dictated by the patient's attending physician from Monday through Friday. SRT ended at hospital discharge. Both groups underwent testing at ICU and hospital discharge, and at 2, 4, and 6 months after enrollment by research personnel blinded to the randomization assignment.

Study Patients

Inclusion criteria were admission to a medical ICU, being 18 years or older, mechanical ventilation via endotracheal tube or noninvasive ventilation by mask, and an arterial oxygen partial pressure to fractional inspired oxygen ($\text{PaO}_2/\text{FIO}_2$) ratio less than 300. Exclusion criteria were inability to walk without assistance prior to the acute ICU illness (use of cane or walkers were not exclusions), cognitive impairment prior to acute ICU illness described by surrogate, as nonverbal, acute stroke, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) greater than 50, neuromuscular disease impairing weaning from mechanical ventilation, acute hip fracture, unstable cervical spine or pathologic fracture, mechanically ventilated more than 80 hours or current hospitalization (including transferring hospital) more than 7 days, or

others for do not intubate on admission, considered to be moribund by the primary attending, or enrolled in another research study.

Randomization

Patients were randomly assigned, using a computer-generated variably sized approach (in block sizes of 2, 4, 6, or 8), to SRT or usual care.

Study Measurements and Procedures

The SRT protocol contained 3 exercise types: passive range of motion, physical therapy, and progressive resistance exercises, and was administered by a rehabilitation team for a total of 3 separate sessions every day of hospitalization for 7 days per week.⁶ The team comprised a physical therapist, an ICU nurse, and a nursing assistant. Passive range of motion included 5 repetitions for each upper and lower extremity joint. Physical therapy included bed mobility, transfer training, and balance training. These exercises included transfer to the edge of the bed; safe transfers to and from bed, chair, or commode; seated balance activities; pre-gait standing activities (forward and lateral weight shifting, marching in place); and ambulation. Progressive resistance exercise included dorsiflexion, knee flexion and extension, hip flexion, elbow flexion and extension, and shoulder flexion. Resistance was added through the use of elastic resistance bands (TheraBand, Hygienic Corporation). Both the physical therapy and resistance training targeted lower extremity functional tasks and activities of daily living (for further details of the implementation of SRT modalities, see trial protocol in [Supplement 1](#)).

The patient's level of consciousness determined suitability for receipt of physical therapy or progressive resistance exercise, and ability to complete the exercises.¹² When patients were unconscious, the 3 sessions consisted of passive range of motion. Once the patient gained consciousness, physical therapy and progressive resistance exercise were introduced. Being free from mechanical ventilation was not a prerequisite for any of the exercise sessions. The usual care group received no rehabilitation per treatment protocol. Physical therapy could be ordered as part of routine care, but only Monday through Friday.

Study Outcomes

The primary end point was hospital LOS, defined to include hospital calendar days (or any portion of a calendar day) at the enrolling hospital and at any long-term acute care facility to which the patient was directly transferred. Research team members were not involved in the decision for hospital discharge (ie, the primary end point). Hospital floor medical teams separate from the ICU teams were responsible for hospital discharge. Study days were days of hospitalization following randomization.

Secondary outcomes included physical function and health-related quality of life. Physical function was measured using both performance-based and self-report instruments. Performance-based tests included the Short Performance Physical Battery (SPPB) and muscular strength as determined by handgrip dynamometer (Jamar, Lafayette Instrument) and from a hand-held dynamometer (microFET2, Hoggan Health Industries).

SPPB scores were derived from performance of 3 components: a 4-meter walk, chair sit-to-stand, and a balance test.¹³ Muscular strength of the shoulder flexors, elbow flexors and extensors, hip flexors, knee flexors and extensors, and ankle dorsiflexors was measured thrice bilaterally. The maximum values from each test were averaged to produce a single composite value of muscular strength. Self-report tests consisted of the short form Functional Performance Inventory (FPI),¹⁴ and the physical functioning scale of the medical outcomes study 36-Item Short Form Health Survey (SF-36 PFS).¹⁵ Health-related quality of life was measured using the SF-36 physical health survey (SF-36 PHS) and mental health survey (SF-36 MHS) component summary scores and Mini-Mental State Examination (MMSE) score. Measures of physical function were obtained at ICU discharge, hospital discharge and 2, 4, and 6 months after enrollment. Health-related quality-of-life measures were obtained at hospital discharge and 2, 4, and 6 months after enrollment. The SF-36 and the FPI were not administered at ICU discharge as they were not considered relevant to the patient at this time. The FPI was not administered at hospital discharge for the same reason. Post-hoc outcomes were the number of days that patients were alive and breathing without ventilator assistance (ventilator-free days), ICU-free and hospital-free days to day 28.¹⁶ Adverse events were quantified by deaths, device removals, reintubations, and patient falls during physical therapy (for classification of adverse events, see trial protocol in Supplement 1).

Statistical Analysis

The initial plan was to accrue 326 participants to provide 80% power for detecting a 30% decrease in the median hospital LOS at the 5% 2-sided level of significance assuming an exponential LOS distribution, a 20% in-hospital mortality, and that 5% of the remaining patients would withdraw prior to discharge, resulting in 247 discharges.

The projected 30% decrease in the primary outcome (hospital LOS) is slightly larger than the decrease observed in a previous quality improvement report,⁶ but, as described below, there was a greater expected effect with the current intervention due to a greater potential for exposure to the SRT after ICU discharge in this study. An important feature of the previous quality improvement report was that the intervention was delivered only in the ICU. Hence, the effect reported was for intervention delivered only in the ICU, not after ICU discharge. Despite the intervention being limited to the ICU, there was a 24% adjusted reduction in hospital LOS (hazard ratio [HR], 1.31). The current study design delivered the SRT from ICU admission through hospital discharge and due to the addition of progressive resistance exercise, there was a much greater clinical effect expected.

The in-hospital mortality and dropout were both less than expected and enrollment was stopped after 300 patients were accrued, 257 of whom were discharged.

Kaplan-Meier methods were used to estimate hospital LOS, and a log-rank test was used to assess the difference between groups. Patients who died or dropped out before discharge were censored in the analyses. A Cox proportional hazards regression model was used to estimate the hazard ratio. Because there

were concerns that censoring (particularly from deaths) might be informative, 2 extremes were considered—assuming all the patients who died would have been discharged on the day of their death and that all the patients who died would have had the longest hospital stays. The same assumptions were made regarding the patients who simply withdrew even though there is less reason to believe that those would be informative. Analyses were repeated under the possible combinations of assumptions regarding the deaths and dropouts. For each of these scenarios, unadjusted analyses and analyses adjusted for those variables related to in-hospital death (sex, mean arterial pressure, partial pressure of carbon dioxide [PaCO_2], PaO_2 , FIO_2 , and Acute Physiology and Chronic Health Evaluation [APACHE] score) were conducted. χ^2 Tests were used to assess group differences in-hospital and after discharge deaths and Wilcoxon rank-sum tests were used to assess group differences in ventilator-free and ICU-free days. Median differences of medians and 95% confidence intervals were generated using bootstrap methods with 10 000 bootstrap samples. The significance threshold was $P < .05$ for each outcome and testing was 2-sided. Due to the lack of adjustment for multiple testing, the secondary analyses should be considered exploratory. The statistical software was SAS (SAS Institute), version 9.4.

For secondary outcomes assessed longitudinally, a mixed-effects repeated measures analysis of variance model was used to assess differences in these measures between the SRT and usual care groups at discharge, 2, 4, and 6 months. An unstructured covariance matrix was used to account for the within-patient correlation over time.


χ^2 and Wilcoxon rank-sum tests were used to assess differences in patient characteristics between those patients with and without missing data. Those characteristics predictive of missingness (due either to death or withdrawal) were included in the longitudinal mixed models. These covariates included age, race, BMI, ICU diagnosis, mean arterial pressure, PaCO_2 , $\text{PaO}_2/\text{FIO}_2$ ratio, APACHE score, and number of comorbid conditions. Multiple imputation was also used to assess the sensitivity of the results to the missing at random assumption. To be conservative, it was assumed that all dropouts would follow a pattern similar to that seen among the control patients (usual care group).¹⁷ One hundred data sets were generated using the SAS MI procedure (SAS Institute), a repeated measures mixed model was run on each data set, and results were combined using the SAS MIANALYZE procedure (SAS Institute).¹⁸ Covariates related to missing data were included in the imputations and in the adjusted mixed models. The imputation analyses included all patients.

Results

Study Patients

From October 2009 through November 2014, 4804 patients with acute respiratory failure were screened, 618 were eligible, and 300 were randomized (Figure 1) and followed up for up to 6 months after the enrollment date (last follow-up visit, November 2014). There were 84 patients in the SRT group (56%) vs 81 in the usual care group (54%) who com-

Figure 1. Flow of Patients Through the Study of Rehabilitation for Patients With Acute Respiratory Failure



BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); SRT, standardized rehabilitation therapy.

^a Patients could have more than 1 exclusion. Either patient or surrogate may have provided or refused consent.

^b One patient after completing intervention was deemed technically ineligible; the patient was consented and randomized to SRT but was found to be unable to walk prior to study and included in the primary analysis.

pleted the 6-month follow-up. There were no clinically important differences in baseline characteristics between the 2 groups (Table 1).

Study Interventions

For the SRT group, the median days to first therapy exercise were 1 (interquartile range [IQR], 0-2) for passive range of motion, 3 (IQR, 1-6) for physical therapy, and 4 (IQR, 2-7) for progressive resistance exercise, whereas the days to first therapy exercise for the usual care group were 7 (IQR, 4-10). The mean percentage of study days SRT patients received therapy was 87.1% (SD, 18.4%) for passive range of motion, 54.6% (SD, 27.2%) for physical therapy, and 35.7% (SD, 23.0%) for progressive resistance exercise. The mean percentage of study days usual care patients received physical therapy was 11.7% (SD, 14.5%). For the SRT group, the median days of delivery of therapy per participant was 8.0 (IQR, 5.0-14.0) for passive range of motion, 5.0 (IQR, 3.0-8.0) for physical therapy, and 3.0 (IQR, 1.0-5.0) for progressive resistance exercise. The median days of delivery of physical therapy for the usual care group was 1.0 (IQR, 0.0-8.0).

Primary Outcomes and Hospital Data

The median hospital LOS was 10 days (IQR, 6 to 17) for the SRT group and 10 days (IQR, 7 to 16) for the usual care group (median difference, 0 [95% CI, -1.5 to 3], $P = .41$) (Table 2 and Figure 2). The estimated hazard ratio (SRT to usual care) was 1.11 (95% CI, 0.86 to 1.45). There were no differences between groups in the number of days taking a vasopressor, Confusion Assessment Method for the ICU-positive days, days receiving intravenous sedative drugs, days with restraint, or net ICU-related fluid balance (Table 2). Sensitivity analyses were performed for the primary outcome as described in the methods. The assumptions regarding the censored observations made little difference to the outcome, with a median 9 to 10 days in the SRT group and 10 days in the usual care group across the various scenarios. Hazard ratios ranged from 1.03 to 1.11 (with SRT patients more likely to get discharged) unadjusted for covariates and from 1.06 to 1.18 after adjusting for those covariates predictive of in-hospital death. The difference between groups was nonsignificant in each sensitivity analysis ($P > .22$).

Table 1. Baseline Characteristics for Patients With Acute Respiratory Failure Receiving Standard Rehabilitation Therapy (SRT) vs Usual Care

	No. (%)		
	All (N = 300)	SRT (n = 150)	Usual Care (n = 150)
Age, mean (SD), y	56 (15)	55 (17)	58 (14)
Sex			
Women	166 (55.3)	84 (56.0)	82 (54.7)
Men	134 (44.7)	66 (44.0)	68 (45.3)
Race/ethnicity			
Hispanic or Latino	4 (1.3)	2 (1.3)	2 (1.3)
Black or African American	64 (21.3)	33 (22.0)	31 (20.7)
White	232 (77.3)	115 (76.7)	117 (78.0)
APACHE III score, mean (SD) ^a	76 (27)	76 (26)	75 (27)
Intensive care unit diagnosis			
Coma	5 (1.7)	1 (0.7)	4 (2.7)
Acute respiratory failure			
Without chronic lung disease	203 (67.7)	98 (65.3)	105 (70.0)
With chronic lung disease	92 (30.7)	51 (34.0)	41 (27.3)
Home oxygen	59 (19.7)	32 (21.3)	27 (18.0)
Dialysis prehospital	24 (8.0)	13 (8.7)	11 (7.3)
Mean arterial pressure, mean (SD), mm Hg	75.1 (22.4)	76.2 (22.3)	74.1 (22.5)
PaCO ₂ , mean (SD), mm Hg	44.1 (17.2)	44.4 (18.2)	43.8 (16.2)
Pao ₂ /Fio ₂ ratio, mean (SD)	178.6 (83.8)	182.0 (81.2)	175.1 (86.4)
Noninvasive ventilation	21 (7.0)	11 (7.3)	10 (6.7)
Shock	69 (23.0)	36 (24.0)	33 (22.0)

Abbreviation: APACHE, Acute Physiology and Chronic Health Evaluation.

^a APACHE III¹⁹ score ranged from 0 to 299. A higher score indicates an increased risk of mortality.

Secondary Outcomes

Performance-based and self-reported measures of physical function are shown in Table 3. None of the scores were significantly different between groups at either ICU or hospital discharge. Strength values from handgrip and from handheld dynamometer did not differ between treatment groups at any of the measurement time points. The SPPB, SF-36 PFS, and FPI scores were not significantly different between groups at 2 or 4 months. However, each of these outcomes was significantly greater in the SRT group at the 6-month follow-up visit. At hospital discharge there was no difference in the proportion of SRT patients who could perform the 4-meter walk vs usual care (71% vs 61%, $P = .15$). By 6 months, those percentages had increased to 96% for the SRT group vs 88% for the usual care group ($P = .037$).

Health-related quality-of-life measures are shown in Table 3. SF-36 PHS, SF-36 MHS, and MMSE scores were not significantly different between groups at any time points.

The estimated intervention effects when analyses were repeated using multiple imputation assuming conservatively that all dropouts followed the pattern seen in the control group were decreased by approximately 40%. For example, the intervention effects at 6 months decreased from 1.06 to 0.60 for SPPB, 12.2 to 7.3 for SF-36 PFS, 0.21 to 0.12 for FPI, and 3.39 to 2.12 for SF-36 PHS. Only the SF-36 PFS effect remained significant ($P = .04$); the other P values were .11 for FPI, .16 for SPPB, and .19 for SF-36 PHS.

Outpatient physical therapy was not an intervention per treatment protocol; there was no difference in the number of patients (self-reported at each follow-up visit) who received

outpatient or home physical therapy between hospital discharge and the 6-month follow-up visit (41 SRT patients vs 39 usual care patients, $P = .69$).

There were no differences in discharge destination between the SRT group and the usual care group (ie, home, long-term acute care, skilled nursing, or rehabilitation hospital) (eTable 1 in Supplement 2). Similarly, there were no differences between groups in post-index hospitalization readmissions or discharge emergency department visits without a hospital readmission. The percentage of each study group discharged from the hospital who were alive and hospital readmission-free at 6 months was 48.7% for the SRT group and 44.7% for the usual care group ($P = .63$). Post-hoc analyses indicated that the median number of ventilator-free days was 24 for both groups (median difference, 0 [95% CI, -2 to 1], $P = .59$), and the median number of ICU-free days was 19 for both groups (median difference, 0 [95% CI, -1.5 to 3], $P = .83$).

Missing Data

Death during the hospital stay was less than expected (12% observed vs 20% expected) as was death during the follow-up period (12% observed vs 15% expected). Dropout during the hospital stay was also less than expected (2% observed vs 5% expected). However, dropout during follow-up was greater than expected (24% observed from discharge to 6-month follow-up vs 10% expected). Neither dropout nor mortality differed between the study groups. Characteristics of those with and without missing data and those who did and did not drop out are shown in eTable 2 and eTable 3 in Supplement 2. Characteristics were fairly well balanced for those patients who re-

Table 2. Outcomes for Standard Rehabilitation Therapy (SRT) vs Usual Care Among Patients With Acute Respiratory Failure

	Median (IQR)		Median Difference (95% CI)	P Value
	SRT (n = 150)	Usual Care (n = 150)		
Hospital days (primary outcome)	10.0 (6 to 17)	10.0 (7 to 16)	0 (−1.5 to 3)	.41 ^a
Free days ^b				
Hospital	18 (7 to 22)	18 (9 to 21)	0 (−3 to 1.5)	.96 ^c
Ventilator	24 (19 to 26)	24 (20 to 26)	0 (−2 to 1)	.59 ^c
Intensive care unit				
Days	7.5 (4 to 14)	8.0 (4 to 13)	0 (−2.5 to 2)	.68 ^a
Free days ^b	19 (8 to 23)	19 (12 to 24)	0 (−1.5 to 3)	.83 ^c
Intravenous sedation ^d				
Days	2 (1 to 5)	2 (0 to 4)	0 (0 to 1.5)	.11
Days, %	30.8 (0.8 to 54.1)	27.1 (0 to 50.0)	3.8 (−5.5 to 14.5)	.14
Vasopressor				
Days	0 (0 to 1)	0 (0 to 1)	0 (0 to 0)	>.99
Days, %	0 (0 to 6.7)	0 (0 to 8.3)	0 (0 to 0)	.90
ICU fluid balance, cc	−68.5 (−806.6 to 664.4)	−148.8 (−766.8 to 520.2)	53.9 (−270.3 to 281.2)	.89
Restraint				
Days	1 (0 to 4)	1 (0 to 3)	0 (−1 to 1)	.71
Days, %	25.0 (0 to 55.8)	25.0 (0 to 50.0)	0 (−16.7 to 12.3)	.82
CAM-ICU ^e				
Negative				
Days	2 (0 to 3)	2 (0 to 4)	0 (−1 to 1)	.88
Days, %	24.5 (0 to 44.8)	20 (0 to 50.0)	3.4 (−5.0 to 10.1)	.91
Positive				
Days	0 (0 to 1)	0 (0 to 1)	0 (0 to 0)	.77
Days, %	0 (0 to 12.5)	0 (0 to 9.1)	0 (0 to 0)	.71
RASS score of 4 or 5 ^f				
Days	1 (0 to 4)	1 (0 to 3)	0 (−1 to 1)	.43
Days, %	14.6 (0 to 36.9)	14.3 (0 to 33.3)	1.8 (−6.7 to 10.5)	.71

Abbreviations: CAM-ICU, Confusion Assessment Method for the Intensive Care Unit²⁰; IQR, interquartile range; RASS, Richmond Agitation Sedation Scale.²¹

^a Log-rank test.

^b All free days are based on 28 days.

^c Wilcoxon ranked sum.

^d Intravenous sedation days were defined as any part of a day a continuous intravenous delivery occurred of fentanyl, morphine, midazolam, lorazepam, propofol or dexmedetomidine. Percentage of restraint days, CAM-ICU-positive days, CAM-ICU-negative days, and RASS score 4 or 5 days represent the percentage of ventilator days.

^e CAM-ICU scores were positive or negative for delirium.

^f RASS score ranged from −3 (moderate sedation) to 4 (combative).


mained in the study. Of the patients included in the follow-up analyses, APACHE III scores were lower (better) in the usual care group.

Adverse Events

There were no differences in adverse event reporting between study groups (eTable 4 in Supplement 2). The majority of adverse events captured were not specifically related to SRT delivery. Specific to SRT, there were no untoward events such as endotracheal tube removal, vascular access device removal, patient near-fall or fall, or cardiac arrest. However, there was an episode of asymptomatic bradycardia during a progressive resistance exercise session lasting less than 1 minute, with the patient completing the session afterwards.

Discussion

In this randomized, assessor-blinded study of SRT vs usual care for patients with acute respiratory failure, there was no difference in hospital LOS between groups. Similarly, SRT did not affect ventilator-free days or ICU-free days. Functional-related and health-related quality-of-life outcomes were similar for the 2 study groups at hospital discharge.

Figure 2. Length of Stay for Patients With Acute Respiratory Failure Receiving SRT vs Usual Care

SRT indicates standardized rehabilitation therapy. Time zero indicates time of randomization.

The amount of exercise delivered and performed while in-hospital was substantially different between SRT and usual care groups. The usual care group received physical therapy for only

Table 3. Secondary Outcomes: Physical Function Measures and Health-Related Quality of Life for Patients With Acute Respiratory Failure, by Group

Measurement	Group	ICU Discharge			Hospital Discharge			2-Month Follow-up			4-Month Follow-up			6-Month Follow-up		
		Least Square Means (95% CI)	No. of Patients Providing Data	No. of Patients	Least Square Means (95% CI)	No. of Patients Providing Data	No. of Patients	Least Square Means (95% CI)	No. of Patients Providing Data	No. of Patients	Least Square Means (95% CI)	No. of Patients Providing Data	No. of Patients	Least Square Means (95% CI)	No. of Patients Providing Data	
Physical Function																
Short Physical Performance Battery score ^a	SRT	1.6 (1.0 to 2.2)	86	106	4.7 (4.0 to 5.4)	88	88	8.7 (8.1 to 9.4)	88	88	8.9 (8.2 to 9.6)	88	88	9.0 (8.3 to 9.7)	84	
	Usual care	1.9 (1.3 to 2.4)	98	98	4.7 (4.0 to 5.4)	98	98	7.8 (7.1 to 8.5)	76	76	8.0 (7.2 to 8.7)	79	79	8.0 (7.2 to 8.7)	81	
	Difference	-0.3 (-1.1 to 0.5)			-0.01 (-1.0 to 0.9)			0.9 (-0.01 to 1.9)			1.0 (-0.03 to 1.9)			1.1 (0.04 to 2.1)		
	P Value ^b	.46			.97			.05			.06			.04		
Dynamometer strength, lb	SRT	20.3 (17.9 to 22.8)	67	100	23.7 (21.6 to 25.8)	84	84	28.5 (26.3 to 30.8)	84	85	28.8 (26.5 to 31.0)	85	85	31.1 (28.8 to 33.4)	78	
	Usual care	22.8 (20.4 to 25.1)	77	86	23.9 (21.7 to 26.2)	86	73	28.0 (25.6 to 30.4)	73	75	29.6 (27.2 to 31.9)	75	75	30.8 (28.4 to 33.1)	77	
	Difference	-2.4 (-5.8 to 1.0)			-0.2 (-3.3 to 2.9)			0.5 (-2.8 to 3.8)			-0.8 (-4.1 to 2.5)			0.4 (-2.9 to 3.7)		
	P Value ^b	.16			.90			.76			.63			.82		
Handgrip strength, kg	SRT	20.0 (17.8 to 22.3)	78	104	22.6 (20.6 to 24.6)	104	87	27.2 (25.1 to 29.2)	87	87	29.0 (26.8 to 31.2)	87	87	29.3 (26.9 to 31.6)	83	
	Usual care	20.9 (18.7 to 23.1)	88	94	24.3 (22.2 to 26.4)	94	74	26.0 (23.8 to 28.1)	74	77	27.2 (24.9 to 29.4)	77	77	27.2 (24.8 to 29.6)	81	
	Difference	-0.8 (-4.0 to 2.3)			-1.7 (-4.6 to 1.2)			1.2 (-1.8 to 4.2)			1.8 (-1.3 to 5.0)			2.0 (-1.3 to 5.4)		
	P Value ^b	.60			.25			.43			.25			.23		
SF-36 physical functioning scale score ^c	SRT			108	38.4 (33.2 to 43.7)	108	89	47.4 (41.8 to 53.1)	89	86	52.2 (46.7 to 57.7)	86	86	55.9 (50.0 to 61.7)	82	
	Usual care			100	38.3 (32.8 to 43.8)	100	77	43.0 (37.0 to 49.0)	77	77	47.2 (41.4 to 53.0)	77	77	43.6 (37.5 to 49.7)	79	
	Difference				0.1 (-7.6 to 7.8)			4.4 (-3.9 to 12.7)			5.0 (-3.0 to 13.0)			12.2 (3.8 to 20.7)		
	P Value ^b				.97			.29			.22			.001		
Functional Performance Inventory score ^d	SRT						2.0 (1.9 to 2.1)	89	89	2.2 (2.1 to 2.3)	86	86	2.2 (2.1 to 2.4)	83		
	Usual care						2.0 (1.9 to 2.1)	75	75	2.1 (1.9 to 2.2)	77	77	2.0 (1.9 to 2.2)	79		
	Difference						-0.03 (-0.2 to 0.1)			0.1 (-0.03 to 0.3)			0.2 (0.04 to 0.4)			
	P Value ^b						.74			.11			.02			
Health-Related Quality of Life																
SF-36 physical health summary score ^e	SRT			108	30.2 (28.4 to 32.1)	108	89	33.4 (31.4 to 35.5)	89	86	36.0 (33.8 to 38.2)	86	86	36.9 (34.6 to 39.3)	82	
	Usual care			100	30.3 (28.4 to 32.2)	100	77	32.2 (31.0 to 34.4)	77	77	33.7 (31.4 to 36.0)	77	77	33.5 (31.1 to 36.0)	79	
	Difference				-0.1 (-2.8 to 2.7)			1.2 (-1.8 to 4.3)			2.3 (-0.9 to 5.5)			3.4 (-0.02 to 7.0)		
	P Value ^b				.96			.43			.16			.05		
SF-36 mental health summary score ^e	SRT			108	43.6 (41.5 to 45.7)	108	89	46.3 (43.8 to 48.8)	89	86	47.8 (45.5 to 50.2)	86	86	48.8 (46.3 to 51.3)	82	
	Usual care			100	43.3 (41.2 to 45.5)	100	77	46.2 (43.6 to 48.8)	77	77	47.7 (45.2 to 50.1)	77	77	46.4 (43.8 to 49.0)	79	
	Difference				0.3 (-2.7 to 3.3)			0.1 (-3.5 to 3.7)			0.2 (-3.2 to 3.6)			2.4 (-1.2 to 6.0)		
	P Value ^b				.86			.96			.91			.19		
Mini-Mental State Examination score ^c	SRT			114	25.4 (24.7 to 26.1)	114	88	26.7 (25.9 to 27.5)	88	86	27.6 (27.0 to 28.2)	86	86	27.6 (27.0 to 28.2)	84	
	Usual care			104	25.1 (24.3 to 25.8)	104	75	26.8 (26.0 to 27.7)	75	78	27.2 (26.5 to 27.8)	78	78	27.0 (26.4 to 27.6)	81	
	Difference				0.3 (-0.7 to 1.3)			-0.1 (-1.3 to 1.1)			0.4 (-0.5 to 1.3)			0.6 (-0.2 to 1.4)		
	P Value ^b				.55			.86			.37			.17		

Abbreviations: ICU, intensive care unit; SRT, standardized rehabilitation therapy.

Metric conversion factor: To convert pounds to kilograms, divide by 0.45.

^a Short Physical Performance Battery minimal clinically important difference is 1 unit.^{13,22}

^b Treatment effect at the given visit.

^c SF-36 physical functioning scale and Mini-Mental State Examination were performed on hospital discharge and following appointments.

^d Functional Performance Inventory was performed starting at first outpatient follow-up. Self-report mechanisms use higher scores to indicate greater levels of functioning.

^e SF-36 mental and physical health summary minimal clinically important differences are 3 to 5 units.¹⁵

12% of the study days and never received resistance training. In contrast, in the SRT group, passive range of motion occurred in 87% of study days, physical therapy in 55%, and progressive resistance exercise in 36%, with no significant hospital-based outcome differences observed. The volume of exercise delivered to SRT patients was delivered with 7 days per week availability. This structure may differ from the current practice in many US ICUs.²³ Others have also reported on the real-life delivery of ICU-related exercise being less than expected by ICU practitioners.²⁴⁻²⁶ In view of these data, it is unclear what ICU exercise dose is required to affect outcomes by hospital discharge for patients with acute respiratory failure.

Following discharge, handgrip strength or strength measured by handheld dynamometer and health-related quality of life remained similar for the 2 groups. But from these exploratory analyses, the physical function measures (SPPB, SF-36 PFS, and FPI) were different at 6 months. The separation of the 2 groups' self-reported and objectively measured functional data over 6 months of follow-up contrasts with the lack of difference for hospital-centered outcomes.

These findings from the exploratory analyses may highlight the emerging role of placing long-term outcomes within critical care clinical trial design not only as a secondary outcome, but possibly as the primary outcome.²⁷⁻³⁰ In view of the SPPB, SF-36 PFS, and FPI data at 6 months, the SRT group demonstrated a potential signal of improvement compared with the usual care group that was not evident at hospital discharge. It is not obvious what aspect of the SRT may have accounted for the differences at 6 months; however, both the physical therapy and the progressive resistance training emphasized lower extremity function. The exposure in the hospital may have inclined the SRT group to have greater movement while in the outpatient setting.

The findings from this study contrast with the outcomes of the study by Schweickert and colleagues,⁷ which found greater improvements in activities of daily living at hospital discharge in an early ICU rehabilitation group than the control group, but no difference in hospital LOS either. The study by Walsh and colleagues³¹ reported post-ICU hospital-based

rehabilitation, including increased physical and nutritional therapy, did not improve physical recovery or quality-of-life scores at 3 months after enrollment. Outpatient-focused patient-level functional outcome differences were not detected in the study by Denehy and colleagues,⁹ which linked an inpatient rehabilitation exercise repertoire with outpatient exercise instructions for a cohort of patients who were critically ill. Moss and colleagues³² found that an intensive physical therapy program compared with a standard physical therapy program in which the intensive program continued for up to 28 days from randomization, including the outpatient setting, did not improve long-term physical functional performance at 6 months.

Study limitations include a higher than expected drop-out (lost to follow-up and withdrawals, 24%) following hospital discharge. Also, there was no intervention following discharge; future study of ICU-initiated rehabilitation programs may need to include a bridge program of some outpatient exercise content to further optimize outcomes.^{31,33}

Another potential limitation was that there was no explicit sedation protocol; the lack of a sedation protocol may have allowed patients in both groups to spend unnecessary days either unconscious or with a positive Confusion Assessment Method score.^{34,35} Given that the intervention group had approximately 30% of ventilator days associated with intravenous continuous drip medications, and patients were unarousable on 15% of ventilator days, sedation may have been a barrier to receipt of early exercise. These data indicate the challenge of delivering a treatment modality requiring a conscious, engaged patient. Other modalities have been proposed such as functional electrical stimulation for the unconscious patient.³⁶ Additionally, multiple tests may have led to a spurious significant finding for the functional tests.

Conclusions

Among patients hospitalized with acute respiratory failure, SRT compared with usual care did not decrease hospital LOS.

ARTICLE INFORMATION

Author Affiliations: Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington (Morris); Department of Health and Exercise Science, Wake Forest University, Winston Salem, North Carolina (Berry, Hauser); Section on Pulmonary, Critical Care, Allergy, and Immunologic Disease, Wake Forest University, Winston Salem, North Carolina (Files, Thompson, Flores, Dhar, Chmelo, Bakhru, Campbell, Mote, Chatterjee, Young); Department of Biostatistical Sciences, Wake Forest University, Winston Salem, North Carolina (Lovato, Case); Department of Neurology, Wake Forest University, Winston Salem, North Carolina (Sarwal); Physiotherapy Department, University of Melbourne, Melbourne, Australia (Parry); Francis Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio (Winkelman); Department of Critical Care, Respiratory Institute, Cleveland Clinic, Cleveland,

Ohio (Hite); Division of Geriatrics, Wake Forest University, Winston Salem, North Carolina (Nicklas).

Author Contributions: Dr Morris had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Morris, Berry, Hauser, Dhar, Chmelo, Case, Hite, Nicklas.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Morris, Berry, Thompson, Hauser, Case, Parry, Mote, Chatterjee.

Critical revision of the manuscript for important intellectual content: Berry, Files, Flores, Dhar, Chmelo, Lovato, Case, Bakhru, Sarwal, Parry, Campbell, Winkelman, Hite, Nicklas, Chatterjee, Young.

Statistical analysis: Lovato, Case, Chatterjee.

Obtained funding: Morris, Berry, Hite.

Administrative, technical, or material support: Morris, Berry, Files, Thompson, Hauser, Flores,

Dhar, Bakhru, Sarwal, Parry, Mote, Nicklas, Chatterjee.

Study supervision: Morris, Berry, Files, Thompson, Dhar, Chatterjee.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bakhru reports consulting for Hill Rom Company. Dr Chatterjee reports part-time employment with the US Department of Veterans Affairs and the US Navy. No other disclosures were reported.

Funding/Support: This work was supported by the National Institutes of Health, National Institute of Nursing Research, and National Heart, Lung, and Blood Institute.

Role of the Funder/Sponsor: The sponsors did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The opinions contained in this article are those of the authors and do not represent the opinions of the US Department of Veterans Affairs nor the US Department of Defense.

Previous Presentation: Selected data in this article were presented at the Australian Physiotherapy Association meeting; October 3-6, 2015; Brisbane, Australia.

REFERENCES

- Hermans G, Van Mechelen H, Clerckx B, et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness: a cohort study and propensity-matched analysis. *Am J Respir Crit Care Med.* 2014;190(4):410-420.
- Herridge MS, Tansey CM, Matté A, et al; Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med.* 2011;364(14):1293-1304.
- Fan E, Dowdy DW, Colantuoni E, et al. Physical complications in acute lung injury survivors: a 2-year longitudinal prospective study. *Crit Care Med.* 2014;42(4):849-859.
- Pandharipande PP, Girard TD, Jackson JC, et al; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. *N Engl J Med.* 2013;369(14):1306-1316.
- Bailey P, Thomsen GE, Spuhler VJ, et al. Early activity is feasible and safe in respiratory failure patients. *Crit Care Med.* 2007;35(1):139-145.
- Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. *Crit Care Med.* 2008;36(8):2238-2243.
- Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomized controlled trial. *Lancet.* 2009;373(9678):1874-1882.
- Burtin C, Clerckx B, Robbeets C, et al. Early exercise in critically ill patients enhances short-term functional recovery. *Crit Care Med.* 2009;37(9):2499-2505.
- Denehy L, Skinner EH, Edbrooke L, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months of follow-up. *Crit Care.* 2013;17(4):R156.
- Puthucherry ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness [published correction appears in *JAMA*. 2014;311(6):625]. *JAMA.* 2013;310(15):1591-1600.
- Needham DM, Korupolu R, Zanni JM, et al. Early physical medicine and rehabilitation for patients with acute respiratory failure: a quality improvement project. *Arch Phys Med Rehabil.* 2010;91(4):536-542.
- De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA.* 2002;288(22):2859-2867.
- Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol.* 1994;49(2):M85-M94.
- Leidy NK, Hamilton A, Becker K. Assessing patient report of function: content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD). *Int J Chron Obstruct Pulmon Dis.* 2012;7:543-554.
- Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. *Ann Med.* 2001;33(5):350-357.
- The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med.* 2000;342(18):1301-1308.
- Ratitch B, O'Kelly M. Implementation of pattern-mixture models using standard SAS/STAT procedures. <http://pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SPO4.pdf>. Accessed May 26, 2016.
- SAS Institute. *SAS/STAT 9.3 SAS User's Guide*. Cary, NC: SAS Institute; 2011.
- Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. *Chest.* 1991;100(6):1619-1636.
- Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med.* 2001;29(7):1370-1379.
- Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med.* 2002;166(10):1338-1344.
- Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc.* 2006;54(5):743-749.
- Hodgin KE, Nordon-Craft A, McFann KK, Mealer ML, Moss M. Physical therapy utilization in intensive care units: results from a national survey. *Crit Care Med.* 2009;37(2):561-566.
- Nydahl P, Ruhl AP, Bartoszek G, et al. Early mobilization of mechanically ventilated patients: a 1-day point-prevalence study in Germany. *Crit Care Med.* 2014;42(5):1178-1186.
- Hodgson C, Bellomo R, Berney S, et al; TEAM Study Investigators. Early mobilization and recovery in mechanically ventilated patients in the ICU: a binational, multicentre, prospective cohort study. *Crit Care.* 2015;19:81.
- Berney SC, Harrold M, Webb SA, et al. Intensive care unit mobility practices in Australia and New Zealand: a point prevalence study. *Crit Care Resusc.* 2013;15(4):260-265.
- Hudson LD, Lee CM. Neuromuscular sequelae of critical illness. *N Engl J Med.* 2003;348(8):745-747.
- Elliott D, Davidson JE, Harvey MA, et al. Exploring the scope of postintensive care syndrome therapy and care: engagement of noncritical care providers and survivors in a second stakeholders meeting. *Crit Care Med.* 2014;42(12):2518-2526.
- Iwashyna TJ. Trajectories of recovery and dysfunction after acute illness, with implications for clinical trial design. *Am J Respir Crit Care Med.* 2012;186(4):302-304.
- Cooper DJ, Rosenfeld JV, Murray L, et al; DECRA Trial Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Decompressive craniectomy in diffuse traumatic brain injury. *N Engl J Med.* 2011;364(16):1493-1502.
- Walsh TS, Salisbury LG, Merriweather JL, et al; RECOVER Investigators. Increased hospital-based physical rehabilitation and information provision after intensive care unit discharge: the RECOVER randomized clinical trial. *JAMA Intern Med.* 2015;175(6):901-910.
- Moss M, Nordon-Craft A, Malone D, et al. A Randomized Trial of an Intensive Physical Therapy Program for Patients with Acute Respiratory Failure. *Am J Respir Crit Care Med.* 2016;193(10):1101-1110.
- Brummel NE, Girard TD, Ely EW, et al. Feasibility and safety of early combined cognitive and physical therapy for critically ill medical and surgical patients: the Activity and Cognitive Therapy in ICU (ACT-ICU) trial. *Intensive Care Med.* 2014;40(3):370-379.
- Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med.* 2000;342(20):1471-1477.
- Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med.* 2013;41(1):263-306.
- Parry SM, Berney S, Koopman R, et al. Early rehabilitation in critical care (eRICC): functional electrical stimulation with cycling protocol for a randomised controlled trial. *BMJ Open.* 2012;2(5):e001891.

Point Prevalence Study of Mobilization Practices for Acute Respiratory Failure Patients in the United States

Sarah Elizabeth Jolley, MD, MSc¹; Marc Moss, MD²; Dale M. Needham, MD, PhD³; Ellen Caldwell, MS⁴; Peter E. Morris, MD⁵; Russell R. Miller, MD, MPH⁶; Nancy Ringwood, RN, BSN⁷; Megan Anders, MD⁸; Karen K. Koo, MD⁹; Stephanie E. Gundel, RD, CD⁴; Selina M. Parry, PhD¹⁰; Catherine L. Hough, MD, MSc⁴; on behalf of the Acute Respiratory Distress Syndrome Network Investigators

¹Section of Pulmonary and Critical Care Medicine, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA.

²Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Colorado, Boulder, CO.

³Division of Pulmonary and Critical Care Medicine, Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD.

⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA.

⁵Division of Pulmonary and Critical Care Medicine, Department of Medicine, Wake Forest University, Winston-Salem, NC.

⁶Division of Pulmonary and Critical Care Medicine, Department of Medicine, Intermountain Hospital/University of Utah, Salt Lake City, UT.

⁷Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA.

⁸Department of Anesthesiology, University of Maryland, College Park, MD.

⁹Swedish Medical Center, Seattle, WA.

¹⁰Department of Physiotherapy, University of Melbourne, Melbourne, VIC, Australia.

Drs. Jolley, Moss, Needham, Morris, Miller, Koo, and Hough contributed to study concept and design, data acquisition and interpretation, and study conduct. Dr. Jolley wrote the first version of the article. Drs. Ringwood, Anders, Gundel, and Parry contributed to data acquisition and study conduct. Ms. Caldwell performed the data analysis and contributed to data interpretation. All authors contributed to revision of the article, and all authors approved the final article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (<http://journals.lww.com/ccmjournal>).

Supported, in part, by grant 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health which funds the Louisiana Clinical and Translational Science Center (to Dr. Jolley). Dr. Jolley, Dr. Moss, Dr. Needham, Ms. Caldwell, Dr. Morris, Dr. Miller, Dr. Ringwood, Dr. Koo, Dr. Gundel, Dr. Parry, and Dr. Hough on this study received funding for this work (NIH/non-industry). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Dr. Jolley received funding from Lyric Pharmaceuticals, received support for article research from the National Institutes of Health (NIH), and disclosed other support (Travel for protocol development meeting for Lyric Pharmaceuticals for

Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

DOI: 10.1097/CCM.0000000000002058

work unrelated to this article). Dr. Moss received support for article research from the NIH. Dr. Needham received support for article research from the NIH. His institution received funding from the National Heart, Lung, and Blood Institute (NHLBI). Dr. Ringwood received support for article research from the NIH. Her institution received funding from the NHLBI. Dr. Anders disclosed other support. Dr. Hough received support for article research from the NIH. Her institution received funding from the NIH NHLBI. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: sjolle@lsuhsc.edu

Objective: Early mobility in mechanically ventilated patients is safe, feasible, and may improve functional outcomes. We sought to determine the prevalence and character of mobility for ICU patients with acute respiratory failure in U.S. ICUs.

Design: Two-day cross-sectional point prevalence study.

Setting: Forty-two ICUs across 17 Acute Respiratory Distress Syndrome Network hospitals.

Patients: Adult patients (≥ 18 yr old) with acute respiratory failure requiring mechanical ventilation.

Interventions: We defined therapist-provided mobility as the proportion of patient-days with any physical or occupational therapy-provided mobility event. Hierarchical regression models were used to identify predictors of out-of-bed mobility.

Measurements and Main Results: Hospitals contributed 770 patient-days of data. Patients received mechanical ventilation on 73% of the patient-days mostly ($n = 432$; 56%) ventilated via an endotracheal tube. The prevalence of physical therapy/occupational therapy-provided mobility was 32% (247/770), with a significantly higher proportion of nonmechanically ventilated patients receiving physical therapy/occupational therapy (48% vs 26%; $p \leq 0.001$). Patients on mechanical ventilation achieved out-of-bed mobility on 16% ($n = 90$) of the total patient-days. Physical therapy/occupational therapy involvement in mobility events was strongly associated with progression to out-of-bed mobility (odds ratio, 29.1; CI, 15.1–56.3; $p \leq 0.001$). Presence of an endotracheal tube and delirium were negatively associated with out-of-bed mobility.

Conclusions: In a cohort of hospitals caring for acute respiratory failure patients, physical therapy/occupational therapy–provided mobility was infrequent. Physical therapy/occupational therapy involvement in mobility was strongly predictive of achieving greater mobility levels in patients with respiratory failure. Mechanical ventilation via an endotracheal tube and delirium are important predictors of mobility progression. (*Crit Care Med* 2016; XX:00–00)

Key Words: early mobility; intensive care unit acquired weakness; intensive care unit rehabilitation

Acute respiratory failure survivors experience long-term morbidity after critical illness (1–3). Physical functional impairments reduce overall health-related quality of life for survivors increasing healthcare utilization and unemployment (1, 4, 5). Early physical and occupational therapy (PT/OT) for respiratory failure patients improves functional outcomes at hospital discharge (6–10).

PT/OT utilization in the ICU remains low. One-day point prevalence studies in Germany and Australia/New Zealand report most patients on mechanical ventilation (MV) do not receive out-of-bed mobility in the ICU. Across 116 German hospitals, ICU administrators reported only 8% of ventilated patients received out-of-bed mobility (11) and across 38 Australian/New Zealand ICUs, only 3% achieved sitting at the edge of the bed with none standing, transferring to chair or walking (12).

Across the United States, the prevalence of ICU mobility, as part of routine clinical care, remains unknown. As the literature supporting mobility expands, estimates of current clinical practice are necessary to inform implementation efforts. Our aim was to report the prevalence of PT/OT-provided mobility in respiratory failure patients, define the type and frequency of ICU mobility and identify factors associated with mobility progression.

METHODS

We performed a 2-day cross-sectional point prevalence study across acute respiratory distress syndrome (ARDS) Network (ARDSNet) hospitals. Hospitals were invited to participate in the two study dates, 3 weeks apart (Wednesday, January 15, 2014, and Tuesday, February 4, 2014); participation was voluntary. Each ARDSNet site contributed data from at least one hospital. In total, 17 (39%) of 44 hospitals participated, with two hospitals completing estimates outside of the prespecified study dates. Each site obtained institutional review board approval with waiver of consent for the observational study.

Patient Selection

We included adult (≥ 18 yr old) patients diagnosed with acute respiratory failure (requiring > 48 hr of MV) at any point during their ICU stay physically located in the ICU at noon. MV was defined as any ventilation via an endotracheal tube (ETT), tracheostomy tube, or noninvasive positive pressure ventilation. Since we aimed to capture any patient who would have met criteria for early mobility in earlier trials (9), ongoing MV use was not required for eligibility.

Mobility Events

A therapist-provided mobility event was defined as receipt of at least one PT/OT-provided event on a study day. Mobility events not performed by a therapist were also recorded such that we ascertained any mobility event performed on a patient with respiratory failure on either study date. Events were reported by PT/OT and/or nursing using bedside real-time event recording on custom-made case report forms. Events were subsequently confirmed verbally between study coordinators and the bedside nurse and categorized using a published hierarchical ICU mobility scale (13). Standardized forms allowed for free text of any activities performed outside of the standardized mobility scale. Study coordinators received training on the activity case report forms prior to the study date. Mobility events performed by multiple providers (e.g., PT/OT and bedside nursing) were reported on a single form. Out-of-bed mobility was defined as sitting at the edge of the bed, standing, standing and moving to chair, marching in place, or walking. Adverse outcomes that occurred during a mobility session were coded using international consensus adverse outcome guidelines (14).

Patient Demographics/Clinical Characteristics

Trained abstractors abstracted physiologic data from the medical record with values reported as that closest to 8 AM on the study date. Study coordinators interviewed bedside nurses to obtain reasons mobility did not occur and invasive catheter data. Potential medical exclusions were defined using published ICU mobility safety guidelines (15).

ICU Characteristics

Administrators for participating ICUs were contacted after study completion to participate in a survey regarding ICU characteristics. Medical directors ($n = 25$) and nurse managers ($n = 15$) participated with at least one hospital administrator from each of the 17 hospitals contributing data.

Statistical Analysis

The prevalence of therapist-provided mobility was estimated as the proportion of patient-days with any therapist-provided mobility event during the two study days. Patients contributing data to both study dates were included in the prevalence estimates and logistic regression models the large time interval between events. Hierarchical multivariable logistic regression models with random effects for ICU site were used to evaluate predictors of therapist-provided therapy and out-of-bed mobility. Predictors of interest based on steering committee expert consensus included: MV, vasoactive agent use, coma (Richmond Agitation Sedation Score [RASS] of -4 or -5), agitation (RASS, ≥ 2), intravascular catheter location, sedative infusion use, weight, and delirium (Confusion Assessment Method-ICU [CAM-ICU] positive/negative). Missing CAM-ICU status was categorized as CAM-ICU unable to assess and included as a unique category. All statistical analyses were completed using SAS software (SAS Corporation, Cary, NC).

RESULTS

ICU Characteristics

A total of 42 ICUs from 17 hospitals participated. Most ICUs were medical (51%), trauma (12%), or mixed medical/surgical (9%) ICUs. ICUs averaged 23 beds in the unit (SD, 7) with six ICUs (SD, 3) in the hospital. Most hospitals reported physician-initiated mobility (73%) and more than half (53%) reported use of a mobility protocol.

Patient Baseline Characteristics

A total of 744 unique patients contributed 770 patient-days of data after exclusion of 17 patients (2.1%) who were ineligible due to ICU discharge prior to noon (**Fig. S1**, Supplemental Digital Content 1, <http://links.lww.com/CCM/C222>; **legend**, Supplemental Digital Content 3, <http://links.lww.com/CCM/C224>). Twenty-six patients (4%) were in the ICU on both study

dates. Patients were mostly middle aged (mean age, 56 yr; SD, 16), men (60%), and most were ambulatory (80%) and independent with activities of daily living (78%) prior to admission. Most (62%) received care in a medical ICU (**Table 1**).

Study Day Characteristics

Patients received MV, via an ETT (ETT: $n = 432$, 56%; tracheostomy: $n = 81$, 10%) or noninvasively ($n = 47$, 6%) on 72% ($n = 566$) of the patient-days with a mean FiO_2 of 0.43 (SD, 0.14) and positive end-expiratory pressure (PEEP) of 7 (SD, 3) cm H_2O . On 6% ($n = 48$) of the patient-days, patients were receiving more than 60% FiO_2 , and on 7% ($n = 56$) of the patient-days, they received more than 10 cm H_2O of PEEP. Patients received more than 60% FiO_2 and more than 10 PEEP on 3% ($n = 21$) of the patient-days. Patients were on an infusion of a vasoactive medications on 21% of the ($n = 174$) patient-days and received hemodialysis on 15%

TABLE 1. Patient Characteristics Stratified by Presence of Mechanical Ventilation

	All ($n = 770$)	Mechanical Ventilation ($n = 559$) ^a	No Mechanical Ventilation ($n = 211$) ^a	<i>p</i>
Age, mean $\pm$ SD ^b	56 $\pm$ 16	56 $\pm$ 16	57 $\pm$ 16	0.69
Male, <i>n</i> (%)	465 (60)	330 (59)	135 (64)	0.24
ICU category ^c				
Medical	477 (62)	374 (67)	103 (49)	< 0.001
Surgical	238 (31)	158 (28)	80 (38)	
Neurologic	55 (7)	27 (5)	28 (13)	
Reason for admission ^d				
ARDS	140 (18)	117 (21)	23 (11)	0.002
Chronic obstructive pulmonary disease exacerbation	33 (4)	23 (4)	10 (5)	0.86
Sepsis from lung source	96 (13)	88 (16)	8 (4)	< 0.001
Sepsis from other source	103 (13)	79 (14)	24 (11)	0.38
Hemorrhage	39 (5)	23 (4)	16 (8)	0.08
Trauma	59 (8)	37 (7)	22 (10)	0.11
Malignancy	18 (2)	10 (2)	8 (4)	0.17
ARDS diagnosis during hospitalization	279 (36)	237 (43)	42 (20)	< 0.001
Ambulatory at baseline	533 (80)	379 (80)	154 (82)	0.46
Independent with activities of daily living at baseline	505 (78)	359 (78)	146 (80)	0.55
Mode of ventilation ^e , <i>n</i> (%)				
Endotracheal tube	432 (56)	432 (77)	NA ^e	
Tracheostomy tube	81 (11)	81 (15)	NA	
Noninvasive positive pressure	46 (6)	46 (8)	NA	
Ventilation (noninvasive positive pressure ventilation)				
FiO_2 , mean $\pm$ SD		0.43 $\pm$ 0.14	NA	
Positive end-expiratory pressure (cm H_2O), mean $\pm$ SD		7 $\pm$ 3	NA	

(Continued)

TABLE 1. (Continued). Patient Characteristics Stratified by Presence of Mechanical Ventilation

	All (n = 770)	Mechanical Ventilation (n = 559) ^a	No Mechanical Ventilation (n = 211) ^a	p
Vasoactive infusions ^d , n (%)				
Vasopressors	159 (21)	149 (27)	10 (5)	< 0.001
Inotropes	15 (2)	12 (2)	3 (1)	0.72
Neither	606 (79)	408 (73)	198 (94)	< 0.001
Body mass index, n (%)				
≤ 18.5	32 (5)	22 (5)	10 (6)	0.82
18.5–25	156 (25)	113 (25)	43 (25)	
25–30	174 (28)	124 (27)	50 (29)	
> 30	264 (42)	197 (43)	67 (39)	
Weight (kg), mean ± sd	89 ± 31	90 ± 33	87 ± 26	0.10
Hemodialysis, n (%)	112 (15)	96 (18)	16 (8)	0.001
Type of hemodialysis, n (%)				
Continuous	63 (8)	55 (10)	8 (4)	0.003
Intermittent	49 (7)	41 (8)	8 (4)	
RASS, median (IQR)	0 (–2 to 0)	–1 (–3 to 0)	0 (–1 to 0)	< 0.001
Agitation (RASS ≥ +2) ^f , n (%)	31 (4)	28 (5)	3 (1)	0.06
Delirium, n (%)				
Coma (RASS –4 or –5)	94 (12)	84 (15)	10 (5)	< 0.001
Delirium (CAM-ICU positive)	113 (15)	89 (16)	24 (11)	
No delirium (CAM-ICU negative)	219 (28)	139 (25)	80 (38)	
No category	344 (45)	247 (44)	97 (46)	
Sedative/analgesia infusions, n (%)				
Benzodiazepines	65 (8)	64 (11)	1 (0.5)	< 0.001
Dexmedetomidine	63 (8)	49 (9)	14 (7)	0.42
Propofol	162 (21)	158 (28)	4 (2)	< 0.001
Opioids	215 (28)	200 (36)	15 (7)	< 0.001
None	430 (56)	251 (45)	179 (85)	< 0.001
Sedative/analgesia boluses, n (%)				
Benzodiazepines	116 (15)	105 (19)	11 (5)	< 0.001
Opioids	288 (37)	215 (39)	73 (35)	0.37
None	456 (59)	320 (57)	136 (65)	0.08
CAM-ICU score, n (%)				
Negative	221 (46)	141 (39)	80 (68)	< 0.001
Positive	116 (24)	92 (26)	24 (21)	
Unable to perform	140 (29)	127 (35)	13 (11)	
Antipsychotic use, n (%)	119 (16)	94 (17)	25 (12)	0.12

(Continued)

TABLE 1. (Continued). Patient Characteristics Stratified by Presence of Mechanical Ventilation

	All (<i>n</i> = 770)	Mechanical Ventilation (<i>n</i> = 559) ^a	No Mechanical Ventilation (<i>n</i> = 211) ^a	<i>p</i>
Intravascular catheters, <i>n</i> (%)				
Central venous catheter				< 0.001
Femoral	32 (4)	28 (5)	4 (2)	
All other sites	451 (60)	349 (65)	102 (49)	
None	263 (35)	162 (30)	101 (49)	
Hemodialysis				
Femoral	19 (2)	17 (3)	2 (1)	0.87
All other sites	92 (12)	78 (14)	14 (7)	
None	659 (86)	464 (83)	195 (92)	
Arterial				< 0.001
Femoral	36 (5)	31 (6)	5 (2)	
All other sites	267 (35)	214 (39)	53 (26)	
None	451 (60)	302 (55)	149 (72)	
Chest tube	107 (14)	76 (14)	31 (15)	0.81
Intraaortic balloon pump	4 (0.5)	4 (0.7)	0 (0)	0.50
Left ventricular assist device	8 (1)	5 (0.9)	3 (1)	0.82
Foley catheter	606 (80)	470 (86)	136 (66)	< 0.001
Rectal tube	134 (18)	111 (20)	23 (11)	0.005
Potential contraindication to mobility ^a	112 (15)	99 (18)	13 (6)	< 0.001

ARDS = acute respiratory distress syndrome, CAM-ICU = Confusion Assessment Method-ICU, IQR = interquartile range, NA = not applicable, RASS = Richmond Agitation Sedation Scale.

^aMissing data: acute respiratory distress syndrome diagnosis (*n* = 3 of mechanically ventilated patients, 0.4%), ambulation status (*n* = 24 of nonmechanically ventilated, 112 of mechanically ventilated, 18%), activity of daily living (*n* = 29 of nonmechanically ventilated, 97 of mechanically ventilated, 16%). *Fio₂*, *n* = 14 (2.5%), positive end-expiratory pressure *n* = 31 (5.5%), body mass index *n* = 144 (18.7%), weight *n* = 55 (7.1%), hemodialysis *n* = 22 (2.9%), Richmond Agitation Sedation Scale (RASS) *n* = 130 (16.9%), Confusion Assessment Method-ICU *n* = 293 (38.1%), antipsychotics *n* = 10 (1.3%), central venous catheter *n* = 24 (3.1%), arterial line *n* = 16 (2%), chest tube *n* = 19 (2.4%), intraaortic balloon pump *n* = 19 (2.4%), left ventricular assist device *n* = 19 (2.4%), Foley *n* = 16 (2%), rectal tube *n* = 16 (2%).

^bAge > 90 coded as 90 for calculation (*n* = 2 of mechanically ventilated, 0.3% of total cohort).

^cICU types categorized as medical include: medical *n* = 389 (51%), medical/cardiac *n* = 2 (0.3%), cardiac *n* = 15 (2%), medical/surgical *n* = 71 (9%) ICU types categorized as surgical: surgical *n* = 69 (9%), cardiac surgery *n* = 29 (4%), burns *n* = 19 (3%), trauma *n* = 91 (12%), cardiothoracic *n* = 28 (4%), pediatric *n* = 2 (0.3%), ICU types categorized as neurologic include: neurologic *n* = 55 (7%).

^dCategories are not mutually exclusive.

^eHigh frequency oscillatory ventilation use, *n* = 1 (0.1%), extracorporeal membrane oxygenation use, *n* = 8 (1%).

^fCategorized as RASS ≥ +2, RASS < +2, no RASS reported.

^gContraindications defined per previously published mobility safety recommendations: Hodgson et al (15).

(*n* = 112) of the patient-days (63 [8%] continuous, 49 [7%] intermittent). Sedative infusions were used on 37% of the patient-days (*n* = 294) with most patients receiving propofol infusion (propofol: 21%, *n* = 163; benzodiazepines: 9%, *n* = 68; dexmedetomidine: 8%, *n* = 63). The median RASS score was 0 (interquartile range [IQR], −2 to 0), with 15% (*n* = 97) of patient-days spent in a “coma” (i.e., RASS −4 or −5). Median RASS scores differed significantly between mechanically (median, −1; IQR, −3 to 0) and nonmechanically ventilated (median, 0; IQR, −1 to 0) patients (*p* < 0.001). Delirium was present on 22% (*n* = 113) of the patient-days although 281 patient-days (36%) had no CAM-ICU assessment documented (Table 2). A potential safety exclusion was

documented on 15% of the patient-days (*n* = 112) and more frequently reported in mechanically ventilated patients (18% mechanically ventilated vs 6% nonmechanically ventilated; *p* ≤ 0.001). The most commonly reported exclusions were medical instability (21%), coma (12%), and weakness (11%) (Fig. 1).

Therapist-Provided Mobility

Patients were treated by PT/OT on 247 patient-days for an overall prevalence of therapist-provided ICU mobility of 32% (247/770). Nonmechanically ventilated patients were significantly more likely to receive PT/OT than mechanically ventilated patients (48% vs 26%; *p* < 0.001).

TABLE 2. Predictors of Out-of-Bed Mobility for Patients Ventilated Via an Endotracheal Tube

Clinical Predictor	All (<i>n</i> = 432)	Out-of-Bed Mobility (<i>n</i> = 45)	In-Bed Mobility (<i>n</i> = 387)	<i>p</i>
Vasoactive agent (vasopressor and/or inotrope), <i>n</i> (%)	140 (32)	8 (18)	132 (34)	0.04
Benzodiazepine or propofol infusion, <i>n</i> (%)	191 (44)	15 (33)	176 (46)	0.16
Bolus benzodiazepine use, <i>n</i> (%)	86 (20)	4 (9)	82 (21)	0.08
Opioid infusion, <i>n</i> (%)	173 (40)	17 (38)	156 (40)	0.87
Bolus opioid use, <i>n</i> (%)	176 (41)	15 (33)	161 (42)	0.37
Intravascular catheter (no catheter referent), <i>n</i> (%)				
Internal jugular, femoral, subclavian, or radial catheter	316 (73)	27 (60)	289 (75)	0.04
Unknown	7 (2)	0 (0)	7 (2)	
Delirium assessment (no delirium CAM-ICU negative referent), <i>n</i> (%)				
Delirium (CAM-ICU positive)	73 (17)	7 (16)	66 (17)	0.05
Unable to assess (CAM-unable)	114 (26)	5 (11)	109 (28)	
Delirium status unknown (CAM-missing)	148 (34)	18 (40)	130 (34)	
Agitation assessment (no agitation RASS < 2 referent), <i>n</i> (%)				
Agitation (RASS ≥ 2)	21 (5)	0 (0)	21 (5)	0.001
Agitation status unknown (RASS missing)	49 (11)	12 (27)	37 (10)	
Physical or occupational therapy involvement, <i>n</i> (%)	88 (20)	38 (84)	50 (13)	< 0.001
ICU type (medical ICU referent), <i>n</i> (%)				
Neurologic ICU	22 (5)	3 (7)	19 (5)	0.57
Surgical ICU	121 (28)	15 (33)	106 (27)	
Ambulatory prior to admission (not ambulatory referent), <i>n</i> (%)				
Ambulatory	310 (72)	35 (78)	275 (71)	0.33
Unknown	60 (14)	3 (7)	57 (15)	
Age (yr), mean (sd)	56 (16)	59 (15)	55 (16)	0.11
Weight (kg), mean (sd)	90 (31)	78 (24)	92 (32)	0.001

CAM-ICU = Confusion Assessment Method-ICU, RASS = Richmond Agitation Sedation Scale.

All Mobility Events

Patients received mobility events from any provider type on 65% (*n* = 501) of the total 770 patient-days. Most events were provided by nursing (68%) with most activity sessions involving one provider (44%). Two care providers were involved in 15% (*n* = 118) of sessions, whereas few sessions (*n* = 47; 6%) involved more than two providers. Providers involved in activity sessions included: physical, occupational, respiratory and speech therapists or technicians, nurses, physicians, hospital assistants, advanced care providers, and patient family.

Activity delivered in the absence of PT/OT was of lower intensity (*p* < 0.001 compared with PT/OT-delivered activity) with 21% (*n* = 43/247) of patients achieving out-of-bed mobility without PT/OT involvement. Most mobility events for patients on MV (208/336; 62%) consisted of passive activities (range of motion or passively moved to chair). Mechanically ventilated patients usually participated in a single session/day (median, 1; IQR, 0–2).

Nonmechanically ventilated patients received mobility on 80% (*n* = 168) of the patient-days, with a median one session per day (IQR, 1–2). Significantly more mobility sessions occurred in non-mechanically versus mechanically ventilated patients (*p* < 0.001).

Out-of-Bed Mobility in Patients on MV

Mechanically ventilated patients achieved out-of-bed mobility on 16% (*n* = 90) of the patient-days progressing to sitting at the edge of the bed on 6% (*n* = 31), standing on 2% (*n* = 13), transferring to chair from standing on 3% (*n* = 18), marching in place on 1% (*n* = 5), and walking on 4% (*n* = 23) of patient-days (Fig. 2). Nonmechanically ventilated patients were significantly more likely than mechanically ventilated patients to achieve out-of-bed mobility (56% vs 16%; *p* < 0.001) (Fig. S2, Supplemental Digital Content 2, <http://links.lww.com/CCM/C223>; legend, Supplemental Digital Content 3, <http://links.lww.com/CCM/C224>).




Figure 1. Reasons for no reported mobility. Presence of coma and medical instability were the most commonly reported reasons for lack of ICU mobility.

Adverse Events

Seven potential safety events occurred in 807 mobility events (0.9%). Potential safety events included new arrhythmias ($n = 3$), oxygen desaturations ($< 85\%$ for > 3 min; $n = 2$), hypotension (mean arterial pressure, < 55 mm Hg for > 3 min; $n = 1$) and an endotracheal dislodgement ($n = 1$). Six (86%) of these events occurred in patients receiving lower level mobility, with four events occurring during range of motion and two during passive chair transfer. The single ETT dislodgement occurred during an in-bed passive range of motion session.

92 kg receiving only in-bed mobility, $p = 0.001$), it was not independently associated in the adjusted model (OR, 0.99; 95% CI, 0.98–1.00).

Among patients receiving MV via an ETT, PT/OT involvement remained highly associated with out-of-bed mobility (Table 4; adjusted OR, 138.4; 95% CI, 29.8–643.5; $p < 0.001$). Presence of delirium or coma remained negatively associated with out-of-bed mobility (delirium present: adjusted OR, 0.13, 95% CI, 0.02–0.75; coma adjusted: OR, 0.05, 95% CI, 0.01–0.40; $p = 0.02$).




Figure 2. Highest level of mobility achieved by patients on the study dates. Patients on mechanical ventilation were significantly less likely to achieve out-of-bed mobility compared with patients off mechanical ventilation ($p < 0.001$). Reported categories are mutually exclusive. OT = occupational therapy, PT = physical therapy.

Predictors of ICU Mobility

PT/OT involvement was strongly associated with progression to out-of-bed mobility (Table 3; adjusted odds ratio [OR], 26.1; 95% CI, 14.2–47.9; $p < 0.001$). Use of MV via an endotracheal or tracheostomy tube was negatively associated with achieving out-of-bed mobility (ETT: adjusted OR, 0.10, 95% CI, 0.05–0.20; tracheostomy tube: adjusted OR, 0.20, 95% CI, 0.09–0.47; $p < 0.001$) as was presence of delirium (adjusted OR, 0.41; 95% CI, 0.18–0.93; $p = 0.003$). Although weight was significantly associated with out-of-bed mobility in bivariate analysis (mean weight 78 kg in patients achieving out-of-bed mobility vs

Hospital-Level Variance

There was significant variation in clinical practice between participating hospitals. PT/OT participation in mobility varied with a minimum participation of 7% ($n = 3/45$) to a maximum of 74% ($n = 31/42$) in some study hospitals ($p = 0.03$). Achievement of out-of-bed mobility for mechanically ventilated patients varied between 4% ($n = 2/45$) and 67% ($n = 26/39$) between study hospitals ($p = 0.04$). Significant between-hospital differences remained after adjustment for patient demographics with between-hospital differences accounting for 66% (SE, 0.31) of the overall model variance.

TABLE 3. Hierarchical Multivariable Logistic Regression Model of Factors Associated With Out-of-Bed Mobility^a

Clinical Predictor	OR	95% CI	p
Age (yr)	1.02	1.00–1.03	0.07
ICU type (medical ICU referent)			
Neurologic ICU	0.45	0.14–1.44	0.11
Surgical ICU	1.50	0.72–3.09	
Ambulatory prior to admission (not ambulatory referent)			
Ambulatory	1.58	0.75–3.34	0.20
Unknown	0.80	0.29–2.18	
Route of MV (no MV referent)			
Endotracheal tube	0.10	0.05–0.20	< 0.001
Tracheostomy tube	0.21	0.08–0.52	
Noninvasive positive pressure ventilation	0.56	0.19–1.74	
Vasoactive agent (vasopressor and/or inotrope)	0.59	0.23–1.49	0.24
Weight (kg) ^b	0.99	0.98–1.00	0.02
Agitation assessment (no agitation RASS < 2 referent)			
Agitation (RASS ≥ 2)	0.15	0.01–1.87	0.06
Agitation status unknown (RASS missing)	2.13	0.92–4.90	
Bolus opioid use	0.84	0.43–1.62	0.57
Bolus benzodiazepine use	0.73	0.28–1.91	0.49
Delirium assessment (no delirium CAM-ICU negative referent)			
Delirium (CAM-ICU positive)	0.37	0.15–0.89	
Unable to assess (CAM-unable)	0.15	0.05–0.44	
Delirium status unknown (CAM-missing)	0.35	0.17–0.74	0.003
Intravascular catheter (no catheter referent)			
Internal jugular, femoral, subclavian, or radial catheter	0.58	0.31–1.07	0.07
Unknown	0.17	0.02–1.34	
Physical therapy or occupational therapy involvement	29.1	15.1–56.3	< 0.001

CAM-ICU = Confusion Assessment Method-ICU, MV = mechanical ventilation, OR = odds ratio, RASS = Richmond Agitation Sedation Scale.

^aOut-of-bed mobility: sitting at the edge of the bed, standing, marching in place, and walking.

^bMissing weight data (*n* = 55 patients, 715/770 patients included in final model).

DISCUSSION

These data represent the first U.S. estimates of mobility in routine clinical practice for respiratory failure patients. Patients with respiratory failure received therapist-provided mobility on 32% of patient-days. Out-of-bed mobility was delivered on a minority of patient-days to mechanically ventilated patients (16%), with patients rarely progressing to walking (4% of patient-days). PT/OT involvement was strongly associated with mobility progression, whereas MV via an ETT and delirium were negatively associated.

Our prevalence estimates of ICU mobility are similar to prior estimates from Germany and Australia/New Zealand (11, 12). Unlike the prior studies, we included two prevalence dates on

different weekdays to account for daily variation in rehabilitation care to better estimate prevalence. Additionally, we captured actual rather than reported mobility. Despite reducing the chance of misclassification with two separate study dates, our estimates remained low. Our estimates were comparable to those reported in Germany where only 24% of mechanically ventilated patients received mobility with 8% mobilizing out of bed (11) and Australia/New Zealand where no (0/391) patients on MV sat out of bed, stood or ambulated (12).

The low levels of mobility observed highlight discrepancies between reported and actual delivery in clinical practice. Survey of ICU administrators across Michigan reported ICU mobility use in 39% of their mechanically ventilated patients

TABLE 4. Hierarchical Multivariable Logistic Regression Model of Factors Associated With Out-of-Bed Mobility Restricted to Patients on Mechanical Ventilation Via an Endotracheal Tube^a

Clinical Predictor	OR	95% CI	p
Age (yr)	1.05	1.01–1.09	0.02
ICU type (medical ICU referent)			
Surgical ICU	3.96	0.90–17.38	0.15
Neurologic ICU	0.74	0.08–6.93	
Ambulatory prior to admission (not ambulatory referent)			
Ambulatory	2.44	0.52–11.68	0.41
Unknown	1.03	0.11–9.62	
Vasoactive agent (vasopressor and/or inotrope)	0.59	0.16–2.19	0.43
Weight (kg) ^b	0.97	0.95–1.00	0.02
Delirium assessment (no delirium CAM-ICU negative referent)			
Delirium (CAM-ICU positive)	0.13	0.02–0.75	0.02
Unable to assess (CAM-unable)	0.05	0.01–0.40	
Delirium status unknown (CAM-missing)	0.21	0.04–1.09	
Benzodiazepine or propofol infusion	1.43	0.39–5.25	0.59
Bolus benzodiazepine use	0.40	0.08–1.98	0.26
Opioid infusion	2.01	0.58–7.03	0.27
Bolus opioid use	0.37	0.10–1.39	0.14
Physical therapy or occupational therapy involvement	138.4	29.75–643.49	< 0.001

CAM-ICU = Confusion Assessment Method-ICU, OR = odds ratio.

^aOut-of-bed mobility: sitting at the edge of the bed, standing, marching in place, and walking.^bMissing weight data (*n* = 29 patients, 403/432 patients included in final model).

with 10% achieving ambulatory status upon ICU discharge (16). Similarly, survey of nurse managers across Washington state reported 47% of mechanically ventilated patients received out-of-bed mobility (17). Our results suggest that reported and actual delivery of mobility may differ substantially and further studies are needed to understand reasons for this discordance.

Presence of PT/OT involvement was strongly associated with mobility in our cohort. Quality improvement studies suggest dedicated ICU therapists enhance access to mobility (11, 18–20). Stepwise progression through a therapy-driven ICU mobility protocol resulted in increased mobility uptake with length of stay and mortality reductions in a cohort of respiratory failure patients (7, 8). Randomized early involvement of PT/OT for mechanically ventilated patients improved functional independence at discharge (9, 21). Our findings support earlier evidence suggesting therapist involvement may increase mobility progression.

Although PT/OT involvement was strongly associated with out-of-bed activity, it was not required. Nursing providers provided most of the activity events in our cohort either alone or in conjunction with PT/OT and patients achieved out-of-bed mobility in the absence of PT/OT on 21% of patient-days. Nursing staff may represent an expandable workforce for ICU mobility delivery; however, little is known regarding their

potential role in optimal mobility delivery. Similarly, it is not known if the most common activities provided by nurses—passive movement in and out of bed—should be considered as part of “ICU mobility” at all. Furthermore, the large PT/OT association may reflect institutional commitment to mobility rather than staffing. If PT/OT involvement is a surrogate marker of institutional mobility commitment, then increasing PT/OT staffing alone may be insufficient to increase mobility intensity. This disconnect between culture and staffing may explain why prevalence across countries remains low (11, 12) despite institution of high-intensity staffing models. Qualitative studies indicate that factors beyond staff including degree of buy-in, perceived workload, and rehabilitation training are important for implementation and sustainability of an ICU rehab program (22). Studies are needed to better understand the influence of these organizational factors in ICU mobility uptake.

MV via an ETT and delirium were important negative predictors of out-of-bed mobility in our study. Our results support prior notions that MV via an ETT is an important barrier to ICU mobility despite multiple safety studies. Studies report adverse event rates of less than 1% in respiratory failure patients (6, 14, 23). Our adverse event rate was 0.9%; most of the events were minor. The single ETT dislodgment occurred in a patient

receiving passive range of motion. Yet, intubation remains a frequently reported reason for mobility avoidance. Data are needed regarding methods for overcoming potential barriers between perceived and actual safety of mobility in intubated patients.

Delirium in critically ill patients represents an increasingly recognized predictor of worse outcomes after critical illness (24). Despite this, many patients in our cohort received no CAM-ICU delirium screening on our study dates. This lack of routine CAM-ICU administration is not unique to our cohort. Across Michigan ICUs, only 31% of ICUs performed routine delirium assessments for mechanically ventilated patients (16). Report of delirium assessment as part of standard practice was predictive of report of higher level activity (OR, 15.6 vs 4.5; $p = 0.006$ delirium vs no delirium assessment) in the Michigan cohort (16). Similarly, in our cohort, patients who underwent screening were frequently delirious, and delirium was predictive of failure to achieve higher mobility levels. While early mobility is associated with reductions in delirium duration (9), there is little data guiding mobilization practices specifically in delirious patients.

Predictably, we found significant between-hospital variation around mobility utilization. Studies identify site as a significant predictor of ICU mobility (23, 25). Between-hospital variation explained 66% of our overall cohort variance after adjustment for patient factors. Hospitals that provided out-of-bed mobility often did so in patients with greater severity of illness or organ dysfunction. This suggests that local care practices exert substantial effects on the overall uptake of ICU mobility. A number of studies support the need for broad multidisciplinary, ICU culture change for acceptance of ICU mobility (9, 22, 26, 27). Utilization of high-performing hospitals as a care model for ICU mobility delivery may serve to increase access broadly while use of ICU mobility quality initiatives may enhance local uptake.

There are several potential limitations to our study. First, mobility assessments were unblinded potentially leading to greater mobility delivery. Efforts were made to limit knowledge of the study and the relatively low observed prevalence makes it unlikely that single day escalation of mobility efforts biased the overall estimates. Second, participation was voluntary and limited to ARDSNet hospitals reflecting sites with larger clinical and research infrastructure and/or targeted interest in mobility potentially limiting the generalizability of our results. Third, restriction of study dates to weekdays rather than weekends may lead to overestimation of ICU activity as activities generally occur less frequently on weekends. Finally, despite our attempts to exclude patients with potential contraindications to mobility, we were unable to reliably exclude them due to inconsistent charting. Contraindications varied throughout the study date, changing mobility eligibility over time, and potential contraindications conflicted across centers depending on institutional mobility comfort level. It is possible that our estimates underestimate the true prevalence of ICU mobility in medically eligible patients.

CONCLUSIONS

In a cohort of hospitals caring for acute respiratory failure patients, PT/OT-provided mobility occurred infrequently.

PT/OT involvement in ICU mobility was strongly predictive of out-of-bed mobility for patients on MV. MV via an ETT and presence of delirium were negatively associated with out-of-bed mobility. There was significant variability around ICU mobility delivery between hospitals.

REFERENCES

- Herridge MS, Tansey CM, Matté A, et al; Canadian Critical Care Trials Group: Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011; 364:1293–1304
- Wunsch H, Guerra C, Barnato AE, et al: Three-year outcomes for Medicare beneficiaries who survive intensive care. *JAMA* 2010; 303:849–856
- Fan E, Dowdy DW, Colantuoni E, et al: Physical complications in acute lung injury survivors: A two-year longitudinal prospective study. *Crit Care Med* 2014; 42:849–859
- Herridge M, Cameron JI: Disability after critical illness. *N Engl J Med* 2013; 369:1367–1369
- Needham DM, Dinglas VD, Morris PE, et al; NIH NHLBI ARDS Network: Physical and cognitive performance of patients with acute lung injury 1 year after initial trophic versus full enteral feeding. EDEN trial follow-up. *Am J Respir Crit Care Med* 2013; 188:567–576
- Bailey P, Thomsen GE, Spuhler VJ, et al: Early activity is feasible and safe in respiratory failure patients. *Crit Care Med* 2007; 35:139–145
- Morris PE, Goad A, Thompson C, et al: Early intensive care unit mobility therapy in the treatment of acute respiratory failure. *Crit Care Med* 2008; 36:2238–2243
- Morris PE, Griffin L, Berry M, et al: Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failure. *Am J Med Sci* 2011; 341:373–377
- Schweickert WD, Pohlman MC, Pohlman AS, et al: Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial. *Lancet* 2009; 373:1874–1882
- Burtin C, Clerckx B, Robbeets C, et al: Early exercise in critically ill patients enhances short-term functional recovery. *Crit Care Med* 2009; 37:2499–2505
- Nydahl P, Ruhl AP, Bartoszek G, et al: Early mobilization of mechanically ventilated patients: A 1-day point-prevalence study in Germany. *Crit Care Med* 2014; 42:1178–1186
- Berney SC, Harrold M, Webb SA, et al: Intensive care unit mobility practices in Australia and New Zealand: A point prevalence study. *Crit Care Resusc* 2013; 15:260–265
- Hodgson C, Needham D, Haines K, et al: Feasibility and inter-rater reliability of the ICU Mobility Scale. *Heart Lung* 2014; 43:19–24
- Sricharoenchai T, Parker AM, Zanni JM, et al: Safety of physical therapy interventions in critically ill patients: A single-center prospective evaluation of 1110 intensive care unit admissions. *J Crit Care* 2014; 29:395–400
- Hodgson CL, Stiller K, Needham DM, et al: Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. *Crit Care* 2014; 18:658
- Miller MA, Govindan S, Watson SR, et al: ABCDE, but in that order? A cross-sectional survey of Michigan ICU sedation, delirium and early mobility practices. *Ann Am Thorac Soc* 2015; 12:1066–1071
- Jolley SE, Dale CR, Hough CL: Hospital-level factors associated with report of physical activity in patients on mechanical ventilation across Washington State. *Ann Am Thorac Soc* 2015; 12:209–215
- Engel HJ, Needham DM, Morris PE, et al: ICU early mobilization: From recommendation to implementation at three medical centers. *Crit Care Med* 2013; 41(9 Suppl 1):S69–S80

19. Needham DM, Korupolu R, Zanni JM, et al: Early physical medicine and rehabilitation for patients with acute respiratory failure: A quality improvement project. *Arch Phys Med Rehabil* 2010; 91:536–542
20. Zanni JM, Korupolu R, Fan E, et al: Rehabilitation therapy and outcomes in acute respiratory failure: An observational pilot project. *J Crit Care* 2010; 25:254–262
21. Kayambu G, Boots R, Paratz J: Physical therapy for the critically ill in the ICU: A systematic review and meta-analysis. *Crit Care Med* 2013; 41:1543–1554
22. Eakin MN, Ugbah L, Arnautovic T, et al: Implementing and sustaining an early rehabilitation program in a medical intensive care unit: A qualitative analysis. *J Crit Care* 2015; 30:698–704
23. Mendez-Tellez PA, Dinglas VD, Colantuoni E, et al: Factors associated with timing of initiation of physical therapy in patients with acute lung injury. *J Crit Care* 2013; 28:980–984
24. Pandharipande PP, Girard TD, Ely EW: Long-term cognitive impairment after critical illness. *N Engl J Med* 2014; 370:185–186
25. Dinglas VD, Colantuoni E, Ciesla N, et al: Occupational therapy for patients with acute lung injury: Factors associated with time to first intervention in the intensive care unit. *Am J Occup Ther* 2013; 67:355–362
26. Hopkins RO, Spuhler VJ, Thomsen GE: Transforming ICU culture to facilitate early mobility. *Crit Care Clin* 2007; 23:81–96
27. Pawlik AJ, Kress JP: Issues affecting the delivery of physical therapy services for individuals with critical illness. *Phys Ther* 2013; 93:256–265

Adapting the ABCDEF Bundle to Meet the Needs of Patients Requiring Prolonged Mechanical Ventilation in the Long-Term Acute Care Hospital Setting: Historical Perspectives and Practical Implications

Michele C. Balas, PhD RN, APRN-NP, CCRN, FCCM¹ John W. Devlin, PharmD, FCCM, FCCP²
Avelino C. Verceles, MD³ Peter Morris, MD⁴ E. Wesley Ely, MD, MPH, FCCM^{5,6}

¹ Center of Excellence in Critical and Complex Care, Ohio State University College of Nursing, Columbus, Ohio

² Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Northeastern University School of Pharmacy, Boston, Massachusetts

³ Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore Maryland

⁴ Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, Kentucky

⁵ Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Center for Health Services Research, Vanderbilt University School of Medicine, Nashville, Tennessee

⁶ Geriatric Research, Education and Clinical Center (GRECC) Service, Department of Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, Tennessee

Address for correspondence Michele C. Balas, PhD, RN, APRN-NP, CCRN, FCCM, The Ohio State University College of Nursing, 368 Newton Hall, 1585 Neil Avenue, Columbus, OH 43210 (e-mail: balas.17@osu.edu).

Semin Respir Crit Care Med 2016;37:119–135.

Abstract

When robust clinical trials are lacking, clinicians are often forced to extrapolate safe and effective evidence-based interventions from one patient care setting to another. This article is about such an extrapolation from the intensive care unit (ICU) to the long-term acute care hospital (LTACH) setting. Chronic critical illness is an emerging, disabling, costly, and yet relatively silent epidemic that is central to both of these settings. The number of chronically critically ill patients requiring prolonged mechanical ventilation is expected to reach unprecedented levels over the next decade. Despite the prevalence, numerous distressing symptoms, and exceptionally poor outcomes associated with chronic critical illness, to date there is very limited scientific evidence available to guide the care and management of this exceptionally vulnerable population, particularly in LTACHs. Recent studies conducted in the traditional ICU setting suggest interprofessional, multicomponent strategies aimed at effectively assessing, preventing, and managing pain, agitation, delirium, and weakness, such as the ABCDEF bundle, may play an important role in the recovery of the chronically critically ill. This article reviews what is known about the chronically critically ill, provide readers with some important historical perspectives on the ABCDEF bundle, and address some controversies and practical implications of adopting the ABCDEF bundle into the everyday care of patients requiring prolonged mechanical ventilation in the LTACH setting. We believe developing

Keywords

- ▶ ABCDEF bundle
- ▶ chronic critical illness
- ▶ long-term acute care hospital
- ▶ pain
- ▶ sedation
- ▶ delirium

Issue Theme Controversies and Evolving Concepts in Critical Care; Guest Editors: Rodrigo Cartin-Ceba, MD, MSc, Sonal Pannu, MD, MSc, and Ognjen Gajic, MD, MSc

Copyright © 2016 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0035-1570361>.
ISSN 1069-3424.

new and better ways of addressing both the science and organizational aspects of managing the common and distressing symptoms associated with chronic critical illness and prolonged mechanical ventilation will ultimately improve the quality of life for the many patients and families admitted to LTACHs annually.

Advances in technology, ground-breaking research, and adoption of evidence-based practices have substantially improved intensive care unit (ICU) survival rates.^{1,2} This improved survival, however, is often accompanied by a painful, protracted, and challenging course of recovery.^{3–5} Chronic critical illness, now recognized as a distinct, complex syndrome of physiologic abnormalities and organ dysfunction,⁶ is a devastating condition whose incidence is increasing to unprecedented levels.³ Despite its incidence and human and financial costs, chronic critical illness has attracted surprisingly little interventional research and disturbingly few advances have been made to improve the care of this exceptionally vulnerable population. This is particularly true for the subgroup of chronically critically ill patients requiring prolonged mechanical ventilation (PMV) in the long-term acute care hospital (LTACH) setting.

As outlined in recent clinical practice guidelines from the *Society of Critical Care Medicine (SCCM)*,⁷ pain, agitation, delirium, and weakness are major issues confronting critically ill patients, their families, clinicians, and payers. These common conditions, which generally remain poorly recognized and managed,^{7–9} are now believed to play an important role in the multiple transitions and challenges critically ill patients encounter during the course of their recovery. Recent evidence generated in the traditional ICU setting suggests that the daily use of a multicomponent bundle that incorporates evidence-based interventions targeting pain, agitation, oversedation, delirium, weakness, and mechanical ventilation discontinuation, by an interprofessional ICU team, is feasible, safe, and improves patient-centered outcomes.¹⁰ This evidenced-based strategy is referred to as the ABCDEF bundle (i.e., Assess, prevent, and manage pain; Both Spontaneous Awakening Trials (SATs) and Spontaneous Breathing Trials (SBTs); Choice of analgesia and sedation; Delirium assess, prevent, and manage; Early mobility and exercise; and Family engagement and empowerment.)

While there is evidence suggesting that chronically critically ill patients frequently experience many of the same noxious symptoms as their acutely ill counterparts,⁶ to date it remains unclear whether applying strategies such as the ABCDEF bundle *late* in the course of serious illness will reduce symptom burden and improve clinical outcomes. This article reviews what is known about chronic critical illness, provide readers with important historical perspectives on the ABCDEF bundle, and address controversies and practical implications of adopting the ABCDEF bundle into the routine care for patients requiring PMV in the LTACH setting.

Chronic Critical Illness, PMV, and LTACHs

The number of “chronically critically ill” (i.e., patients recovering from an extended ICU stay, PMV, and/or tracheostomy placement)¹¹ is expected to reach 600,000 within a decade with associated hospital costs nearing \$60 billion annually.¹² Nearly all chronically critically ill patients report experiencing at least one distressing symptom (e.g., pain, fatigue, dyspnea, or thirst) during their course of their illness.^{4,6,13–15} Severe functional and cognitive impairment is also common in this group,^{3,14,16–20} with 90% of patients experiencing chronic partial muscle denervation²¹ and as many as 74% having delirium and/or coma 6 months after hospital discharge.¹⁴ Unfortunately, factors such as intubation, delirium, and oversedation frequently preclude chronically critically ill patients from being able to effectively communicate their needs and symptom experience.¹³ Family and friends who function in a “caregiver” role are not immune to the toll of chronic critical illness, with many experiencing poor physical health, severe depressive symptoms, and severe financial stress.^{18,22–24} The disturbances in family life are often substantial and permanent. For example, one study reported that after a prolonged ICU stay, some families needed to move to a less expensive home, declare bankruptcy, postpone educational plans, or delay medical care for another family member.²⁴

Fewer than 10% of patients requiring PMV (i.e., a mechanical ventilation duration of at least 21 days)²⁵ are discharged directly home from the hospital.¹¹ While historically cared for in either traditional ICUs and/or step-down units, these patients are increasingly being managed in LTACHs.³ Over a 5-year period from 2004 to 2009, the number of LTACH transfers more than doubled.²⁶ Either hospital based or free standing, LTACHs are centers that specialize in providing complex wound care, comprehensive rehabilitation, and mechanical ventilation discontinuation.²⁷ Originally created to facilitate discharge of medically complex patients from acute care hospitals,²⁷ it is estimated that the 412 U.S. LTACHs admit more than 130,000 patients and account for more than \$5 billion in Medicare expenditures annually.^{28,29}

Because of the debilitating nature of chronic critical illness, LTACH stays for patients requiring PMV are typically complicated and associated with several poor outcomes.^{3,18–20,30} These outcomes include high 1-year mortality rates (44–77%),^{18,19} severe functional impairment at LTACH discharge,²⁰ and diminished quality of life.^{14,16–19,31} While returning home functionally independent is often an important goal for patients and their families,³⁰ this is a rather rare outcome in this population.³¹

Rather, patients requiring PMV often experience multiple transitions in care in the year following their original hospital admission (median of four), which results in further costs and persistent, profound disability.¹⁶ Caregivers of patients requiring PMV are also at risk for poor outcomes, as they were found to have higher depression scores than those reported for caregivers of patients with spinal cord injury, the aged, and patients with Alzheimer disease receiving respite care.²²

Despite these disheartening findings, to date there is very limited scientific evidence available to help clinicians care for the chronically critically ill, particularly those requiring PMV in LTACHs.²⁸ It is also important to note that the relatively few studies that have been conducted in the LTACH setting are frequently limited by the use of administrative data alone and/or lack a comparable control group of chronically critically ill patients cared for in the traditional ICU setting. This begs the question of whether the poor outcomes associated with LTACHs are related to where care is delivered (i.e., traditional ICU vs. LTACH) versus the specific disease process (i.e., chronic critical illness). For example, researchers recently found that while older patients with chronic critical illness transferred to LTACHs invoked higher overall Medicare payments, they experienced similar survival compared with patients who remained in the traditional ICU setting.¹⁷

Chronically critically ill patients who require PMV share some common characteristics that may serve to influence both outcomes and health care delivery patterns. In general, they are older, sicker, and have more comorbidities than their acutely ill counterparts.^{4,26} The most common medical conditions experienced by the chronically critically ill are acute respiratory failure requiring mechanical ventilation and sepsis.²⁶ Hospital-acquired infections are also pervasive, with

over half of chronically critically ill patients admitted with sepsis experiencing this complication.²⁶ Single organ failure in this population is rare, with most chronically critically ill patients experiencing the effects of prolonged, severe, multi-system organ dysfunction/failure that commonly involves the neuroendocrine, respiratory, musculoskeletal, and immune systems.^{5,32} Treatment of the multisystem organ failure seen in chronic critical illness is complex and often includes the use of complicated medication regimens, supportive therapies (e.g., hemodialysis, mechanical ventilation), numerous indwelling devices (e.g., urinary and central venous catheters), and several different consultative services.

Does Symptom Assessment and Management Influence Recovery from Critical Illness?

While many of the noxious symptoms experienced by the seriously ill were previously thought of as unfortunate and inevitable consequences of critical illness,³³ recent evidence suggests that the inappropriate management of these symptoms may not only contribute to the *development* of chronic critical illness but may also actually be *causal* to the poor outcomes experienced by this group.^{7,26} Based on the results of a rigorous body of interventional clinical studies,^{10,34–44} the SCCM's *Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium (PAD) in Adult Patients in the ICU*⁷ currently advocate that pain, sedation, and delirium be routinely assessed; that strategies be employed to maintain patients in a wakeful or lightly sedated state; and that mobilization be employed early and often (see also ►Table 1).

Table 1 ABCDEF bundle–related pain, agitation, and delirium guideline recommendations

• Pain and delirium should be routinely monitored in all adult ICU patients
• Preemptive analgesia and/or nonpharmacologic interventions should be administered to alleviate pain in adult ICU patients prior to chest tube removal
• Intravenous (IV) opioids should be considered as the first-line drug class of choice to treat nonneuropathic pain in critically ill patients
• Either enterally administered gabapentin or carbamazepine, in addition to IV opioids, should be considered for treatment of neuropathic pain
• Thoracic epidural anesthesia/analgesia should be considered for postoperative analgesia in patients undergoing abdominal aortic aneurysm surgery
• Sedative medications should be titrated to maintain a light rather than a deep level of sedation in adult ICU patients, unless clinically contraindicated
• Early mobilization of adult ICU patients should be performed whenever feasible to reduce the incidence and duration of delirium
• Rivastigmine should not be administered to reduce the duration of delirium in ICU patients
• Either daily sedation interruption or a light target level of sedation should be routinely used in mechanically ventilated adult ICU patients
• Sleep should be promoted in adult ICU patients by optimizing patients' environments, using strategies to control light and noise, clustering patient care activities, and decreasing stimuli at night to protect patients' sleep cycles
• An interdisciplinary ICU team approach that includes provider education, preprinted and/or computerized protocols and order forms, and quality ICU rounds checklists should be used to facilitate the use of pain, agitation, and delirium management guidelines or protocols in adult ICUs

Source: Adapted from Barr et al.⁷

One strategy for incorporating the PAD guideline recommendations into everyday care is use of the newly modified ABCDEF bundle.^{33,44–46} While early versions of this bundle have proven safe, feasible, and effective when applied *early* in the course of critical illness in the traditional ICU setting,¹⁰ to date it remains unclear whether applying the bundle *late* in the course of critical illness will reduce symptom burden and improve clinical outcomes in this extremely vulnerable group. It is possible that characteristics of both the chronically critically ill and LTACH setting would necessitate changes to the ABCDEF bundle. Moreover, the bundle itself has been recently revised to include more aggressive assessment, prevention, and management of pain and increased family engagement. Thus, it is important to consider both the level of evidence and history behind the ABCDEF bundle before deciding whether it can, or even should, be applied to patients who require PMV in the LTACH setting.

Evolution of the ABCDEF Bundle

Building the Evidence

Awakening-Protocolized Sedation and Spontaneous Awakening Trials

Over the past 15 years, several investigations focused on reducing sedative medication exposure among mechanically ventilated critically ill adults through two main strategies: protocolized sedation and/or daily SATs (aka daily sedation interruption [DSI]).^{35,39,47} The use of either of these strategies has been shown to reduce the duration of mechanical ventilation, decrease ICU and hospital length of stay (LOS), and lead to a shorter time spent in coma, lower tracheostomy rates, and fewer complications.^{35,39,48} Collectively, these early studies suggested that both protocolized sedation and SATs were safe and not associated with long-term harm.³⁶ We also know that maintaining patients in a lightly sedated, interactive state has important implications for their longer-term psychological health. For example, one study that compared the outcomes of patients managed throughout their ICU stay with a *light* versus *deep* sedation strategy found that light sedation was associated with a lower incidence of posttraumatic stress disorder (PTSD) symptoms, less trouble remembering ICU events, and fewer disturbing ICU memories.⁴⁹ This cumulative evidence led to the PAD guideline recommendation that either DSI/SATs or a light target level of sedation should be routinely used in mechanically ventilated adult ICU patients who require continuous intravenous (IV) sedative therapy.

Breathing

During the late 1990s, researchers demonstrated that interprofessional protocols facilitated mechanical ventilation discontinuation. Just as SATs have been used to promote wakefulness and reduce sedative medication exposure, SBTs were devised as a strategy to reduce the harmful effects of unnecessary mechanical ventilation exposure.⁵⁰ An interprofessional SBT protocol, when compared with physician-driven weaning in controlled studies, was shown to be safe and lead to a significantly shorter time to extubation.^{51,52}

Awakening and Breathing Coordination

Given the demonstrated benefits of SATs and SBTs, Girard and colleagues rigorously evaluated a protocol that paired both interventions.³⁴ The intervention group in this randomized controlled trial (RCT) was managed with the “wake up and breathe” protocol, consisting of protocolized, *safety screen* and *success/failure criteria guided* SATs and SBTs, although the control group received SBTs and patient-targeted sedation according to “usual care.” The daily SATs involved stopping continuously infused narcotics (as long as pain was controlled) and sedatives every day and, if needed, restarting either narcotics or sedatives at half the previous dose and titrating as needed. Patients treated with the combined protocol spent significantly more days breathing without ventilator assistance, were discharged from both the ICU and hospital earlier, had a shorter duration of coma, and were less likely to die compared with patients treated with a SBT strategy alone. For every seven people treated with the ABC approach, one life was saved at 1 year. Importantly, the proven benefits of the ABC protocol were not offset by adverse long-term cognitive and functional outcomes.⁵³

Choice of Sedation and Analgesia

The past two decades have also marked important progress in our understanding of how the *choice* of sedative, particularly when protocolized or used in conjunction with a sedative reduction strategy such as SATs, affects patient outcomes.^{38,54,55} Compared with the benzodiazepines, propofol with its short half-life and reduced volume of distribution is far less likely to accumulate and lead to persistent deep sedation or coma.⁵⁶ Compared with a continuous benzodiazepine sedation strategy, patients treated with dexmedetomidine experience more days alive without delirium or coma, more time at targeted sedation levels, fewer days on mechanical ventilation, and improved ability to communicate pain levels.^{38,54,55} Current evidence also suggests that a nonbenzodiazepine sedation strategy (i.e., propofol or dexmedetomidine) when compared with a benzodiazepine strategy is associated with a reduced duration of mechanical ventilation, shorter LOS, and reduced health care costs.⁵⁷ This evolving evidence led the 2013 PAD guidelines to make a weak recommendation that a nonbenzodiazepine strategy is preferred over benzodiazepine strategy for mechanically ventilated adults.⁷

Delirium Monitoring/Management

At the same time that the hazards of deep sedation and delayed mechanical ventilation discontinuation were emerging, the importance of delirium, a form of acute brain injury characterized by an acute change/fluctuating course in baseline mental status and inattention, plus disorganized thinking or altered level of consciousness, was becoming apparent.^{42,43,58,59} Occurring in up to 80% of mechanically ventilated patients^{42,60} and nearly half of nonmechanically ventilated ICU patients,⁶¹ delirium is sometimes preventable and associated with many serious adverse outcomes.^{42,61–63} Both the occurrence and duration of delirium in the ICU are independently associated with increased short- and

long-term mortality.^{60,64,65} A recent meta-analysis⁶⁶ found delirious patients were 6 times more likely to experience complications, 2.5 times more likely to be discharged to skilled placement, had longer ICU and hospital LOS, and spent an average of 7 days longer on mechanical ventilation. Evidence now exists demonstrating that the impact of ICU delirium extends well beyond the period of acute hospitalization given that patients with delirium experience substantial functional decline,^{67,68} a higher risk of rehospitalization,⁶⁹ and greater long-term neurocognitive impairment.^{70–72}

The 2013 PAD guidelines advocate that all ICU patients should routinely be screened for delirium using a validated instrument such as the Confusion Assessment Method ICU⁴² (CAM-ICU) or the Intensive Care Delirium Screening Checklist⁷³ (ICDSC). Without such assessments, clinicians miss up to 75% of cases of delirium, particularly if the patient is experiencing the predominately hypoactive form that is not accompanied by agitation.^{7–9,74,75} Delirium screening should take place when patients are maximally awake (e.g., after an SAT) given emerging evidence that positive delirium assessments in the more sedated patient might not be as clinically important.⁷⁶

Early Exercise/Mobility

A strategy for whole-body rehabilitation, achieved by the use of SATs, SBTs, and physical therapy–*driven early exercise and mobilization*, was found to be safe and well tolerated by mechanically ventilated patients over 5 years ago.⁴¹ Patients treated with this strategy experienced significantly shorter duration of delirium and coma, had more ventilator-free days, and were more likely to return to independent functional status at hospital discharge than controls. Other more recent studies also found that active mobilization can be initiated safely in the ICU setting,⁷⁷ resulting in improved physical function,⁷⁷ reduced duration of mechanical ventilation,^{78,79} shorter LOS,^{79,80} and lower 1-year mortality.⁷⁸

“Bundling” the Approach

Despite the rigorous evidence supporting the safety and efficacy of light sedation, SATs, SBTs, delirium monitoring/management, and early/exercise mobility, diffusion of these interventions into everyday clinical practice has been challenging.^{33,81} Before the year 2010, one U.S. survey found that only 33% of intensivists used a valid delirium screening tool,⁸² while others reported 30 to 40% managed sedation without an arousal scale.^{83,84} In the same time period, only 40% of ICU providers reported using SATs⁸⁴ and the rates of SBT use ranged from 31 to 42%.⁸⁴ Exercise and early mobility in the ICU were particularly underutilized, with one point prevalence study reporting that less than 2% of intubated patients were mobilized out of bed during their ICU stay.⁸⁵ While these findings may not be surprising to some clinicians, they highlight the gap that often exists between the publication of safe and effective clinical interventions and their adoption into daily ICU practice.

To address this adoption delay and provide a “tight, sticky message” to bedside clinicians regarding the hazards of ICU delirium and weakness, researchers at Vanderbilt University in

2010 suggested a novel “animation and liberation” program. “Liberation” aimed to reduce the harmful effects of sedative medication exposure through target-based sedation protocols, SATs, and SBTs. “Animation” referred to early mobilization, which was known to reduce delirium. This strategy was originally referred to as the Awakening and Breathing Coordination, Choice of Medications, Delirium monitoring/management, and Early mobility (ABCDE) bundle.^{33,45,46,86,87}

Safety and Effectiveness of the ABCDE Bundle

While the safety and efficacy of the individual components of the ABCDE bundle are well established, until recently it remained unclear if the ABCDE bundle would also prove to be safe and effective if adopted into everyday ICU care. In a recent before–after study at one academic medical center, Balas and colleagues sought to address this important question and also identify the facilitators and barriers to ABCDE bundle adoption.⁴⁴ Among the 296 patients evaluated (146 pre- and 150 post-bundle implementation), postimplementation patients spent 3 more days alive breathing without mechanical ventilator assistance. After adjusting for age, sex, severity of illness, comorbidities, and mechanical ventilation status, patients managed with the ABCDE bundle were half as likely to experience delirium and were significantly more likely to be mobilized out of bed at least once during their ICU stay. The hospital mortality rate (pre-19.9 vs. post-11.3%, $p = 0.04$) was significantly lower in the group managed with the ABCDE bundle. Importantly, both self-extubation and reintubation rates were similar between the two groups. It is noteworthy that the positive effectiveness and safety outcomes reported occurred despite a lower-than-expected bundle compliance rate. While the proportion of patients where key ABCDE interventions were conducted significantly increased between the control group and the ABCDE group, the absolute increase in compliance was generally small. These results suggest that incremental improvements in ABCDE compliance are likely to continue to improve patient outcome across repeated quality improvement cycles.

Momentum for implementing an ABCDE bundle approach into everyday ICU care was also significantly aided by the recent support of several national quality and patient safety organizations. For example, in 2011 the *Institute for Healthcare Improvement's* Rethinking Critical Care (IHIRCC) program was established to reduce harm to critically ill patients by decreasing sedation, increasing monitoring and management of delirium, and increasing patient mobility.⁸⁸ A convenience sample of five “early adopters” of the ABCDE bundle was followed over the course of the program to document the process of improvement as well as outcomes. Each of these early adopters reported relative improvements in ICU average LOS (6–28%) and average LOS on the ventilator (3–25%). Other outcomes noted after ABCDE bundle implementation included improvements in sedation scores, percent of patients mobilized, and the number of delirium and sedation scores completed.

While not specifically focused on all aspects of the bundle, several other important studies have recently contributed to our increased understanding of the safety and effectiveness of an ABCDE approach to ICU management. For example, in a

recent multicenter QI project conducted by the *Centers for Disease Control*, significant increases in SATs, SBTs, and percentage of SBTs performed without sedation were mirrored by significant decreases in duration of mechanical ventilation and hospital LOS.⁸⁹ Importantly, this group was also the first to report that increased SAT and SBT use was associated with both a significant decrease in ventilator-associated event risk per episode of mechanical ventilation and infection-related ventilator-associated complications. Another QI project focused on reducing the days of benzodiazepine exposure found this strategy led to an increase in the number of days patients spent alert and delirium free and an increased number of physical therapy/occupational therapy (PT/OT) treatments patients received while in the ICU.⁹⁰ Another before–after evaluation of a SAT/SBT protocol implementation effort in 702 patients significantly reduced the prevalence of delirium/coma and resulted in reduced sedation among critically ill patients.⁹¹

Implementing the ABCDE Bundle: Opportunities, Challenges, and Lessons Learned

Several important ABCDE bundle implementation barriers and facilitators have been identified in the literature (►Table 2). For example, the aforementioned IHI project

Table 2 Facilitators and barriers of successful ABCDEF bundle implementation^{87,88,92}

Facilitators to adoption
Performance of daily interdisciplinary rounds
Engagement of key implementation leaders and garnering top-down leadership support
Sustained, diverse educational efforts
The bundle's quality and strength
Structural characteristics of the ICU
Organization-wide patient safety culture
ICU culture of quality improvement
Implementation planning/training/support and prompts
Early focus on “low-hanging fruit”
Realistic goal setting
Active reminders
Utilizing appropriate consultative services (e.g., psychiatry, occupational therapy)
Barriers to adoption
Intervention-related issues (e.g., timing of trials, fear of adverse events)
Communication challenges
Knowledge deficits
Workload concerns
Documentation burden
Excessive turnover
Staff morale issues
Excessive use of registry staff

highlighted the importance of utilizing pharmacists' expertise in developing protocols that emphasize an analgesedation approach to PAD management and removing lorazepam or continuous infusions from preprinted order forms. Other important implementation strategies included a focus on ensuring that sedation and delirium assessments are accurate, that targeted sedation scores are revised to reflect a more awake and engaged patient, and that a mobility team be established to facilitate early mobilization. In addition, key QI lessons learned from the IHI project included the importance of testing changes on a small scale (e.g., one patient, one time, starting with the easiest patients first), feeding back both process and outcome data regularly to ICU clinicians, providing education that is both sufficient and regular, and overcoming preconceived notions and traditions.

Extending the Evidence: Importance of Assessing, Preventing, and Managing Pain and Family Engagement/Empowerment

Like most clinical improvement processes, the ABCDE bundle continues to evolve over time. One of the earliest criticisms of the bundle was the belief that it understated the importance of assessing, preventing, and managing pain. While the original ABC protocol did specifically allow for the administration of continuously infused opioids during the SAT process when active pain was present,³⁴ the misperception existed that pain medication should always be held during SATs and SBTs, regardless of whether pain is present. Given the prevalence and outcomes associated with unrecognized/undertreated pain,⁷ this was accepted as a fair criticism and a misperception that should be addressed.

Another important fault of the original ABCDE bundle was that it tended to ignore the patient's family, a critical component of any ICU team. During critical illness, family members can help the patient make sense of the illness experience and support their loved one's psychological well-being by providing reassurance, hope, information, a sense of normality, and distraction from the ICU environment.^{93–100} Families can also provide reorientation and are often the first to detect early signs of delirium.^{101,102} For example, Black et al¹⁰¹ tested the effect of a family psychological support intervention facilitated by nurses on delirium rates and psychological recovery. Intervention patients in this study showed less delirium than usual care (29–77%) and had significantly lower Sickness Impact Profile scores up to 12 weeks after the intervention. The use of diaries coauthored by health providers and family visitors with the intent of helping patients make sense of their memories and ICU experiences following discharge was also shown to decrease PTSD.⁹⁹

While clinical trials have yet to characterize the precise benefit associated with active family involvement in ABCDEF bundle implementation, from a humanistic perspective the empowerment of family members to be equal participants in ICU patient care is clearly an appropriate goal of medical care (see discussion available for medical teams and families at www.icudelirium.org). Moreover, it is also possible that engaging family members in the care of ICU patients may lead to several other important outcomes including better

recognition and treatment of PAD and weakness, delivery of important nonpharmacologic stress relieving and reorientation interventions (e.g., provision of human touch, music, sensory aids, family photos), enhancing ICU team performance by asking if certain interventions are being utilized, and more open and effective communication among patients and ICU clinicians.

In response to the aforementioned provider concerns, the terms associated with the letters A and B of the bundle have been changed and an additional letter (i.e., F) has been added (see **Fig. 1**). The A in the new ABCDEF bundle now refers to Assess, prevent, and manage pain. While a patient's self-report of pain remains the gold standard, in the case where patients are unable to do so, the new bundle suggests clinicians utilize either the Behavioral Pain Scale (BPS)¹⁰³ or the Critical-Care Pain Observation Tool (CPOT).¹⁰⁴ The CPOT and BPS are both valid and reliable pain scales used to guide the assessment and treatment of pain in critically ill adults. The B in the bundle now stands for Both SATs and SBTs. The term *both* was chosen purposively to reflect the importance of making sure these two interventions are used concomitantly given that the success of a SBT may be predicated by the completion of the SAT. Finally, the F in the bundle refers to Family engagement and empowerment. This letter is used to emphasize the importance of family rounding, family visitation and the families' role in reducing delirium, provision of good end-of-life care, and effective transitional care.

Given the importance of the new PAD guidelines and the heightened interest in the ABCDEF bundle, the SCCM has devoted a substantial amount of time, talent, and resources to effectively disseminating and implementing this important bundle. A wealth of valuable information on this new initiative can be found at www.iculiberation.org. Here, those who are interested can find the most recent PAD guidelines, copies of the

recommended PAD assessment tools, and links to upcoming events. Additionally, through the generous support of the *Gordon and Betty Moore Foundation*, the SCCM will soon select 60 hospitals (i.e., 20 in each of three regions around the country) for specific training in ABCDEF bundle implementation in an attempt to create lean, sustainable, and highly functioning interprofessional ICU teams that partner with patients and families to create a safe and comfortable ICU environment.

Controversies and Practical Implications of Adopting the ABCDEF Bundle into the Care of the Chronically Critically Ill in LTACHs

Overarching Issues

As Kahn and Carson describe, a lack of robust clinical trials conducted in the LTACH setting has forced LTACH administrators and clinicians to extrapolate the results of studies conducted in the traditional ICU setting and rely on their own clinical experience to define the standard that care should be delivered for patients requiring PMV in the LTACH setting.²⁸ Importantly, no studies have evaluated the safety and effectiveness of the new ABCDEF bundle in the LTACH setting. While intuitively it would seem that implementation of this bundle into the care of patients who require PMV in LTACHs might be safe and beneficial, there are several important factors that need to be considered before this assumption can be made.

Based on the lessons learned from the traditional ICU setting, it is clear that effective ABCDEF bundle adoption in the LTACH setting would be dependent on both individual (i.e., health care provider) and health system (i.e., LTACH) factors. Strong support and "buy-in" from LTACH administration would be needed to facilitate the necessary changes in the institutional culture that a multifaceted practice change requires. Preemptively addressing both the factors that will




Fig. 1 ABCDEF bundle components and tools.

facilitate bundle adoption as well as known barriers to its use (see ► **Table 2**) would be critical to the success of any LTACH ABCDEF bundle implementation effort.

Fortunately, there is reason to believe that many LTACHs do embrace the characteristics necessary for this type of system change. For example, one nation-wide system of LTACHs embarked on a QI initiative to establish a “*Ventilator Management and Weaning Best Practice*” effort.¹⁰² Many of the best practice characteristics identified during the development of this QI project are nearly identical to those factors that are likely most important in the facilitation of ABCDEF bundle adoption in the LTACH setting. For example, the most successful weaning occurred in those LTACHs where a collaborative multidisciplinary plan of care was used in a consistent way on a 24/7 basis. Other important factors included constant team communication and collaboration, mutual respect for the contributions of all disciplines to the weaning process, and early intervention by rehabilitation services (see also ► **Table 3**).

The optimal level of staffing, resources, professional mix, and rounding patterns is an important issue to address before the ABCDEF bundle can be effectively implemented in the LTACH setting. Physical and occupational therapists, given their rehabilitation focus, will have an important role during implementation efforts, including the development of evidence-based mobilization protocols, identification of the

optimal measurement tools to assess and monitor physical function, evaluation of the necessary equipment to support mobilization efforts, and identification of ways to best define and monitor safety-related outcomes. Speech/language therapists, currently more widely used in the LTACH than in the acute ICU setting, would be especially helpful in addressing the various communication and swallowing challenges experienced during PMV. They would also play an important role in further facilitating cognitive recovery, reducing aspiration risk, and expediting enteral nutrition. Most importantly, the use of a SLT may help facilitate the persons’ participation in their own care and decision-making process by maximizing the opportunity to communicate and exert “free choice.”¹⁰⁶

While the role that pharmacists, nurses, and respiratory therapists play in ABCDEF bundle implementation in the traditional ICU setting has been described,^{86,87} how these professions should function and interact in the LTACH setting remains unclear. There are known differences, for example, in nurse-to-patient staffing levels in the ICU versus LTACH setting (i.e., usually 1:2 vs. 1:4–6) that may prove challenging and necessitate changes in the ABCDEF bundle and the way it is implemented. The fact that the use of outsourced nurses is higher in the LTACH setting than in the ICU¹⁰⁷ may affect the type, intensity, and frequency of the ABCDEF-related training and education that is required. Finally, while care

Table 3 Similarities and differences in organizational elements needed for successful ABCDEF bundle implementation in ICU vs. LTACH settings

Facilitators of ABCDEF bundle implementation ^{44,105}	Facilitators of successful ventilator weaning in LTACH ¹⁰²
Strong administrative support	Leadership team had respect for one another’s skills, knowledge, and abilities and possesses a single focus that supports the efforts and contributions of the various disciplines Administrative support, involvement, and clear expectations for productive, goal-driven patient care conferences Provided sufficient time for physicians and staff to participate in care conferences
Performance of interdisciplinary rounds	All clinicians had a clear understanding and acceptance of every discipline’s role, contribution, and value in the process
Engagement of key implementation leaders	Care conference leader who can focus the team, assure documentation of a multidisciplinary plan for all patients that is followed and monitored by all team members
Sustained, diverse educational and implementation efforts	Provision of multidisciplinary education programs related to ventilators and ventilator management that recognize and use the expertise of respiratory therapy staff
Organizational wide quality and patient safety culture	Use of advanced practice nurse, case manager, or utilization review coordinator to monitor and facilitate patient progress toward a timely discharge
Reduced workload and efficient documentation	Appropriate staffing patterns to support “24/7” weaning, allowing continual monitoring of patients for tolerance, anxiety, and fatigue are supported philosophically as well as financially Consistent numbers of respiratory therapy staff 24 h/d, flex staffing to support changes in numbers of mechanically ventilated patients Licensed nurse (RNs and LPNs) patient ratios of 1:4 to 1:6
Low turnover, high staff morale, and less use of registry staff	Retention programs and strategies to retain experienced staff, assure staff are satisfied, motivated, and feel valued by the organization

coordinating conferences are common in most LTACHs, these conferences are more likely to occur weekly rather than the daily rounding and quality checklist generation that occurs in most traditional ICUs.¹⁰⁸ Ideally, for effective bundle implementation in the LTACH setting, rounding would occur at least once a day and include those professions responsible for intervention delivery and assessment. At a minimum, this would include the patients' nurse, respiratory therapist, pharmacist, physical therapist, and physician/advanced practice provider. A template of an ABCDEF bundle-related rounding tool is provided in ▶Table 4.

The success of any QI effort, such as the ABCDEF bundle implementation, requires standardization. The pain, sedation, and delirium assessment tools that are most valid, reliable, and appropriate for specific populations (e.g., patients requiring PMV) will need to be identified. Moreover, the frequency of each assessment and the personnel best suited for their administration and documentation will need to be defined. How and where the results of the SAT, SBT, and early mobilization safety screen and success/failure criteria will be documented will also need to be determined.

Intervention-Related Knowledge Deficits and Practical Implications

Assess, Prevent, and Manage Pain

Until the epidemiology of pain in the LTACH setting is better understood, it must be assumed that pain is as ubiquitous and poorly controlled as it is in most acute care ICUs.⁷ Among LTACH patients requiring PMV, while levels of wakefulness and thus the ability of patients to self-report pain is likely to be greater than that of the ICU, some LTACH patients will still be unable to effectively communicate pain due to a delay in tracheostomy decannulation or cognitive impairment (i.e., delirium). Although findings from several studies suggest that verbal complaints of pain among cognitively impaired individuals are reliable and valid, verbal reports of pain generally decrease as the degree of cognitive impairment increases.¹⁰⁹ We also know that clinical staff often discount complaints of pain in persons with cognitive impairment because of inconsistent pain reports, thus elevating the risk for the under-recognition and undertreatment of pain.¹⁰⁹ Although non-verbal ICU pain scales such as the CPOT or the BPS have yet to be validated in the LTACH setting, their utility in the context of

critical illness has been demonstrated. Finally, we would suggest that LTACH clinicians should not rely solely on nonspecific symptoms of pain (e.g., tachycardia, hypertension, or generalized agitation) when characterizing the level of pain in this subpopulation given the multitude of factors that may affect these conditions.

In the ICU setting, parenteral opioids such as fentanyl, morphine, and hydromorphone are often administered as continuous infusions. These medications are the mainstay of pain (and sometimes sedation) management, given the ease by which these agents can be titrated and the frequent lack of reliable oral or enteral access in this population. In the LTACH setting, the decreased availability of continuous bedside monitor usually precludes the use of continuous IV opioid infusions. Moreover, given that most patients requiring PMV have a reliable enteral method of medication administration and the fact that levels of pain in this setting may be more chronic and consistent, oral (enteral) morphine, oxycodone, and hydromorphone are the mainstays of opioid therapy in the LTACH setting. Sustained release opioid formulations should never be crushed and administered via a gastric or enteral tube. When administered orally (enterally), opioids undergo first-pass metabolism and thus have a duration of action that far exceeds that of IV formulations thus facilitating administration 4 to 6 hour/day. With the onset of action of oral opioids rarely exceeding 15 minutes, they can often replace IV opioids for the treatment of breakthrough pain. The QTc interval should be measured at least weekly with a 12-lead ECG for any patient receiving chronic methadone therapy. A fentanyl patch can alternatively be applied to a patient with chronic pain who does not have functioning gut access, although it is important to note that fentanyl patch takes 12 hours to start working and continues to deliver fentanyl for 12 hours after patch removal given the depot effect that is created.

A prior use of high-dose opioid therapy in the ICU for periods longer than 1 week should inform all LTACH opioid prescribing decisions regardless of the level of pain documented. Opioid withdrawal reactions may mimic the symptoms of other syndromes such as delirium and should be managed with a tapering dose of scheduled opioid therapy over at least a week. LTACH clinicians should define opioid dosing requirements using both clinical assessment and the recommendations from equianalgesic opioid conversion

Table 4 ABCDEF bundle daily rounding tool

A—Results of previous 24-h pain assessments. Incorporation and reporting of nonpharmacologic and pharmacologic pain management strategies
B—Results of SAT and SBT safety screens and trials including target and actual RASS/SAS ratings
C—Review of current medication list and identification of any potentially deliriogenic medications (e.g., anticholinergics, benzodiazepines)
D—Results of previous 24-h delirium assessments
E—Results of early mobility safety screen and trial. Current activity level
F—Did family visit with patient in past 24 h? When were they last updated on plan of care? Do they have any concerns? Include in rounds as able and they can be empowered to help keep the team aware of components of the ABCDEFs that were not performed

guidelines for all new LTACH admissions (or patients who were temporarily readmitted back to the acute care ICU). Although non-opioid analgesics such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-convulsants are frequently used in the LTACH setting to avoid the safety concerns associated with opioids (e.g., constipation, respiratory depression) data supporting the use of these agents in the LTACH setting are sparse and the NSAIDs must be used with caution in this site given the increased risks for bleeding and renal insufficiency that may occur in frail populations such as the chronically critically ill.

Both SATs and SBTs

While patients receiving PMV do consume high cumulative amounts of sedatives, opioids, and antipsychotics over the course of their LTACH stay,¹¹⁰ it is rare for either sedatives or opioids to be administered as a continuous IV infusion in this setting. It should be noted that oral (enteral) or single-dose IV administration of opioids and/or benzodiazepines can still reduce wakefulness, the ability to follow simple commands and respiratory drive will affect the ability to conduct a successful SBT. Clinicians should therefore consider a patient's current status and the requirements of the SBT screen before administering opioid or benzodiazepine therapy before all planned SBTs. Research is required on how SAT and SBT screening and success criteria should be adjusted from what is currently in the ICU for patients with PMV being managed in the LTACH.

Given the lack of empiric evidence for the benefits of SATs in the setting of PMV, several important factors would need to be considered before their adoption into routine care. First, it would be necessary for health care providers to have the training and education necessary to use valid, reliable, and objective measures of a patient's sedation level to guide the awakening process. As suggested in the new SCCM guidelines, both the Richmond Agitation-Sedation Scale¹¹¹ (RASS) and Sedation Agitation Scale¹¹² (SAS) are the most valid and reliable sedation assessment tools for measuring both the quality and depth of sedation in various clinical situations involving adult ICU patients. While it is unclear exactly how many LTACHs currently use either of these tools, given the experience in traditional ICUs their adoption into care can be accomplished with minimal time and training. Next, considering how long chronically critically ill patients may have been exposed to sedatives (in particular the benzodiazepines) in the acute care setting, it will be very important for staff in the LTACH setting to closely monitor their patients for signs of acute withdrawal syndrome should SATs be utilized. In fact, this may be an important question to ask to the transferring facility prior to LTACH admission. Finally, when developing a SAT protocol, it will be important for the LTACH to consider what should be incorporated in the SAT safety screen and success/failure criteria. Some example criteria, which have been used in prior studies in the acute care setting, are provided in ►Table 5.

Until very recently, there was little information regarding the role of SBTs in the context of PMV. Traditionally, the process of liberating patients from PMV was divided into two

phases: (1) identifying and correcting, if possible, the physiological barriers to weaning and (2) applying a systematic approach to ventilator discontinuation.¹¹⁴

One recent, single-center RCT conducted in patients requiring PMV in the LTACH setting compared weaning duration between patients managed with pressure support with those managed with unassisted breathing through a tracheostomy collar.¹¹³ Patients were included in the study if they received mechanical ventilation for at least 21 days and excluded for the following reasons: cardiopulmonary instability, profound neurological deficits, bilateral phrenic-nerve injury, previous admission to the LTACH, and a life expectancy of less than 3 months. Patients randomized to the pressure support arm received gradual systematic reductions in pressure support as tolerated. Patients randomized to tracheostomy collar were disconnected from the ventilator each morning and allowed to breathe on their own through their tracheostomy (i.e., similar to a SBT). During the first 2 days of the protocol, the SBT group was reconnected to the ventilator at night and assist-control ventilation was instituted for the next 12 hours.

Patients managed with the tracheostomy approach had a shorter weaning time and, after adjustment for baseline covariates, were more likely to be successfully weaned (hazard ratio [HR] = 1.43; 95% confidence interval [CI]: 1.03–1.98; $p = 0.03$). Although survival rates at 6 and 12 months were similar between the two groups, this study is important for LTACH clinicians given that it is the first to provide empirical support for the use of SBTs (albeit different from SBT protocols seen in the acute care setting) in the context of PMV.²⁸

One of the most interesting findings of this study, however, was what occurred immediately before the randomization process. In this time period, 500 patients underwent a screening procedure that consisted of unassisted breathing via a tracheostomy collar for up to 5 days. A total of 160 (32%) patients passed this initial tracheostomy challenge and thus were unable to be randomized into the study. This finding strongly suggests that many LTACH patients may be ready to be liberated from the ventilator much earlier than expected.

Choice of Sedation

Agitation is frequent among LTACH patients requiring PMV and has been shown to be greater among patients at the time of LTACH admission who are less severely ill, are transferred from an academic medical center (vs. a community hospital), had delirium, and who had benzodiazepine therapy discontinued at the acute care hospital.¹¹⁵ Every effort should be made to identify the source of agitation in any LTACH patient requiring PMV before a sedating medication is administered given that common sources of agitation such as pain, delirium, hypoxemia, sleep disturbances, and acute infection are not likely to respond to the administration of a sedative medication such as a benzodiazepine. Patients who are anxious should receive constant reassurance from clinicians and family. Agitation from a withdrawal reaction from the chronic use of an opioid or benzodiazepine at the acute care hospital should always be investigated. Low-dose oral (enteral) therapy with diazepam that is slowly down-titrated

Table 5 Potential SAT, SBT, and exercise/mobilization safety screen and success failure criteria for patients requiring prolonged mechanical ventilation in the LTACH setting^{44,113}

SAT safety screen criteria
A patient will be ineligible for a SAT if any of the following criteria are met:
1. Active seizures
2. Acute alcohol/benzodiazepine withdrawal
3. Use of neuromuscular blockade
4. Suspected elevated intracranial pressure
5. Documentation of myocardial infarction in past 24 h
6. Current RASS score >2
SAT success/failure criteria
A SAT will be considered a failure should the patient display any of the following criteria:
1. RASS score >2 for >5 min
2. Pulse ox <88% for >5 min
3. Respirations >35 BPM for ≥5 min
4. Acute cardiac arrhythmia
5. Two or more of the following: heart rate increase ≥20 per minute BPM, heart rate <55 BPM, use of accessory muscles, abdominal paradox, diaphoresis or dyspnea
SBT safety screen criteria
A patient will be ineligible for a SBT if any of the following criteria are met:
1. Cardiopulmonary instability as reflected by:
a. Requiring vasopressor support (e.g., dopamine >5 µg/kg/min)
b. Oxygen saturation as measured by pulse oximetry (SpO ₂) <90% with fractional inspired O ₂ concentration (FIO ₂) >0.40 and PEEP >5 cm H ₂ O
2. Profound neurological deficits (defined as Glasgow coma scale < 7)
3. Bilateral phrenic-nerve injury
4. Life expectancy less than 3 mo (e.g., metastatic cancer that has not responded to medical or surgical therapy)
SBT success/failure criteria
A SBT will be considered a failure should the patient display any of the following criteria:
1. Heart rate > [(220-age) × 0.8] beats/min
2. Systolic pressure < 80 mm Hg
3. SpO ₂ < 90%
4. Patient request
5. Two of the following criteria simultaneously: respiratory rate > 35 breaths/min, systolic pressure > 180 mm Hg, agitation as reflected by the inability to remain motionless for 1 min, diaphoresis
Exercise safety screen criteria
A patient will be ineligible for exercise/mobilization if any of the following criteria are met:
1. RASS score < -3
2. FIO ₂ >0.6
3. Set PEEP >10 cm H ₂ O
4. Increasing doses of vasopressor infusions in the past 2 h
5. Evidence of active MI
6. Administration of a new antiarrhythmic agent
7. Receiving therapies that restrict mobility (e.g., wound vacuum, open-abdomen)
Injuries in which mobility is contraindicated (e.g., unstable fractures)
Exercise success/failure criteria

(Continued)

Table 5 (Continued)

An exercise session will be considered a failure should the patient display any of the following criteria:
1. Symptomatic drop in mean arterial pressure
2. Heart rate <50 or >130 BPM $\geq$ 5 min
3. Respiratory rate <5 or >40 BPM $\geq$ 5 min
4. Systolic blood pressure >180 mm Hg $\geq$ 5 min
5. Pulse oximetry reading <88% $\geq$ 5 min
6. Marked ventilator dyssynchrony
7. Patient distress
8. New arrhythmia or evidence of active MI
9. Concern for airway device integrity or endotracheal removal
10. Fall to knees

Abbreviations: BPM, breaths per minute; LTACH, long-term acute care hospital; PEEP, positive end-expiratory pressure.

over a 10- to 14-day period should be employed in all situations where persistent agitation related to benzodiazepine withdrawal is likely.¹¹⁶ In all other instances, the use of benzodiazepine therapy in this population should be very limited, given that will increase the risk for delirium and falls. Antipsychotics should not be administered for the treatment of agitation in patient without delirium, given the many safety concerns with the chronic use of these agents. In patients in whom a clear source for their agitation is not identified, nonpharmacologic interventions like a sitter or restraints may sometimes need to be temporarily instituted.

Delirium Assessment, Prevention, and Management

The fact that coma, delirium, and depression are prevalent among LTACH patients requiring PMV may not be surprising given the acuity, age, and high psychoactive medication use in this population.^{117,118} Among one cohort of 478 patients admitted to a LTACH for PMV, 142 (30%) had persistent coma and/or delirium and were unable to ever be evaluated for depressive disorders. Of the remaining 336 patients, 142 (42%) were diagnosed with depressive disorders. The presence of a depressive disorder was associated with a significantly higher rate of weaning failure and was independently associated with higher mortality. The fact that the LTACH LOS was significantly higher among patients with delirium suggests that these symptoms should be regularly evaluated in the LTACH setting. As noted previously, both the CAM-ICU and ICDSC are valid and reliable delirium assessment tools for use with mechanically ventilated patients.

Reversible, preventable causes for delirium should always be identified in the LTACH setting. Nonpharmacologic strategies, including reorientation, use of hearing aids, environmental modifications, and early mobilization, may help reduce the burden of delirium in this setting. Sleep promoting strategies that include the ear plugs and the occasional use of non-benzodiazepine sleep aids may also reduce the incidence of delirium. Administration of scheduled antipsychotic therapy to prevent or treat delirium in LTACH patients requiring PMV is common despite the lack of any evidence that antipsychotic therapy prevents delirium or improves the

outcome of delirium in either ICU or LTACH populations.^{117,119} One recent evaluation of LTACH patients requiring PMV found that among the 39% of patients, scheduled antipsychotic therapy was administered on 52% of the LTACH admission days and was independently associated with a significantly greater incidence of delirium, psychiatric evaluation, and sitter use. While antipsychotic therapy may have a role for those LTACH patients with more severe delirium-associated symptoms (e.g., hallucinations, agitation), their current risk:benefit ratio does not support routine use and thus the continued use of antipsychotic therapy for any patient requiring PMV who is transferred to the LTACH should always be questioned.

Early Mobility/Exercise

Most patients admitted to medical center-based ICUs who require PMV and survive the initial catastrophic episode of shock, respiratory failure, or overwhelming infection are often lost to follow-up upon transfer from the medical center to the community LTACH. Often, physical rehabilitation is deescalated in the LTACH rather than advanced due to the frailty, multiple comorbidities, chronic disability of older patients, and limited LTACH resources. This situation results in regression of any functional or physical gains achieved in the medical center, and accelerates a downward spiral toward nursing home care. There are a few small studies that compare progressive, intense physical rehabilitation to usual care,¹²⁰ in chronically critically ill, ICU survivors in the LTACH setting; and none of these have modified current standards of care. Thus, these patients have extended LTACH stays that frequently lack goal-directed physical therapy to meet the rehabilitation needs of many ICU survivors. Recently, several epidemiologic studies revealed the magnitude of economic strain and resource allocation required in caring for this growing population.^{3,16,17} Although some LTACH patients may not meet rehabilitation criteria, the lack of evidence-based studies and resources have limited a more aggressive approach toward the rehabilitation of these patients.

One of the major barriers to conducting effective mobility-based rehabilitation in the LTACH population is the profound

degree of weakness and disability of this population, which precludes their ability to participate in the majority of physical therapy maneuvers, let alone walk. One small pilot study functionally assessed 14 older survivors of critical illness requiring PMV in a university-based LTACH, using a battery of validated measures of strength (handgrip), physical performance battery (SPPB), mobility (gait speed), balance, and coordination (short and endurance [6-minute walk], estimated VO_2 by upper extremity bicycle ergometry).¹²¹ This functional testing demonstrated weakness (handgrip = 20 ± 8 kg, $n = 9$; reference = 45 ± 8 kg men, 28 ± 6 women¹²²), impaired balance and coordination¹²³ (SPPB score = 4, $n = 9$, severe disability <8), poor mobility (gait speed = 0.26 ± 0.30 m/s, reference >1 m/s¹²⁴), and low endurance (6-minute walk distance = 57 ± 126 ft, $n = 5$, reference = $2,070 \pm 305$ ft¹²⁵; and estimated $\text{VO}_2 = 6.1 \pm 1.2$ mL/kg/min, $n = 4$, reference 27–31 mL/kg/min; METS 1.8 ± 0.3). These results contextualized these patients' severe weakness, functional impairment, and disability but more importantly demonstrated feasibility in rehabilitating these patients.

A rehabilitation protocol which addresses these patients' severe disability and immobility best allows for LTACH patients of varying functional ability to perform exercise maneuvers (►Table 6). When combined with achieving strenuous targeted effort goals, the incorporation of exercise protocols similar to this have demonstrated improvements not only in functional outcomes (activities of daily living, basic mobility, i.e., rolling and sit to stand) but also in clinical outcomes such as decreasing ventilator days, increasing

weaning success, and discharge home.¹²⁶ Thus, the incorporation of patient-oriented rehabilitation protocols may be key to effectively introducing the “early mobility” principles of the ABCDEF bundle into the LTACH setting.

Family Engagement/Empowerment

Given the known physical, psychological, and financial stress that caregivers experience, it is important to consider how best to engage patients' family members effectively in the care of their loved ones while they are in the LTACH setting. While this is in evolution and certainly a focus of the SCCM's ICU Liberation collaborative program (www.ICUliberation.org), there are certain concepts that have already been emphasized and embraced by patients and families during and following the ICU experience. Rather than repeat them here, we refer the reader to the following: <http://www.icudelirium.org/family.html>.

Conclusion

Developing new and better ways of managing the common and distressing symptoms associated with chronic critical illness had great potential to improve the quality of life for the large number of patients admitted annually to LTACHs. While yet to be tested in the LTACH setting, there is evidence from the traditional ICU setting that the ABCDEF bundle may possibly improve the care and outcomes of the chronically critically ill. We have discussed elements of this care bundle that would be logically adapted for use in the LTACH setting

Table 6 Simplified exercise protocol for LTACH patients requiring PMV

	Bed dependent	Chair dependent	Ambulatory
Muscle strengthening (functional)	Leg pressure Hip extension/abduction (supine) Closed kinetic terminal knee extension Ankle dorsiflexion Proprioceptive Neuromuscular facilitation Scapular depression Lat pulls Triceps Hand putty	Modified sit to stand Modified step ups Hip extension/abduction (standing) Closed kinetic terminal knee extension Ankle dorsiflexion Proprioceptive Neuromuscular facilitation Shoulder flexion/abduction Lat pulls Triceps Hand putty	Squats Step ups Hip extension/abduction (standing) Lat pulls Deltoid flies Triceps Biceps Hand putty
Muscle endurance	Sitting edge of bed (30–60 s rhythmic stabilization) Leg press (30 s) Supine leg raise (reverse) (30 s)	Restorator (30–60 s) Upper and lower extremity Standing balance: Unilateral stance Rhomberg Modified sit to stand Modified step up	Stationary bicycle (60–90 s) Upper body ergometry (60–90 s) Squats Step ups Modified military press Triceps
Aerobic	Wheelchair mobility	Stationary bicycle Upper body ergometry Ambulation	Treadmill Stationary bicycle Upper body ergometry Ambulation

Abbreviations: LTACH, long-term acute care hospital; PMV, prolonged mechanical ventilation.

Note: A protocol developed for all mobility levels to allow all patients to benefit from rehabilitation that addresses all aspects of fitness (muscle strengthening, muscle endurance, and aerobic capacity).

within the context of appropriately designed research and quality improvement studies monitoring for safety and effectiveness. This article was written to propose a role for such an interprofessional interventional approach to the care of the thousands of patients suffering from chronic critical illness.

References

- Hartl WH, Wolf H, Schneider CP, Küchenhoff H, Jauch K-W. Secular trends in mortality associated with new therapeutic strategies in surgical critical illness. *Am J Surg* 2007;194(4): 535–541
- Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. *JAMA* 2014; 311(13):1308–1316
- Kahn JM, Benson NM, Appleby D, Carson SS, Iwashyna TJ. Long-term acute care hospital utilization after critical illness. *JAMA* 2010;303(22):2253–2259
- Carson SS. Definitions and epidemiology of the chronically critically ill. *Respir Care* 2012;57(6):848–856, discussion 856–858
- Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. *Am J Respir Crit Care Med* 2010;182(4):446–454
- Wiencek C, Winkelman C. Chronic critical illness: prevalence, profile, and pathophysiology. *AACN Adv Crit Care* 2010;21(1): 44–61, quiz 63
- Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 2013;41(1):263–306
- Peterson JF, Pun BT, Dittus RS, et al. Delirium and its motoric subtypes: a study of 614 critically ill patients. *J Am Geriatr Soc* 2006;54(3):479–484
- Sprong PE, Riekerk B, Hofhuis J, Rommes JH. Occurrence of delirium is severely underestimated in the ICU during daily care. *Intensive Care Med* 2009;35(7):1276–1280
- Balas MC, Vasilevskis EE, Olsen KM, et al. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle. *Crit Care Med* 2014;42(5):1024–1036
- Cox CE, Carson SS. Medical and economic implications of prolonged mechanical ventilation and expedited post-acute care. *Semin Respir Crit Care Med* 2012;33(4):357–361
- Zilberberg MD, Shorr AF. Prolonged acute mechanical ventilation and hospital bed utilization in 2020 in the United States: implications for budgets, plant and personnel planning. *BMC Health Serv Res* 2008;8:242–242
- Nelson JE, Meier DE, Litke A, Natale DA, Siegel RE, Morrison RS. The symptom burden of chronic critical illness. *Crit Care Med* 2004;32(7):1527–1534
- Nelson JE, Tandon N, Mercado AF, Camhi SL, Ely EW, Morrison RS. Brain dysfunction: another burden for the chronically critically ill. *Arch Intern Med* 2006;166(18):1993–1999
- Scheinhorn DJ, Chao DC, Stearn-Hassenpflug M, LaBree LD, Heltsley DJ. Post-ICU mechanical ventilation: treatment of 1,123 patients at a regional weaning center. *Chest* 1997; 111(6):1654–1659
- Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. *Ann Intern Med* 2010;153(3): 167–175
- Kahn JM, Werner RM, David G, Ten Have TR, Benson NM, Asch DA. Effectiveness of long-term acute care hospitalization in elderly patients with chronic critical illness. *Med Care* 2013;51(1):4–10
- Cox CE, Martinu T, Sathy SJ, et al. Expectations and outcomes of prolonged mechanical ventilation. *Crit Care Med* 2009;37(11): 2888–2894, quiz 2904
- Carson SS, Bach PB, Brzozowski L, Leff A. Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients. *Am J Respir Crit Care Med* 1999;159(5, Pt 1):1568–1573
- Scheinhorn DJ, Hassenpflug MS, Votto JJ, et al; Ventilation Outcomes Study Group. Post-ICU mechanical ventilation at 23 long-term care hospitals: a multicenter outcomes study. *Chest* 2007;131(1):85–93
- Fletcher SN, Kennedy DD, Ghosh IR, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. *Crit Care Med* 2003;31(4): 1012–1016
- Douglas SL, Daly BJ. Caregivers of long-term ventilator patients: physical and psychological outcomes. *Chest* 2003;123(4): 1073–1081
- Im K, Belle SH, Schulz R, Mendelsohn AB, Chelluri L. QOL-MV Investigators. Prevalence and outcomes of caregiving after prolonged (> or =48 hours) mechanical ventilation in the ICU. *Chest* 2004;125(2):597–606
- Swoboda SM, Lipsett PA. Impact of a prolonged surgical critical illness on patients' families. *Am J Crit Care* 2002;11(5):459–466
- MacIntyre NR, Epstein SK, Carson S, Scheinhorn D, Christopher K, Muldoon S. National Association for Medical Direction of Respiratory Care. Management of patients requiring prolonged mechanical ventilation: report of a NAMDRC consensus conference. *Chest* 2005;128(6):3937–3954
- Kahn JM, Le T, Angus DC, et al; ProVent Study Group Investigators. The epidemiology of chronic critical illness in the United States. *Crit Care Med* 2015;43(2):282–287
- Munoz-Price LS. Long-term acute care hospitals. *Clin Infect Dis* 2009;49(3):438–443
- Kahn JM, Carson SS. Generating evidence on best practice in long-term acute care hospitals. *JAMA* 2013;309(7):719–720
- MedPAC Reforms Target LTACHs. *Home health. Case in Point* 2014; 12(2):23–23
- Ehlenbach WJ. The sobering reality of outcomes when older adults require prolonged mechanical ventilation. *J Am Geriatr Soc* 2014;62(1):183–185
- Dermot Frengley J, Sansone GR, Shakya K, Kaner RJ. Prolonged mechanical ventilation in 540 seriously ill older adults: effects of increasing age on clinical outcomes and survival. *J Am Geriatr Soc* 2014;62(1):1–9
- Cabrera-Cancio MR. Infections and the compromised immune status in the chronically critically ill patient: prevention strategies. *Respir Care* 2012;57(6):979–990, discussion 990–992
- Vasilevskis EE, Ely EW, Speroff T, Pun BT, Boehm L, Dittus RS. Reducing iatrogenic risks: ICU-acquired delirium and weakness—crossing the quality chasm. *Chest* 2010;138(5):1224–1233
- Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008; 371(9607):126–134
- Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000;342(20):1471–1477
- Kress JP, Gehlbach B, Lacy M, Pliskin N, Pohlman AS, Hall JB. The long-term psychological effects of daily sedative interruption on critically ill patients. *Am J Respir Crit Care Med* 2003;168(12): 1457–1461
- Kress JP, Pohlman AS, Hall JB. Effects of sedative interruption in critically ill, mechanically ventilated patients receiving midazolam or propofol. *J Clin Outcomes Manag* 2001;8(2):33–39
- Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in

- mechanically ventilated patients: the MENDS randomized controlled trial. *JAMA* 2007;298(22):2644–2653
- 39 Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. *Crit Care Med* 1999;27(12):2609–2615
- 40 Mehta S, Burry L, Martinez-Motta JC, et al; Canadian Critical Care Trials Group. A randomized trial of daily awakening in critically ill patients managed with a sedation protocol: a pilot trial. *Crit Care Med* 2008;36(7):2092–2099
- 41 Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* 2009;373(9678):1874–1882
- 42 Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). *JAMA* 2001;286(21):2703–2710
- 43 Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001;29(7):1370–1379
- 44 Balas MC, Vasilevskis EE, Olsen KM, et al. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle. *Crit Care Med* 2014;42(5):1024–1036
- 45 Morandi A, Brummel NE, Ely EW. Sedation, delirium and mechanical ventilation: the 'ABCDE' approach. *Curr Opin Crit Care* 2011;17(1):43–49
- 46 Pandharipande P, Banerjee A, McGrane S, Ely EW. Liberation and animation for ventilated ICU patients: the ABCDE bundle for the back-end of critical care. *Crit Care* 2010;14(3):157–157
- 47 Hager DN, Dinglas VD, Subhas S, et al. Reducing deep sedation and delirium in acute lung injury patients: a quality improvement project. *Crit Care Med* 2013;41(6):1435–1442
- 48 Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. *Crit Care Med* 2004;32(6):1272–1276
- 49 Treggiari MM, Romand JA, Yanez ND, et al. Randomized trial of light versus deep sedation on mental health after critical illness. *Crit Care Med* 2009;37(9):2527–2534
- 50 Hooper MH, Girard TD. Sedation and weaning from mechanical ventilation: linking spontaneous awakening trials and spontaneous breathing trials to improve patient outcomes. *Crit Care Clin* 2009;25(3):515–525, viii
- 51 Esteban A, Alía I, Gordo F, et al; The Spanish Lung Failure Collaborative Group. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. *Am J Respir Crit Care Med* 1997;156(2, Pt 1):459–465
- 52 Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996;335(25):1864–1869
- 53 Jackson JC, Girard TD, Gordon SM, et al. Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial. *Am J Respir Crit Care Med* 2010;182(2):183–191
- 54 Jakob SM, Ruokonen E, Grounds RM, et al; Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. *JAMA* 2012;307(11):1151–1160
- 55 Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely EW. SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients. *Crit Care Med* 2010;38(12):2311–2318
- 56 Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. *Crit Care Clin* 2009;25(3):431–449, vii
- 57 Bioc JJ, Magee C, Cucchi J, et al. Cost effectiveness of a benzodiazepine vs a nonbenzodiazepine-based sedation regimen for mechanically ventilated, critically ill adults. *J Crit Care* 2014;29(5):753–757
- 58 Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013
- 59 Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med* 1990;113(12):941–948
- 60 Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *JAMA* 2004;291(14):1753–1762
- 61 Thomason JWW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. *Crit Care* 2005;9(4):R375–R381
- 62 McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence and clinical course in older patients. *J Am Geriatr Soc* 2003;51(5):591–598
- 63 Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital length of stay. *Intensive Care Med* 2001;27(12):1892–1900
- 64 Lin S-M, Liu C-Y, Wang C-H, et al. The impact of delirium on the survival of mechanically ventilated patients. *Crit Care Med* 2004;32(11):2254–2259
- 65 Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. *Am J Respir Crit Care Med* 2009;180(11):1092–1097
- 66 Zhang Z, Pan L, Ni H. Impact of delirium on clinical outcome in critically ill patients: a meta-analysis. *Gen Hosp Psychiatry* 2013;35(2):105–111
- 67 Balas MC, Happ MB, Yang W, Chelluri L, Richmond T. Outcomes Associated With Delirium in Older Patients in Surgical ICUs. *Chest* 2009;135(1):18–25
- 68 Brummel NE, Jackson JC, Pandharipande PP, et al. Delirium in the ICU and subsequent long-term disability among survivors of mechanical ventilation. *Crit Care Med* 2014;42(2):369–377
- 69 McNicoll L, Pisani MA, Inouye SK. One-year outcomes following delirium in older ICU patients. *J Am Geriatr Soc* 2004;52(Suppl 4):S2, A4
- 70 Pandharipande PP, Girard TD, Jackson JC, et al; BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. *N Engl J Med* 2013;369(14):1306–1316
- 71 Girard TD, Jackson JC, Pandharipande PP, et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. *Crit Care Med* 2010;38(7):1513–1520
- 72 Jackson JC, Gordon SM, Hart RP, Hopkins RO, Ely EW. The association between delirium and cognitive decline: a review of the empirical literature. *Neuropsychol Rev* 2004;14(2):87–98
- 73 Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. *Intensive Care Med* 2001;27(5):859–864
- 74 Pun BT, Gordon SM, Peterson JF, et al. Large-scale implementation of sedation and delirium monitoring in the intensive care unit: a report from two medical centers. *Crit Care Med* 2005;33(6):1199–1205
- 75 Devlin JW, Fong JJ, Schumaker G, O'Connor H, Ruthazer R, Garpestad E. Use of a validated delirium assessment tool improves the ability of physicians to identify delirium in medical intensive care unit patients. *Crit Care Med* 2007;35(12):2721–2724, quiz 2725
- 76 Patel SB, Poston JT, Pohlman A, Hall JB, Kress JP. Rapidly reversible, sedation-related delirium versus persistent delirium in the

- intensive care unit. *Am J Respir Crit Care Med* 2014;189(6):658–665
- 77 Li Z, Peng X, Zhu B, Zhang Y, Xi X. Active mobilization for mechanically ventilated patients: a systematic review. *Arch Phys Med Rehabil* 2013;94(3):551–561
 - 78 Chen Y-H, Lin H-L, Hsiao H-F, et al. Effects of exercise training on pulmonary mechanics and functional status in patients with prolonged mechanical ventilation. *Respir Care* 2012;57(5):727–734
 - 79 Malkoç M, Karadibak D, Yildirim Y. The effect of physiotherapy on ventilatory dependency and the length of stay in an intensive care unit. *Int J Rehabil Res* 2009;32(1):85–88
 - 80 Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. *Crit Care Med* 2008;36(8):2238–2243
 - 81 Clemmer TP. Why the reluctance to meaningfully mobilize ventilated patients? “The answer my friend is blowin’ in the wind”. *Crit Care Med* 2014;42(5):1308–1309
 - 82 Patel RP, Gambrell M, Speroff T, et al. Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. *Crit Care Med* 2009;37(3):825–832
 - 83 Kahn JM, Brake H, Steinberg KP. Intensivist physician staffing and the process of care in academic medical centres. *Qual Saf Health Care* 2007;16(5):329–333
 - 84 Mehta S, Burry L, Fischer S, et al; Canadian Critical Care Trials Group. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. *Crit Care Med* 2006;34(2):374–380
 - 85 Nydahl P, Ruhl AP, Bartoszek G, et al. Early mobilization of mechanically ventilated patients: a 1-day point-prevalence study in Germany. *Crit Care Med* 2014;42(5):1178–1186
 - 86 Balas MC, Vasilevskis EE, Burke WJ, et al. Critical care nurses’ role in implementing the “ABCDE bundle” into practice. *Crit Care Nurse* 2012;32(2):35–38, 40–47, quiz 48
 - 87 Balas MC, Burke WJ, Gannon D, et al. Implementing the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle into everyday care: opportunities, challenges, and lessons learned for implementing the ICU Pain, Agitation, and Delirium Guidelines. *Crit Care Med* 2013;41(9, Suppl 1):S116–S127
 - 88 Bassett R, Adams KM, Danesh V, et al. Rethinking critical care: decreasing sedation, increasing delirium monitoring, and increasing patient mobility. *Jt Comm J Qual Patient Saf* 2015;41(2):62–74
 - 89 Klompas M, Anderson D, Trick W, et al; CDC Prevention Epicenters. The preventability of ventilator-associated events. *Am J Respir Crit Care Med* 2015;191(3):292–301
 - 90 Needham DM, Korupolu R, Zanni JM, et al. Early physical medicine and rehabilitation for patients with acute respiratory failure: a quality improvement project. *Arch Phys Med Rehabil* 2010;91(4):536–542
 - 91 Khan BA, Fadel WF, Tricker JL, et al. Effectiveness of implementing a wake up and breathe program on sedation and delirium in the ICU. *Crit Care Med* 2014;42(12):e791–e795
 - 92 Carrothers KM, Barr J, Spurlock B, Ridgely MS, Damberg CL, Ely EW. Contextual issues influencing implementation and outcomes associated with an integrated approach to managing pain, agitation, and delirium in adult ICUs. *Crit Care Med* 2013;41(9, Suppl 1):S128–S135
 - 93 Happ MB, Swigart VA, Tate JA, Arnold RM, Sereika SM, Hoffman LA. Family presence and surveillance during weaning from prolonged mechanical ventilation. *Heart Lung* 2007;36(1):47–57
 - 94 Karlsson V, Forsberg A, Bergbom I. Relatives’ experiences of visiting a conscious, mechanically ventilated patient—a hermeneutic study. *Intensive Crit Care Nurs* 2010;26(2):91–100
 - 95 Morse JM, Pooler C. Patient-family-nurse interactions in the trauma-resuscitation room. *Am J Crit Care* 2002;11(3):240–249
 - 96 Riggio RE, Singer RD, Hartman K, Sneider R. Psychological issues in the care of critically-ill respirator patients: differential perceptions of patients, relatives, and staff. *Psychol Rep* 1982;51(2):363–369
 - 97 Williams CMA. The identification of family members’ contribution to patients’ care in the intensive care unit: a naturalistic inquiry. *Nurs Crit Care* 2005;10(1):6–14
 - 98 Bergbom I, Askwall A. The nearest and dearest: a lifeline for ICU patients. *Intensive Crit Care Nurs* 2000;16(6):384–395
 - 99 Jones C, Bäckman C, Capuzzo M, et al; RACHEL group. Intensive care diaries reduce new onset post traumatic stress disorder following critical illness: a randomised, controlled trial. *Crit Care* 2010;14(5):R168–R168
 - 100 Davidson JE, Daly BJ, Agan D, Brady NR, Higgins PA. Facilitated sensemaking: a feasibility study for the provision of a family support program in the intensive care unit. *Crit Care Nurs Q* 2010;33(2):177–189
 - 101 Black P, Boore JRP, Parahoo K. The effect of nurse-facilitated family participation in the psychological care of the critically ill patient. *J Adv Nurs* 2011;67(5):1091–1101
 - 102 O’Byrne L, Von Rueden K, Malila F. Evaluating ventilator weaning best practice: a long-term acute care hospital system-wide quality initiative. *AACN Clin Issues* 2002;13(4):567–576
 - 103 Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. *Crit Care Med* 2001;29(12):2258–2263
 - 104 Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. *Am J Crit Care* 2006;15(4):420–427
 - 105 Carrothers KM, Barr J, Spurlock B, Ridgely MS, Damberg CL, Ely EW. Contextual issues influencing implementation and outcomes associated with an integrated approach to managing pain, agitation, and delirium in adult ICUs. *Crit Care Med* 2013;41(9, Suppl 1):S128–S135
 - 106 The Royal College of Speech and Language Therapists. Position Paper: Speech and Language Therapy in Adult Critical Care. London: The Royal College of Speech and Language Therapists; 2006
 - 107 Alvarez MR, Kerr BJ Jr, Burtner J, Ledlow G, Fulton LV. Use of outsourced nurses in long-term acute care hospitals: outcomes and leadership preferences. *J Nurs Adm* 2011;41(2):90–96
 - 108 Weiss CH, Moazed F, McEvoy CA, et al. Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. *Am J Respir Crit Care Med* 2011;184(6):680–686
 - 109 Herr KA, Garand L. Assessment and measurement of pain in older adults. *Clin Geriatr Med* 2001;17(3):457–478, vi
 - 110 Karir V, Hough CL, Daniel S, Caldwell E, Treggiari MM. Sedation practices in a cohort of critically ill patients receiving prolonged mechanical ventilation. *Minerva Anestesiol* 2012;78(7):801–809
 - 111 Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003;289(22):2983–2991
 - 112 Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. *Crit Care Med* 1999;27(7):1325–1329
 - 113 Jubran A, Grant BJB, Duffner LA, et al. Effect of pressure support vs unassisted breathing through a tracheostomy collar on weaning duration in patients requiring prolonged mechanical ventilation: a randomized trial. *JAMA* 2013;309(7):671–677
 - 114 White AC. Long-term mechanical ventilation: management strategies. *Respir Care* 2012;57(6):889–897, discussion 898–899
 - 115 O’Connor H, Al-Qadheeb NS, White AC, Thaker V, Devlin JW. Agitation during prolonged mechanical ventilation at a long-term acute care hospital: risk factors, treatments, and outcomes. *J Intensive Care Med* 2014;29(4):218–224
 - 116 Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of

- analgesic and sedative medications in adult intensive care unit patients. *Crit Care Med* 1998;26(4):676–684
- 117 Al-Qadheeb NS, O'Connor HH, White AC, et al. Antipsychotic prescribing patterns, and the factors and outcomes associated with their use, among patients requiring prolonged mechanical ventilation in the long-term acute care hospital setting. *Ann Pharmacother* 2013;47(2):181–188
- 118 Jubran A, Lawm G, Kelly J, et al. Depressive disorders during weaning from prolonged mechanical ventilation. *Intensive Care Med* 2010;36(5):828–835
- 119 Devlin JW, Al-Qadheeb NS, Skrobik Y. Pharmacologic prevention and treatment of delirium in critically ill and non-critically ill hospitalised patients: a review of data from prospective, randomised studies. *Best Pract Res Clin Anaesthesiol* 2012;26(3):289–309
- 120 Chen S, Su CL, Wu YT, et al. Physical training is beneficial to functional status and survival in patients with prolonged mechanical ventilation. *J Formos Med Assoc* 2011;110(9):572–579
- 121 Verceles A, Wells C, Steinbrenner G, et al. Severe immobility and malnutrition in post ICU patients requiring prolonged mechanical ventilation: an unmet rehabilitation need. *Am J Respir Crit Care Med* 2012;185:A6852
- 122 Massy-Westropp NM, Gill TK, Taylor AW, Bohannon RW, Hill CL. Hand grip strength: age and gender stratified normative data in a population-based study. *BMC Res Notes* 2011;4:127
- 123 Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994;49(2):M85–M94
- 124 Fritz S, Lusardi M. White paper: “walking speed: the sixth vital sign”. *J Geriatr Phys Ther* 2009;32(2):46–49
- 125 Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. *Eur Respir J* 1999;14(2):270–274
- 126 Verceles A, Wells C, Beans J, Jenkins T, Goldberg A. The multimodal rehabilitation of older mechanically ventilated survivors of critical illness improves functional and clinical outcomes. *Am J Respir Crit Care Med* 2014;189:A4166

REVIEW

Open Access



A conceptual framework: the early and late phases of skeletal muscle dysfunction in the acute respiratory distress syndrome

D. Clark Files^{1,2*}, Michael A. Sanchez¹ and Peter E. Morris^{1,2}

Abstract

Patients with acute respiratory distress syndrome (ARDS) often develop severe diaphragmatic and limb skeletal muscle dysfunction. Impaired muscle function in ARDS is associated with increased mortality, increased duration of mechanical ventilation, and functional disability in survivors. In this review, we propose that muscle dysfunction in ARDS can be categorized into an early and a late phase. These early and late phases are based on the timing in relationship to lung injury and the underlying mechanisms. The early phase occurs temporally with the onset of lung injury, is driven by inflammation and disuse, and is marked predominantly by muscle atrophy from increased protein degradation. The ubiquitin-proteasome, autophagy, and calpain-caspase pathways have all been implicated in early-phase muscle dysfunction. Late-phase muscle weakness persists in many patients despite resolution of lung injury and cessation of ongoing acute inflammation-driven muscle atrophy. The clinical characteristics and mechanisms underlying late-phase muscle dysfunction do not involve the massive protein degradation and atrophy of the early phase and may reflect a failure of the musculoskeletal system to regain homeostatic balance. Owing to these underlying mechanistic differences, therapeutic interventions for treating muscle dysfunction in ARDS may differ during the early and late phases. Here, we review clinical and translational investigations of muscle dysfunction in ARDS, placing them in the conceptual framework of the early and late phases. We hypothesize that this conceptual model will aid in the design of future mechanistic and clinical investigations of the skeletal muscle system in ARDS and other critical illnesses.

Introduction

Improvements in general critical care and ventilator management of acute respiratory distress syndrome (ARDS) over the past four decades have led to a significant reduction in mortality, from 80 % in the initial reports to the current rate of 20 % to 30 % reported in clinical trials [1]. These trends have resulted in a growing number of ARDS patients who are ICU survivors: approximately 200,000 people per year in the United States alone [2]. Unfortunately, these patients commonly have lasting sequelae, including increased mortality [3–5], physical and cognitive impairment [6–8], and reduced

quality of life [9]. With the introduction of such outcomes in clinical trials, the skeletal muscle system has been increasingly recognized as a major target organ in ARDS. Clinically apparent skeletal muscle weakness in the critically ill, termed ICU-acquired weakness (ICUAW) [10, 11], occurs in up to 60 % of patients and is independently associated with mortality [12, 13].

We propose, on the basis of observations of animal models and clinical studies, that muscle wasting in patients with ARDS can be divided into early and late phases. These phases differ in pathophysiology and potential underlying mechanisms and can be identified by their relationship to the time course of lung injury, recovery, and resolution. In this review, we will summarize major recent findings regarding clinical and mechanistic investigations into muscle wasting in ARDS and frame them in the context of the early and late phases. We propose that this conceptual framework will enhance the

* Correspondence: dfiles@wakehealth.edu

¹Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA

²Critical Illness Injury and Recovery Research Center Chadwick Miller MD Department of Emergency Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA

design of future clinical and mechanistic investigations and aid in tailoring therapies designed to treat muscle wasting in ARDS.

ARDS is the more severe end of the spectrum of diseases requiring admission to an ICU. Although the muscle-wasting response of patients with ARDS has not been explicitly compared with that of critically ill patients without ARDS (that is, sepsis), patients with ARDS appear to have a very high incidence of ICUAW (up to 60 %) [12–15]. While the animal studies offer some clues to mechanistic differences between muscle wasting in ARDS and sepsis [16], further carefully controlled human studies are needed to determine whether clinical differences exist in the muscle injury and recovery trajectories of sepsis patients with and without concomitant ARDS. For these reasons, in this review, we will focus primarily on muscle wasting in ARDS, although we feel that this paradigm may prove useful in other critical illnesses, such as sepsis.

The diagnosis of intensive care unit-acquired weakness

Since the original report by MacFarlane and Rosenthal [17], muscle wasting associated with critical illness has been called acute quadriparetic myopathy, thick filament myopathy, critical illness myopathy, critical illness polyneuropathy, and ICU-acquired paresis, among other terms. These names reflect the varying associated pathologic and electrophysiologic characteristics. The nomenclature has recently been simplified, and the term ICUAW signifies clinically measureable weakness in a critically ill patient without other known precipitating factors causing nerve or muscle injury [10, 11].

The diagnosis of ICUAW is made by using either manual muscle testing (MMT) or grip strength meters and by using specified cutoff values to denote weakness. Unfortunately, MMT is effort-dependent and insensitive and likely under-represents the degree of muscle dysfunction present in these patients [18–20]. MMT, grip strength meters, and hand-held dynamometers also all lack the ability to clearly discern muscle fatigability, which may contribute to the long-term functional impairments in ICU survivors. Other functional tests - such as the short physical performance battery [21], six-minute walk distance [8], or walk speeds [22] - may provide more information about global function, although these composite functional tests can be affected by factors other than muscle dysfunction and require a cooperative, engaged patient.

Given the limitations of these volitional measurements of muscle function in critically ill patients and survivors, other methods for identifying ICUAW are needed. Nerve conduction and direct muscle stimulation may improve the sensitivity of diagnosing ICUAW in the

non-cooperative patient [23] but are infrequently used at present. Skeletal muscle ultrasound is a promising modality that can non-invasively identify the loss of muscle mass in critically ill patients; muscle echointensity values may yield additional functional information [24, 25]. These modalities remain promising, although further research is needed in this area.

Systemic 'biomarkers' of ICUAW would also be helpful in identifying ICUAW. Creatine phosphokinase, the most common laboratory test used for identification of myositis in other contexts, is not helpful in identifying patients with ICUAW [11, 15]. In a pilot study, peak plasma neurofilament levels were higher in patients with ICUAW, but peak levels were not reached before patients could engage in MMT, limiting the utility of this as a biomarker [26]. Another study of post-cardiac surgery patients found that insulin-like growth factor 1 (IGF-1) levels were suppressed in patients who developed ICUAW but that growth and differentiation factor 15 levels were elevated [27]. Additional studies are needed to identify systemic biomarkers that can reliably identify patients at high risk for developing ICUAW. Identifying such patients may assist in targeted allocation of physical therapy or future pharmacologic interventions.

Phases of muscle dysfunction in acute respiratory distress syndrome

Definition of the early phase

The early phase of muscle dysfunction, which occurs hours to days after the onset of illness, begins with the activation of acute lung and systemic inflammation characteristic of early lung injury. We define the early phase to begin with the onset of the acute illness and terminate when the acute inflammation-driven muscle atrophy program resolves (Fig. 1), usually within days.

Muscle atrophy is the predominant and characteristic feature of early-phase muscle dysfunction and is driven primarily by (a) acute systemic inflammation and (b) limb and diaphragmatic muscle disuse from enforced bed rest and mechanical ventilation, respectively. Nerve, neuromuscular junction (NMJ), or direct myofiber injury or a combination of these may variably initiate atrophy or contribute to muscle weakness during the early phase. Considering the ubiquity of inflammation- and immobility-induced atrophy in these patients, we hypothesize that all patients with ARDS experience early-phase muscle wasting. We propose that atrophy is the most universal feature of ICUAW, although other pathologies such as inflammatory myopathies, polyneuropathies, or combinations also occur. Factors such as age, illness severity, organ failures, medications, malnutrition, and hypoxia may drive the severity or type of muscle dysfunction in an ancillary fashion. The drivers and clinical significance of these differing phenotypes are poorly understood. However, it is clear that




Fig. 1 The early and late phases of muscle wasting in acute respiratory distress syndrome. The early phase of muscle wasting begins with the onset of lung injury and is caused by lung and systemic inflammation and to a lesser degree disuse, both leading to muscle atrophy. The late phase of muscle wasting begins as lung function recovers and acute systemic inflammation resolves. Disuse continues in many patients during the late phase. Muscle function deteriorates in the early phase, and dysfunction persists in many patients during the late phase, which may last for years despite resolution of lung injury and cessation of ongoing muscle atrophy. Factors mediating recovery trajectories in the late phase are poorly understood

both limb [12] and diaphragmatic [28, 29] muscle weakness, regardless of the pathophysiology, independently contribute to early-phase mortality.

Definition of the late phase

The late phase of muscle dysfunction begins following resolution of the early acute lung and systemic inflammation characteristic of the early phase, usually following the first few days of illness and during the recovery phase of lung injury. Muscle atrophy may continue into the late phase, driven by disuse, but this factor usually resolves once patients are no longer bedridden. Similar to early-phase wasting, late-phase muscle weakness may occur from persistent or unresolved nerve or NMJ injury [30, 31].

The characteristic feature of late-phase muscle wasting is that muscle dysfunction persists despite recovery and resolution of lung injury in many patients [8, 20]. Factors such as age, baseline (pre-ARDS) muscle function, medications administered during or after the ICU stay, comorbidities, route of muscle injury (nerve versus NMJ versus myofiber), and nutrition may contribute to both the degree of injury and the rate of muscle functional recovery. However, the clinical characteristics associated with complete, partial, or failed recovery of muscle function in ARDS survivors (Fig. 1) are generally poorly understood.

One fundamental question is whether the recovery of muscle function in the late phase is associated with recovery of muscle mass or alternately whether weakness persists despite recovery of muscle mass. Answering this question would clarify potential mechanisms underlying persistent late-phase weakness. Unfortunately, since pre-hospital functional status of these patients is almost always unknown, it is difficult to know how baseline muscle function contributes to long-term functional outcomes. In many patients, the 'failure to recover' may reflect their baseline functional status pre-ARDS.

Prolonged metabolic disturbances and immune suppression have been described in survivors of burns [32] and sepsis [33]. The term post-intensive care syndrome has been used to refer to the constellation of psychiatric, cognitive, and physical function problems present in ICU survivors, including those with ARDS [34]. The relationship of systemic immunosuppression or hypermetabolism to late-phase skeletal muscle dysfunction in patients with ARDS deserves further attention.

Pharmacologic and nutritional contributions to early- and late-phase muscle wasting

Some of the earliest reports of muscle weakness in critically ill patients associated the presence of what is now

called ICUAW with both glucocorticoids and neuromuscular blockade (NMB) [35, 36]. However, more current evidence suggests that glucocorticoids, but not NMB, is associated with ICUAW [20, 23, 37]. In the most compelling recent evidence, a randomized controlled trial of the neuromuscular blocker cisatracurium for severe ARDS, the incidence of ICUAW, measured by MMT, at hospital discharge was no different from control [38].

The association of ICUAW with glucocorticoids appears stronger than that of NMB. Increased duration of glucocorticoid use is independently associated with increased myosin degradation in the skeletal muscles of critically ill patients on mechanical ventilation [39]. In the ARDS Network Long Term Outcomes study, which followed ARDS survivors enrolled in ARDS network trials, both dose of corticosteroid and ICU length of stay were associated with reduced functional outcomes at 6 and 12 months [20]. These results suggest that drugs or interventions in the ICU, even administered for short durations, can impact long-term outcomes. Other data supporting the importance of glucocorticoids in muscle wasting in ARDS include the fact that the glucocorticoid receptor is an upstream modulator of muscle ring finger 1 (MuRF1) activation [40], an important contributor to early-phase muscle wasting (see "The ubiquitin-proteasome system and muscle ring finger 1" section). Overall, the available data suggest that both endogenous and exogenous glucocorticoids contribute to muscle dysfunction in ARDS.

The role of nutrition in muscle weakness in critical illness and its contribution to muscle wasting is controversial, although recent evidence suggests that increased caloric intake during the early phase does not prevent late-phase muscle dysfunction. In the long-term follow-up of patients with ARDS in the EDEN (early versus delayed enteral nutrition) trial, muscle functional outcomes were unchanged between the two arms at 6 and 12 months [6]. Emerging evidence suggests that early parenteral nutrition (PN) is detrimental for muscle function in these patients [41]. The currently available data suggest that early and full caloric nutrition, either enteral [42] or parenteral [41], does not reduce the incidence of ICUAW in critically ill patients, although future investigation is warranted. Nutritional factors may be more important for improving muscle mass when administered during the late phase.

Early- and late-phase muscle dysfunction in acute respiratory distress syndrome: underlying mechanisms

Mechanisms of early-phase muscle wasting

As mentioned above, the cardinal feature of early-phase muscle dysfunction is atrophy, driven by inflammation and disuse. The net balance of protein synthesis and degradation determines myofiber size. Therefore, atrophy can occur through increased protein degradation,

reduced protein synthesis, or both. In most experimental models of muscle atrophy, increased muscle protein degradation - not reduced protein synthesis - accounts for the loss of muscle mass [43], although some controversy remains [44]. With regard to ARDS-associated muscle dysfunction, both increased protein degradation and reduced protein synthesis contribute to early-phase atrophy, although the former mechanism predominates. In the largest recent study measuring protein synthesis and degradation in critically ill patients (which included, but was not limited to, patients with ARDS), rectus femoris cross-sectional area decreased by 18 % over 10 days. In this study, patients in the early phase (day 1) showed reduced protein synthetic rates compared with fasted controls. At this time point, muscle protein degradation predominated over protein synthesis. By day 7, protein synthetic rate had increased compared with day 1 and fasted controls, likely an attempt of the muscle to recover from the massive protein degradation and atrophy during the inflammation-driven early phase, although the balance remained favoring ongoing atrophy [45].

In recent years, three major pathways have emerged as the primary regulators of muscle atrophy: the calpain-caspase system, the ubiquitin-proteasome system (UPS), and the autophagy-lysosome system (autophagy) [43, 46]. All have been implicated in inflammation and disuse atrophy, but their relative contributions and inter-relationships during the early phase of muscle wasting in ARDS remain incompletely understood.

Inflammation-driven atrophy

Both pro- and anti-inflammatory cytokines are present in the lungs and plasma of patients with ARDS [47]. Many of these pro-inflammatory cytokines are associated with muscle atrophy in humans and rodents, including tumor necrosis factor- α [48], interleukin (IL)-6 [49], IL-1 β , and others [50, 51]. Muscle atrophy occurring via inflammatory cytokines classically requires activation of the transcription factor NF- κ B (nuclear factor kappa light chain enhancer of activated B cells) [52–54], which in turn can increase muscle protein degradation, leading to rapid limb and respiratory muscle myofiber atrophy.

In lung-injured mice, marked early muscle atrophy occurs along with lung inflammation [16]. NF- κ B activation in skeletal muscle is necessary for initiating the muscle atrophy during this early phase [55]. These data suggest that systemic mediators, such as inflammatory cytokines or other soluble factors that activate NF- κ B, are important in the early phase of muscle atrophy in ARDS. These muscle proteolytic pathways may exist in order to provide nutritional substrates to an organism under major stress, such as massive infection or injury. In addition to promoting muscle protein degradation, pro-inflammatory cytokines may promote atrophy through

inhibition of the pro-hypertrophy IGF-1/AKT pathway [56], although this concept has received less attention.

Disuse-driven atrophy

There is little doubt that disuse contributes to the limb muscle atrophy associated with ARDS, given the profound limb and diaphragm disuse that characterizes these patients. In fact, recent work suggests that bed rest may 'prime' skeletal muscle for atrophy by increasing the expression of muscle surface TLR4 (Toll-like receptor 4) receptors, which, when activated, can promote atrophy [57, 58].

However, both animal models and human data support the concept that muscle wasting associated with lung injury is phenotypically different from that induced by immobility alone. A recent report of healthy persons confined to bed rest for one week documented a 4 % loss of lean body mass [57]. In a study of critically ill patients on mechanical ventilation, muscle mass loss was approximately 12 % [45] over that same time period. Likewise, in an animal model of hind-limb immobilization, an approximately 5 % muscle mass loss of the tibialis anterior muscle was seen at day 3.5 [59], and we find an approximately 22 % muscle mass loss in the tibialis anterior of lung-injured mice at this time point [16]. Collectively, these data support the concept that disuse atrophy contributes to the early phase of wasting, but less so than inflammation-driven atrophy.

Molecular targets for attenuating muscle atrophy in the early phase

The ubiquitin-proteasome system and muscle ring finger 1 Animal models and emerging human data suggest that the UPS plays a prominent role in the early phase of limb and diaphragmatic muscle wasting in ARDS. We and others have shown that the UPS-mediated atrophy is prominent in the early phase of muscle wasting in lung-injured mice [16, 55, 60]. The E3 ligase MuRF1, which coordinates the ubiquitination of myosin heavy chain (MyHC) and other contractile proteins for proteasomal degradation [61], is necessary for early-phase atrophy in this model. Support for the importance of this mechanism in ICUAW is the finding that selective MyHC degradation is a salient pathologic feature of critical illness myopathy [62]. Others have shown that 20S proteasome activity is upregulated in the vastus lateralis of patients on mechanical ventilation, which was also associated with upregulation of the forkhead box o (FoxO) transcription factors, MuRF1, and other atrophy-promoting genes [39]. In recent work evaluating serial biopsies in mechanically ventilated patients, the only consistent change in protein expression was in MuRF1 and atrogin 1 expression, both of which were downregulated over time [45], supporting the

observation that this pathway is activated in the early phase. Another study reported reduced MuRF1 levels in the muscles of critically ill patients, although the varying time points for muscle biopsies limit the interpretation of this finding [63]. The currently available human and animal data suggest that the UPS plays a prominent role in the early phase of muscle atrophy in ARDS. As therapeutic agents targeting proteins involved in UPS-mediated atrophy are developed and tested [64], their use in the early phase of ARDS-associated muscle wasting should be considered.

Autophagy Briefly, macroautophagy (autophagy) is a ubiquitous process present in multiple cell types in which cellular proteins and cytoplasm are degraded and recycled via lysosomes. A focus on autophagy in skeletal muscle is relatively underexplored [65]. Increased autophagic flux can cause atrophy, although inhibition of autophagic flux can also induce atrophy, potentially through upregulation of the UPS [65, 66]. Interestingly, both the UPS and autophagy pathways can be regulated by the same FoxO transcription factors [67].

Evidence suggests that autophagy is involved in ARDS-associated muscle wasting. Diaphragmatic disuse due to mechanical ventilation in brain-dead humans is associated with the rapid appearance of autophagosomes and autophagy-related genes and proteins [68]. This finding could be due to either increased flux or a block in distal autophagy processing. In a pig model (combining mechanical ventilation, endotoxin, NMB, and corticosteroids), significant limb muscle atrophy was associated with reduction in critical autophagy genes and proteins [69].

In a prospective study of 600 patients in the EPaNIC (Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients) trial, 122 of whom underwent muscle biopsy, those randomly assigned to late PN had a reduced incidence of ICUAW compared with those with early PN; this result was associated with an increased LC3II-to-LC3I ratio, a marker of autophagosome formation [41]. These data suggest that autophagy induction is associated with improved muscle function.

The role of autophagy during the early phase of muscle wasting in ARDS is complex, given that either accelerated or impaired autophagy may be deleterious to muscle function. Details regarding the role of autophagy and its relationship with the UPS are still emerging, and more work is needed to determine the role of autophagy in the early phase of muscle wasting in ARDS. Other types of muscle autophagy, including microautophagy [70] and chaperone-mediated autophagy [71], also deserve future investigation in this context.

Caspases and calpains Caspases and calpains are early mediators in the breakdown of sarcomeric proteins that

can then undergo degradation by the UPS or autophagy pathway. Caspases and calpains have been investigated more extensively in both endotoxin- and mechanical ventilation-induced diaphragmatic dysfunction but not (to our knowledge) in animal models of lung injury. Supinski and colleagues [72] showed that calpain, caspase, and proteasome activity are upregulated in the diaphragm of endotoxin-treated mice. Likewise, diaphragm calpain activation peaks early (24 h) in the cecal ligation mouse model of sepsis. Co-administration of eicosapentaenoic acid prevented the loss of specific force-generating capacity in the diaphragm and prevented calpain activation [73, 74]. Others have shown that mechanical ventilation in humans causes atrophy and increased caspase 9 activity in diaphragm fibers [75]. As such, calpains and caspases remain attractive potential targets for intervention in the early phase of muscle wasting.

Neuropathy and other pathologies as potential therapeutic targets in the early phase

As mentioned above, polyneuropathy is found in a subset of patients with ICUAW. Critical illness polyneuropathy affects distal axonal sensory and motor nerves, which may lead to myofiber atrophy and contribute to weakness independent of atrophy. Histologically, peripheral nerves with [76, 77] or without [78] axonal degeneration have been described. The polyneuropathy in patients without nerve degeneration has been proposed to be due to a transient negative shift in voltage dependence of sodium channel fast inactivation leading to reduced excitability of the nerve, demonstrated in both rats and humans [79].

Autonomic dysregulation, which may be present in many patients with severe critical illness, may also contribute to polyneuropathy [80]. With this in mind, there has been recent interest in using β -blockade in patients with septic shock [81] as a way to attenuate sympathetic over-activation. Interestingly, stimulation of skeletal muscle β receptors leads to muscle hypertrophy through stimulating protein synthesis [82]. Therefore, muscle function should be incorporated into clinical trial design of future investigations of β -blockade in critical illness.

Epineurial and endneurial vascular leak [83] causing nerve edema is another proposed mechanism. Hyperglycemia, often characteristic of severe critical illness, could further impair nerve or muscle microcirculation [84]. This hypothesis may explain why intensive insulin therapy has been associated with a reduced incidence of ICUAW [85, 86]. Interestingly, the glucose transporter-4 (GLUT4) receptor, which modulates glucose uptake into muscle, appears mislocalized in patients with critical illness myopathy [87].

Additionally, reduced muscle membrane excitability is a common finding on electromyographic studies [23]. A

series of studies has shown impaired sarcoplasmic reticulum calcium handling and impaired sodium channels in muscles of denervated and steroid-treated rodents [88–90], but to our knowledge this has not been studied in the context of lung injury. Owing to altered metabolism or increased muscle fatigue, muscle mitochondrial injury [91, 92] sustained during the early phase may contribute to muscle dysfunction.

Molecular targets for attenuating muscle atrophy in the late phase

Ongoing active muscle proteolysis through increased protein degradation does not appear to be a major contributing factor of weakness during the late phase. The massive inflammation-induced protein degradation has subsided at this time point [16, 45]. Therefore, therapies directed at attenuating muscle proteolysis are less likely to benefit as much as when administered during the early phase.

In contrast, enhancing protein synthesis may be useful during the late phase. Two studies suggest that there is actually already increased protein synthesis in the late phase. One study showed muscle activation of the pro-synthesis AKT-mTOR-S6k (AKT-mammalian target of rapamycin-ribosomal protein S6 kinase) pathway of critically ill patients from muscle biopsies that were obtained predominantly in the late phase [63]; a second study showed increased protein synthesis in the muscles of critically ill patients at day 7 [45]. This may be a compensatory mechanism to recover from the early phase, and studies are needed to determine whether augmenting protein synthesis pathways can improve muscle mass during the late phase. Therefore, we propose that late-phase therapies to improve muscle mass focus on enhancing protein synthesis or other factors to enhance myofiber size, such as through the myostatin pathway [93].

Neuropathy and other pathologies as potential therapeutic targets in the late phase

Evidence suggests that denervation injury may persist into the late phase. In a cohort of mechanically ventilated critically ill patients, muscle biopsies at about day 12 revealed upregulation of the muscle acetylcholine receptor γ mRNA, a marker of muscle denervation [39]. Late-phase wasting may also exist due to persistence of some factors initiated during the early phase, such as disuse, nerve or NMJ injury, excitation contraction uncoupling, inflammatory myopathy, or mitochondrial dysfunction.

Additional targets during the late phase include enhancing muscle regeneration by targeting muscle stem (satellite) cell activation/repair [94]. Additionally, enhancing autophagy, as a way to 'clean up' the misfolded

proteins and other debris that accumulated during the early phase, may theoretically benefit.

Many questions remain about the relationship of the early phase to the late phase. For instance, is late-phase wasting due to persistent injuries sustained in the early phase or are the two phases mechanistically independent? Is late-phase wasting purely a reflection of a return to a pre-hospital level of reduced muscle function in patients with underlying neuromyopathies or sarcopenia? Answering these questions will clarify potential therapies to improve muscle function in ARDS survivors. Figure 2 illustrates potential clinical factors and mechanisms associated with early- and late-phase muscle wasting in ARDS.

Currently available therapeutic approaches

Insulin administration and tight glycemic control appear to reduce ICUAW [85], although this approach has been tempered with the results of the NICE-SUGAR (Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation) trial, which suggested an increased risk of death in the tight glycemic control arm, possibly due to hypoglycemia [95]. Perhaps

strategies that reduce hyperglycemia without the risk of hypoglycemia will reduce the incidence of ICUAW.

Currently, early mobilization/rehabilitation is the most readily available therapy for the attenuation of ICUAW. Evidence has demonstrated that early rehabilitation of critically ill patients is safe and has the benefit of improving other outcomes in addition to muscle strength [96–99]. Emerging evidence suggests that passive loading of the leg in a rat model of mechanical ventilation and paralysis prevented atrophy and degradation of myosin [100]. In a small study of mechanically ventilated critically ill patients, passive movement of the leg attenuated loss of specific force (but not atrophy) measured by single-fiber contraction [101]. We have recently shown that a model of early mobilization in lung-injured mice attenuates the MuRF1-mediated loss of muscle mass and force during the early phase, through an NF- κ B-mediated mechanism [102]. This suggests that early mobility may attenuate the inflammation-induced atrophy in the early phase. As such, early mobilization (even passive movement) remains the best available therapy for critically ill patients to attenuate early- and late-phase muscle wasting in ARDS.

Mediators of ARDS-induced Muscle Dysfunction

Early Phase

- Inflammation (and disuse)-driven myofiber atrophy
 - calpain
 - UPS
 - autophagy
- Myopathy
 - necrotizing
 - impaired SR Ca⁺ handling
- Nerve or NMJ injury
 - vascular mediated nerve injury
 - sodium channelopathy
- Medications (i.e. glucocorticoids)

Late Phase

- Persistence of some early phase injuries
 - disuse atrophy
 - nerve or NMJ injury
 - myopathy
- Failure to regain muscle homeostasis following early phase injury
 - fiber type switch
 - failed muscle regeneration (satellite cells)
 - impaired protein synthesis
 - autophagy
 - hypermetabolism (cachexia)
- Pre-ARDS underlying neuromuscular defects (i.e. sarcopenia)



Fig. 2 Mediators of acute respiratory distress syndrome (ARDS)-induced muscle dysfunction. Skeletal muscle atrophy is the most universal feature of the early phase, which is driven fundamentally by inflammation and disuse. Other factors such as neuropathic injury and medications can exacerbate atrophy (blue arrow) and independently cause muscle dysfunction. Therefore, inhibiting muscle protein degradation is the most promising potential early-phase therapy. The late phase is marked by cessation of inflammation-induced muscle proteolysis and therefore potential treatments at this time point will differ. Mediators of the late phase may involve persistence of some early-phase injuries or a failure to regain muscle homeostasis following the early phase. Late-phase dysfunction may be compounded by underlying pre-ARDS neuromuscular defects. NMJ, neuromuscular junction; SR Ca⁺, sarcoplasmic reticulum calcium; UPS, ubiquitin-proteasome system

Unfortunately, despite evidence that early mobility is safe and effective, there are limitations to its adoption, and implementation worldwide remains low [103, 104].

Neuromuscular electrical stimulation (NMES) may develop as an alternative therapy [105, 106], particularly for those who cannot participate in active physical therapy. In a small study, NMES attenuated type 2 myofiber atrophy, which was associated with relocation of the GLUT4 receptor and improved glucose metabolism [87]. Further research is certainly warranted for this potential therapy.

Conclusions

As new therapies for inhibiting muscle protein degradation become available [64], it will be critical to administer them early in critically ill patients. As we propose that muscle atrophy is the most universal feature of ICUAW and that neuropathy will also lead to downstream myofiber atrophy, therapies that attenuate muscle protein degradation during the early phase have the highest theoretical benefit to improve in-hospital and long-term outcomes. Investigators interested in the early treatment of ARDS, such as the Prevention and Early Treatment of Lung Injury (PETAL) Network, could consider approaches that aim to attenuate the early phase of muscle wasting in patients with ARDS. This approach may open a new paradigm of therapies in ARDS, a syndrome that imparts a profound and lasting effect on the musculoskeletal system.

Abbreviations

AKT: Protein kinase B; ARDS: Acute respiratory distress syndrome; FoxO: Forkhead box o; GLUT4: Glucose transporter-4; ICUAW: Intensive care unit-acquired weakness; IGF-1: Insulin like growth factor 1; IL: Interleukin; MMT: Manual muscle testing; MuRF1: Muscle ring finger 1; MyHC: Myosin heavy chain; NF- κ B: Nuclear factor kappa light chain enhancer of activated B cells; NMB: Neuromuscular blockade; NMES: Neuromuscular electrical stimulation; NMJ: Neuromuscular junction; PN: Parenteral nutrition; UPS: Ubiquitin-proteasome system.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

DCF would like to thank his mentors, Michael T Crow and Landon S King, without whom none of this work would be possible. The authors thank Karen Klein for editorial assistance and Nick Weir at Creative Communications for the illustrations. This work was supported by institutional funds from the Wake Forest School of Medicine, the Department of Medicine (DCF), the Claude D. Pepper Older Americans Independence Center (grant P30-AG21332), the Parker B. Francis Foundation (DCF), the American Thoracic Society Foundation (DCF), the National Institutes of Health (grant 1R01NR011186-01 to PEM), and the Department of the Army (ERMS #12340010 to PEM).

Published online: 02 July 2015

References

- Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. *J Clin Invest*. 2012;122:2731–40.
- Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. *N Engl J Med*. 2005;353:1685–93.
- Brinkman S, Bakhshi-Raiez F, Abu-Hanna A, de Jonge E, de Keizer NF. Determinants of mortality after hospital discharge in ICU patients: literature review and Dutch cohort study. *Crit Care Med*. 2013;41:1237–51.
- Lone NI, Walsh TS. Impact of intensive care unit organ failures on mortality during the five years after a critical illness. *Am J Respir Crit Care Med*. 2012;186:640–7.
- Ferrante LE, Pisani MA, Murphy TE, Gahbauer EA, Leo-Summers LS, Gill TM. Functional trajectories among older persons before and after critical illness. *JAMA Intern Med*. 2015;175:523–9.
- Needham DM, Dinglas VD, Morris PE, Jackson JC, Hough CL, Mendez-Tellez PA, et al. Physical and cognitive performance of patients with acute lung injury 1 year after initial trophic versus full enteral feeding. EDEN trial follow-up. *Am J Respir Crit Care Med*. 2013;188:567–76.
- Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. *Am J Respir Crit Care Med*. 2012;185:1307–15.
- Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med*. 2011;364:1293–304.
- Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme Jr JF. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2005;171:340–7.
- Fan E, Cheek F, Chlan L, Gosselink R, Hart N, Herridge MS, et al. An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. *Am J Respir Crit Care Med*. 2014;190:1437–46.
- Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. *Crit Care Med*. 2009;37:S299–308.
- Ali NA, O'Brien Jr JM, Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. *Am J Respir Crit Care Med*. 2008;178:261–8.
- Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A, et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study and propensity-matched analysis. *Am J Respir Crit Care Med*. 2014;190:410–20.
- Sharshar T, Bastuji-Garin S, Stevens RD, Durand MC, Malissin I, Rodriguez P, et al. Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality. *Crit Care Med*. 2009;37:3047–53.
- De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA*. 2002;288:2859–67.
- Files DC, D'Alessio FR, Johnston LF, Kesari P, Aggarwal NR, Garibaldi BT, et al. A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting. *Am J Respir Crit Care Med*. 2012;185:825–34.
- MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. *Lancet*. 1977;2:615.
- Bohannon RW. Manual muscle testing: does it meet the standards of an adequate screening test? *Clin Rehabil*. 2005;19:662–7.
- Connolly BA, Jones GD, Curtis AA, Murphy PB, Douiri A, Hopkinson NS, et al. Clinical predictive value of manual muscle strength testing during critical illness: an observational cohort study. *Crit Care*. 2013;17:R229.
- Needham DM, Wozniak AW, Hough CL, Morris PE, Dinglas VD, Jackson JC, et al. Risk factors for physical impairment after acute lung injury in a national, multicenter study. *Am J Respir Crit Care Med*. 2014;189:1214–24.
- Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol*. 1994;49:M85–94.
- Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. *JAMA*. 2011;305:50–8.
- Weber-Carstens S, Deja M, Koch S, Spranger J, Buscher F, Wernecke KD, et al. Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. *Crit Care*. 2010;14:R119.
- Connolly B, MacBean V, Crowley C, Lunt A, Moxham J, Rafferty GF, et al. Ultrasound for the assessment of peripheral skeletal muscle architecture in critical illness: a systematic review. *Crit Care Med*. 2015;43:897–905.
- Grimm A, Teschner U, Porzelius C, Ludewig K, Zielske J, Witte OW, et al. Muscle ultrasound for early assessment of critical illness neuromyopathy in severe sepsis. *Crit Care*. 2013;17:R227.

26. Wieske L, Witteveen E, Petzold A, Verhamme C, Schultz MJ, van Schaik IN, et al. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. *Crit Care*. 2014;18:R18.
27. Bloch SA, Lee JY, Wort SJ, Polkey MI, Kemp PR, Griffiths MJ. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. *Crit Care Med*. 2013;41:982–9.
28. Supinski GS, Callahan LA. Diaphragm weakness in mechanically ventilated critically ill patients. *Crit Care*. 2013;17:R120.
29. Demoule A, Jung B, Prodanovic H, Molinari N, Chanques G, Coirault C, et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact: a prospective study. *Am J Respir Crit Care Med*. 2013;188:213–9.
30. Semmler A, Okulla T, Kaiser M, Seifert B, Heneka MT. Long-term neuromuscular sequelae of critical illness. *J Neurol*. 2013;260:151–7.
31. Fletcher SN, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. *Crit Care Med*. 2003;31:1012–6.
32. Hart DW, Wolf SE, Mlacak R, Chinkes DL, Ramzy PI, Obeng MK, et al. Persistence of muscle catabolism after severe burn. *Surgery*. 2000;128:312–9.
33. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis*. 2013;13:260–8.
34. Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. *Crit Care Med*. 2012;40:502–9.
35. Gutmann L, Blumenthal D, Gutmann L, Schochet SS. Acute type II myofiber atrophy in critical illness. *Neurology*. 1996;46:819–21.
36. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. *N Engl J Med*. 1992;327:524–8.
37. Puthucherry Z, Rawal J, Ratnayake G, Harridge S, Montgomery H, Hart N. Neuromuscular blockade and skeletal muscle weakness in critically ill patients: time to rethink the evidence? *Am J Respir Crit Care Med*. 2012;185:911–7.
38. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med*. 2010;363:1107–16.
39. Derde S, Hermans G, Derese I, Guiza F, Hedstrom Y, Wouters PJ, et al. Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. *Crit Care Med*. 2012;40:79–89.
40. Baehr LM, Furlow JD, Bodine SC. Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. *J Physiol*. 2011;589:4759–76.
41. Hermans G, Casaer MP, Clerckx B, Guiza F, Vanhullebusch T, Derde S, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPANIC trial. *Lancet Respir Med*. 2013;1:621–9.
42. Needham DM, Dinglas VD, Bienvenu OJ, Colantuoni E, Wozniak AW, Rice TW, et al. One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial. *BMJ*. 2013;346:f1532.
43. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. *Dis Model Mech*. 2013;6:25–39.
44. Phillips SM, McGlory C. CrossTalk proposal: the dominant mechanism causing disuse muscle atrophy is decreased protein synthesis. *J Physiol*. 2014;592:5341–3.
45. Puthucherry ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. *JAMA*. 2013;310:1591–600.
46. Wing SS, Lecker SH, Jagoe RT. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. *Crit Rev Clin Lab Sci*. 2011;48:49–70.
47. Janz DR, Ware LB. Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials. *Semin Respir Crit Care Med*. 2013;34:537–48.
48. Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. *J Mol Biol*. 2008;384:48–59.
49. Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? *FEBS J*. 2013;280:4131–48.
50. Bhatnagar S, Mittal A, Gupta SK, Kumar A. TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. *J Cell Physiol*. 2012;227:1042–51.
51. Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. *Curr Opin Clin Nutr Metab Care*. 2004;7:265–9.
52. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. *FASEB J*. 2005;19:362–70.
53. Li YP, Lecker SH, Chen Y, Waddell ID, Goldberg AL, Reid MB. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. *FASEB J*. 2003;17:1048–57.
54. Cai D, Frantz JD, Tawa Jr NE, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. *Cell*. 2004;119:285–98.
55. Langen RC, Haegens A, Vernooij JH, Wouters EF, de Winther MP, Carlsen H, et al. NF-kappaB activation is required for the transition of pulmonary inflammation to muscle atrophy. *Am J Respir Cell Mol Biol*. 2012;47:288–97.
56. Schulze PC, Gielen S, Adams V, Linke A, Mobius-Winkler S, Erbs S, et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulin-like growth factor-I in chronic heart failure. *Basic Res Cardiol*. 2003;98:267–74.
57. Drummond MJ, Timmerman KL, Markofski MM, Walker DK, Dickinson JM, Jamaluddin M, et al. Short-term bed rest increases TLR4 and IL-6 expression in skeletal muscle of older adults. *Am J Physiol Regul Integr Comp Physiol*. 2013;305:R216–23.
58. Doyle A, Zhang G, Abdel Fattah EA, Eissa NT, Li YP. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. *FASEB J*. 2011;25:99–110.
59. Caron AZ, Drouin G, Desrosiers J, Trens F, Grenier G. A novel hindlimb immobilization procedure for studying skeletal muscle atrophy and recovery in mouse. *J Appl Physiol* (1985). 2009;106:2049–59.
60. Haegens A, Schols AM, Gorissen SH, van Essen AL, Snepvangers F, Gray DA, et al. NF-kappaB activation and polyubiquitin conjugation are required for pulmonary inflammation-induced diaphragm atrophy. *Am J Physiol Lung Cell Mol Physiol*. 2012;302:L103–10.
61. Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. *Am J Physiol Endocrinol Metab*. 2014;307:E469–84.
62. Larsson L, Li X, Edstrom L, Eriksson LI, Zackrisson H, Argenti C, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. *Crit Care Med*. 2000;28:34–45.
63. Jespersen JG, Nedergaard A, Reitelsheder S, Mikkelsen UR, Diderksen KJ, Agergaard J, et al. Activated protein synthesis and suppressed protein breakdown signaling in skeletal muscle of critically ill patients. *PLoS One*. 2011;6:e18090.
64. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. *Nat Rev Drug Discov*. 2015;14:58–74.
65. Sandri M. Autophagy in skeletal muscle. *FEBS Lett*. 2010;584:1411–6.
66. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M, et al. Autophagy is required to maintain muscle mass. *Cell Metab*. 2009;10:507–15.
67. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. *Cell Metab*. 2007;6:458–71.
68. Hussain SN, Mofarrah M, Sigala I, Kim HC, Vassilakopoulos T, Maltais F, et al. Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy. *Am J Respir Crit Care Med*. 2010;182:1377–86.
69. Banduseela VC, Chen YW, Kultima HG, Norman H, Aare S, Radell P, et al. Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. *Physiol Genomics*. 2013;45:477–86.
70. Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. *Cell Mol Life Sci*. 2012;69:1125–36.
71. Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. *Cell Res*. 2014;24:92–104.
72. Supinski GS, Wang L, Song XH, Moylan JS, Callahan LA. Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. *J Appl Physiol* (1985). 2014;117:921–9.
73. Supinski GS, Callahan LA. Calpain activation contributes to endotoxin-induced diaphragmatic dysfunction. *Am J Respir Cell Mol Biol*. 2010;42:80–7.
74. Supinski GS, Vanags J, Callahan LA. Eicosapentaenoic acid preserves diaphragm force generation following endotoxin administration. *Crit Care*. 2010;14:R35.
75. Tang H, Lee M, Budak MT, Pietras N, Hittinger S, Vu M, et al. Intrinsic apoptosis in mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis. *FASEB J*. 2011;25:2921–36.

76. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. *J Neurol Neurosurg Psychiatry*. 1984;47:1223–31.
77. Bolton CF, Laverty DA, Brown JD, Witt NJ, Hahn AF, Sibbald WJ. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barre syndrome. *J Neurol Neurosurg Psychiatry*. 1986;49:563–73.
78. Latronico N, Fenzi F, Recupero D, Guarneri B, Tomelleri G, Tonin P, et al. Critical illness myopathy and neuropathy. *Lancet*. 1996;347:1579–82.
79. Novak KR, Nardelli P, Cope TC, Filatov G, Glass JD, Khan J, et al. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. *J Clin Invest*. 2009;119:1150–8.
80. Axer H, Grimm A, Porzelius C, Teschner U, Schumacher U, Witte OW, et al. Impairment of small somatic and autonomic nerve fibres in intensive care unit patients with severe sepsis and critical illness polyneuropathy - a single center controlled observational study. *BMC Neurol*. 2013;13:159.
81. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. *JAMA*. 2013;310:1683–91.
82. Sato S, Shirato K, Tachiyashiki K, Imaizumi K. Muscle plasticity and beta-adrenergic receptors: adaptive responses of beta-adrenergic receptor expression to muscle hypertrophy and atrophy. *J Biomed Biotechnol*. 2011;2011:729598.
83. Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. *Acta Neuropathol*. 2003;106:75–82.
84. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. *Lancet Neurol*. 2011;10:931–41.
85. Hermans G, Wilmer A, Meersseman W, Milants I, Wouters PJ, Bobbaers H, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. *Am J Respir Crit Care Med*. 2007;175:480–9.
86. Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. *Neurology*. 2005;64:1348–53.
87. Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, et al. Critical illness myopathy and GLUT4: significance of insulin and muscle contraction. *Am J Respir Crit Care Med*. 2013;187:387–96.
88. Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. *J Physiol*. 2003;547:555–66.
89. Kraner SD, Wang Q, Novak KR, Cheng D, Cool DR, Peng J, et al. Upregulation of the CaV 1.1-ryanodine receptor complex in a rat model of critical illness myopathy. *Am J Physiol Regul Integr Comp Physiol*. 2011;300:R1384–91.
90. Kraner SD, Novak KR, Wang Q, Peng J, Rich MM. Altered sodium channel-protein associations in critical illness myopathy. *Skelet Muscle*. 2012;2:17.
91. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet*. 2002;360:219–23.
92. Weiss SL, Selak MA, Tuluc F, Perales Villarroel J, Nadkarni VM, et al. Mitochondrial dysfunction in peripheral blood mononuclear cells in pediatric septic shock. *Pediatr Crit Care Med*. 2015;16:e4–12.
93. Lee SJ, Reed LA, Davies MV, Gigenrath S, Goad ME, Tomkinson KN, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. *Proc Natl Acad Sci U S A*. 2005;102:18117–22.
94. Wang YX, Rudnicki MA. Satellite cells, the engines of muscle repair. *Nat Rev Mol Cell Biol*. 2012;13:127–33.
95. Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, et al. Hypoglycemia and risk of death in critically ill patients. *N Engl J Med*. 2012;367:1108–18.
96. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet*. 2009;373:1874–82.
97. Morris PE, Goad A, Thompson C, Taylor K, Harry B, Passmore L, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. *Crit Care Med*. 2008;36:2238–43.
98. Burtin C, Clerckx B, Robbeets C, Ferdinande P, Langer D, Troosters T, et al. Early exercise in critically ill patients enhances short-term functional recovery. *Crit Care Med*. 2009;37:2499–505.
99. Needham DM, Korupolu R, Zanni JM, Pradhan P, Colantuoni E, Palmer JB, et al. Early physical medicine and rehabilitation for patients with acute respiratory failure: a quality improvement project. *Arch Phys Med Rehabil*. 2010;91:536–42.
100. Renaud G, Llano-Diez M, Ravara B, Gorza L, Feng HZ, Jin JP, et al. Sparing of muscle mass and function by passive loading in an experimental intensive care unit model. *J Physiol*. 2013;591:1385–402.
101. Llano-Diez M, Renaud G, Andersson M, Marrero HG, Cacciani N, Engquist H, et al. Mechanisms underlying ICU muscle wasting and effects of passive mechanical loading. *Crit Care*. 2012;16:R209.
102. Files DC, Liu C, Pereyra A, Wang ZM, Aggarwal NR, D'Alessio FR, et al. Therapeutic exercise attenuates neutrophilic lung injury and skeletal muscle wasting. *Sci Transl Med*. 2015;7:278ra232.
103. Nydahl P, Ruhl AP, Bartoszek G, Dubb R, Filipovic S, Flohr HJ, et al. Early mobilization of mechanically ventilated patients: a 1-day point-prevalence study in Germany. *Crit Care Med*. 2014;42:1178–86.
104. Berney SC, Harrold M, Webb SA, Seppelt I, Patman S, Thomas PJ, et al. Intensive care unit mobility practices in Australia and New Zealand: a point prevalence study. *Crit Care Resusc*. 2013;15:260–5.
105. Maffiuletti NA, Roig M, Karatzanos E, Nanas S. Neuromuscular electrical stimulation for preventing skeletal-muscle weakness and wasting in critically ill patients: a systematic review. *BMC Med*. 2013;11:137.
106. Parry SM, Berney S, Granger CL, Koopman R, El-Ansary D, Denehy L. Electrical muscle stimulation in the intensive care setting: a systematic review. *Crit Care Med*. 2013;41:2406–18.